<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/uExCHBwkBYmSb66PA-WnCkXaFHsOHJaFxUqa1fKqJ-UG-rPiRSDHvk1FxHPUYk5H15X76rQa8Fe0F3Kyp-Lgag=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"cancer-genomics;computational-biology-and-bioinformatics;melanoma","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-019-0654-5"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["David Liu","Bastian Schilling","Derek Liu","Antje Sucker","Elisabeth Livingstone","Livnat Jerby-Arnon","Lisa Zimmer","Ralf Gutzmer","Imke Satzger","Carmen Loquai","Stephan Grabbe","Natalie Vokes","Claire A. Margolis","Jake Conway","Meng Xiao He","Haitham Elmarakeby","Felix Dietlein","Diana Miao","Adam Tracy","Helen Gogas","Simone M. Goldinger","Jochen Utikal","Christian U. Blank","Ricarda Rauschenberg","Dagmar von Bubnoff","Angela Krackhardt","Benjamin Weide","Sebastian Haferkamp","Felix Kiecker","Ben Izar","Levi Garraway","Aviv Regev","Keith Flaherty","Annette Paschen","Eliezer M. Van Allen","Dirk Schadendorf"],"publishedAt":1575244800,"publishedAtString":"2019-12-02","title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Cancer genomics,Computational biology and bioinformatics,Melanoma"},"journal":{"pcode":"nm","title":"nature medicine","volume":"25","issue":"12","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","description":"Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of response was confounded by melanoma subtype, whereas multiple novel genomic and transcriptomic features predicted selective response, including features associated with MHC-I and MHC-II antigen presentation. Furthermore, previous anti-CTLA4 ICB exposure was associated with different predictors of response compared to tumors that were naive to ICB, suggesting selective immune effects of previous exposure to anti-CTLA4 ICB. Finally, we developed parsimonious models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 ICB in individual tumors, with validation in smaller independent cohorts limited by the availability of comprehensive data. Broadly, we present a framework to discover predictive features and build models of ICB therapeutic response. Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a strong predictor of response across melanoma subtypes.","datePublished":"2019-12-02T00:00:00Z","dateModified":"2020-06-19T00:00:00Z","pageStart":"1916","pageEnd":"1927","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-019-0654-5","keywords":["Cancer genomics","Computational biology and bioinformatics","Melanoma","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig5_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"25","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"David Liu","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Bastian Schilling","url":"http://orcid.org/0000-0001-8859-4103","affiliation":[{"name":"University Hospital Würzburg","address":{"name":"Department of Dermatology, University Hospital Würzburg, Würzburg, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"University Hospital","address":{"name":"Department of Dermatology, University Hospital, Essen, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Center","address":{"name":"German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Derek Liu","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Antje Sucker","affiliation":[{"name":"University Hospital","address":{"name":"Department of Dermatology, University Hospital, Essen, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Center","address":{"name":"German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Elisabeth Livingstone","affiliation":[{"name":"University Hospital","address":{"name":"Department of Dermatology, University Hospital, Essen, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Center","address":{"name":"German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Livnat Jerby-Arnon","affiliation":[{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lisa Zimmer","affiliation":[{"name":"University Hospital","address":{"name":"Department of Dermatology, University Hospital, Essen, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Center","address":{"name":"German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ralf Gutzmer","affiliation":[{"name":"Hannover Medical School","address":{"name":"Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Imke Satzger","affiliation":[{"name":"Hannover Medical School","address":{"name":"Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Carmen Loquai","affiliation":[{"name":"University Medical Center","address":{"name":"Department of Dermatology, University Medical Center, Mainz, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Stephan Grabbe","affiliation":[{"name":"University Medical Center","address":{"name":"Department of Dermatology, University Medical Center, Mainz, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Natalie Vokes","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Claire A. Margolis","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jake Conway","affiliation":[{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Meng Xiao He","affiliation":[{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard University","address":{"name":"Biophysics Program, Harvard University, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Haitham Elmarakeby","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Felix Dietlein","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Diana Miao","url":"http://orcid.org/0000-0003-1754-2319","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Adam Tracy","affiliation":[{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Helen Gogas","affiliation":[{"name":"National and Kapodistrian University of Athens","address":{"name":"First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Simone M. Goldinger","affiliation":[{"name":"University Hospital Zürich","address":{"name":"Department of Dermatology, University Hospital Zürich, Zürich, Switzerland","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jochen Utikal","url":"http://orcid.org/0000-0001-5316-0241","affiliation":[{"name":"University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg","address":{"name":"Department of Dermatology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Center","address":{"name":"Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Christian U. Blank","url":"http://orcid.org/0000-0002-7945-5846","affiliation":[{"name":"The Netherlands Cancer Institute","address":{"name":"Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ricarda Rauschenberg","affiliation":[{"name":"University Hospital Carl Gustav Carus, Technische Universität Dresden","address":{"name":"Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"National Center for Tumor Diseases","address":{"name":"National Center for Tumor Diseases, Dresden, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Centre","address":{"name":"German Cancer Research Centre, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Dagmar von Bubnoff","affiliation":[{"name":"Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg","address":{"name":"Department of Dermatology, Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Angela Krackhardt","affiliation":[{"name":"German Cancer Research Center","address":{"name":"German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"Technische Universität München","address":{"name":"Medizinische Klinik III, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Benjamin Weide","affiliation":[{"name":"University Medical Center Tübingen","address":{"name":"Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sebastian Haferkamp","affiliation":[{"name":"University Hospital Regensburg","address":{"name":"Department of Dermatology, University Hospital Regensburg, Regensburg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Felix Kiecker","affiliation":[{"name":"University Hospital Berlin","address":{"name":"Department of Dermatology, University Hospital Berlin, Berlin, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ben Izar","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Levi Garraway","affiliation":[{"name":"Eli Lilly and Co.","address":{"name":"Eli Lilly and Co., Indianapolis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Aviv Regev","url":"http://orcid.org/0000-0003-3293-3158","affiliation":[{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Keith Flaherty","url":"http://orcid.org/0000-0002-3402-0478","affiliation":[{"name":"Massachusetts General Hospital","address":{"name":"Massachusetts General Hospital, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Annette Paschen","affiliation":[{"name":"University Hospital","address":{"name":"Department of Dermatology, University Hospital, Essen, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Center","address":{"name":"German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Eliezer M. Van Allen","url":"http://orcid.org/0000-0002-0201-4444","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Broad Institute of Harvard and MIT","address":{"name":"Broad Institute of Harvard and MIT, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"eliezerm_vanallen@dfci.harvard.edu","@type":"Person"},{"name":"Dirk Schadendorf","url":"http://orcid.org/0000-0003-3524-7858","affiliation":[{"name":"University Hospital","address":{"name":"Department of Dermatology, University Hospital, Essen, Germany","@type":"PostalAddress"},"@type":"Organization"},{"name":"German Cancer Research Center","address":{"name":"German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"email":"dirk.schadendorf@uk-essen.de","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-019-0654-5">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma">
    <meta name="dc.source" content="Nature Medicine 2019 25:12">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2019-12-02">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2019 The Author(s)">
    <meta name="dc.rights" content="2019 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of response was confounded by melanoma subtype, whereas multiple novel genomic and transcriptomic features predicted selective response, including features associated with MHC-I and MHC-II antigen presentation. Furthermore, previous anti-CTLA4 ICB exposure was associated with different predictors of response compared to tumors that were naive to ICB, suggesting selective immune effects of previous exposure to anti-CTLA4 ICB. Finally, we developed parsimonious models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 ICB in individual tumors, with validation in smaller independent cohorts limited by the availability of comprehensive data. Broadly, we present a framework to discover predictive features and build models of ICB therapeutic response. Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a strong predictor of response across melanoma subtypes.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2019-12-02">
    <meta name="prism.volume" content="25">
    <meta name="prism.number" content="12">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1916">
    <meta name="prism.endingPage" content="1927">
    <meta name="prism.copyright" content="2019 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-019-0654-5">
    <meta name="prism.doi" content="doi:10.1038/s41591-019-0654-5">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-019-0654-5.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-019-0654-5">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma">
    <meta name="citation_volume" content="25">
    <meta name="citation_issue" content="12">
    <meta name="citation_publication_date" content="2019/12">
    <meta name="citation_online_date" content="2019/12/02">
    <meta name="citation_firstpage" content="1916">
    <meta name="citation_lastpage" content="1927">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-019-0654-5">
    <meta name="DOI" content="10.1038/s41591-019-0654-5">
    <meta name="size" content="302526">
    <meta name="citation_doi" content="10.1038/s41591-019-0654-5">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-019-0654-5&amp;api_key=">
    <meta name="description" content="Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of response was confounded by melanoma subtype, whereas multiple novel genomic and transcriptomic features predicted selective response, including features associated with MHC-I and MHC-II antigen presentation. Furthermore, previous anti-CTLA4 ICB exposure was associated with different predictors of response compared to tumors that were naive to ICB, suggesting selective immune effects of previous exposure to anti-CTLA4 ICB. Finally, we developed parsimonious models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 ICB in individual tumors, with validation in smaller independent cohorts limited by the availability of comprehensive data. Broadly, we present a framework to discover predictive features and build models of ICB therapeutic response. Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a strong predictor of response across melanoma subtypes.">
    <meta name="dc.creator" content="Liu, David">
    <meta name="dc.creator" content="Schilling, Bastian">
    <meta name="dc.creator" content="Liu, Derek">
    <meta name="dc.creator" content="Sucker, Antje">
    <meta name="dc.creator" content="Livingstone, Elisabeth">
    <meta name="dc.creator" content="Jerby-Arnon, Livnat">
    <meta name="dc.creator" content="Zimmer, Lisa">
    <meta name="dc.creator" content="Gutzmer, Ralf">
    <meta name="dc.creator" content="Satzger, Imke">
    <meta name="dc.creator" content="Loquai, Carmen">
    <meta name="dc.creator" content="Grabbe, Stephan">
    <meta name="dc.creator" content="Vokes, Natalie">
    <meta name="dc.creator" content="Margolis, Claire A.">
    <meta name="dc.creator" content="Conway, Jake">
    <meta name="dc.creator" content="He, Meng Xiao">
    <meta name="dc.creator" content="Elmarakeby, Haitham">
    <meta name="dc.creator" content="Dietlein, Felix">
    <meta name="dc.creator" content="Miao, Diana">
    <meta name="dc.creator" content="Tracy, Adam">
    <meta name="dc.creator" content="Gogas, Helen">
    <meta name="dc.creator" content="Goldinger, Simone M.">
    <meta name="dc.creator" content="Utikal, Jochen">
    <meta name="dc.creator" content="Blank, Christian U.">
    <meta name="dc.creator" content="Rauschenberg, Ricarda">
    <meta name="dc.creator" content="von Bubnoff, Dagmar">
    <meta name="dc.creator" content="Krackhardt, Angela">
    <meta name="dc.creator" content="Weide, Benjamin">
    <meta name="dc.creator" content="Haferkamp, Sebastian">
    <meta name="dc.creator" content="Kiecker, Felix">
    <meta name="dc.creator" content="Izar, Ben">
    <meta name="dc.creator" content="Garraway, Levi">
    <meta name="dc.creator" content="Regev, Aviv">
    <meta name="dc.creator" content="Flaherty, Keith">
    <meta name="dc.creator" content="Paschen, Annette">
    <meta name="dc.creator" content="Van Allen, Eliezer M.">
    <meta name="dc.creator" content="Schadendorf, Dirk">
    <meta name="dc.subject" content="Cancer genomics">
    <meta name="dc.subject" content="Computational biology and bioinformatics">
    <meta name="dc.subject" content="Melanoma">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Improved survival with ipilimumab in patients with metastatic melanoma; citation_author=FS Hodi; citation_volume=363; citation_publication_date=2010; citation_pages=711-723; citation_doi=10.1056/NEJMoa1003466; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Pembrolizumab versus ipilimumab in advanced melanoma; citation_author=C Robert; citation_volume=372; citation_publication_date=2015; citation_pages=2521-2532; citation_doi=10.1056/NEJMoa1503093; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Overall survival with combined nivolumab and ipilimumab in advanced melanoma; citation_author=JD Wolchok; citation_volume=377; citation_publication_date=2017; citation_pages=1345-1356; citation_doi=10.1056/NEJMoa1709684; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer; citation_author=M Reck; citation_volume=375; citation_publication_date=2016; citation_pages=1823-1833; citation_doi=10.1056/NEJMoa1606774; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial; citation_author=JE Rosenberg; citation_volume=387; citation_publication_date=2016; citation_pages=1909-1920; citation_doi=10.1016/S0140-6736(16)00561-4; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Nivolumab versus everolimus in advanced renal-cell carcinoma; citation_author=RJ Motzer; citation_volume=373; citation_publication_date=2015; citation_pages=1803-1813; citation_doi=10.1056/NEJMoa1510665; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial; citation_author=TY Seiwert; citation_volume=17; citation_publication_date=2016; citation_pages=956-965; citation_doi=10.1016/S1470-2045(16)30066-3; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer; citation_author=NA Rizvi; citation_volume=348; citation_publication_date=2015; citation_pages=124; citation_doi=10.1126/science.aaa1348; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Genetic basis for clinical response to CTLA-4 blockade in melanoma; citation_author=A Snyder; citation_volume=371; citation_publication_date=2014; citation_pages=2189-2199; citation_doi=10.1056/NEJMoa1406498; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Genomic correlates of response to CTLA-4 blockade in metastatic melanoma; citation_author=EM Allen; citation_volume=350; citation_publication_date=2015; citation_pages=207-211; citation_doi=10.1126/science.aad0095; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy; citation_author=R Cristescu; citation_volume=362; citation_publication_date=2018; citation_pages=eaar3593; citation_doi=10.1126/science.aar3593; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=PD-1 blockade induces responses by inhibiting adaptive immune resistance; citation_author=PC Tumeh; citation_volume=515; citation_publication_date=2014; citation_pages=568-571; citation_doi=10.1038/nature13954; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Mutations associated with acquired resistance to PD-1 blockade in melanoma; citation_author=JM Zaretsky; citation_volume=375; citation_publication_date=2016; citation_pages=819-829; citation_doi=10.1056/NEJMoa1604958; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Resistance to checkpoint blockade therapy through inactivation of antigen presentation; citation_author=M Sade-Feldman; citation_volume=8; citation_publication_date=2017; citation_doi=10.1038/s41467-017-01062-w; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy; citation_author=J Gao; citation_volume=167; citation_publication_date=2016; citation_pages=397-404; citation_doi=10.1016/j.cell.2016.08.069; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Loss of PTEN promotes resistance to T cell-mediated immunotherapy; citation_author=W Peng; citation_volume=6; citation_publication_date=2016; citation_pages=202-216; citation_doi=10.1158/2159-8290.CD-15-0283; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma; citation_author=S George; citation_volume=46; citation_publication_date=2017; citation_pages=197-204; citation_doi=10.1016/j.immuni.2017.02.001; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=Sci. Transl. Med.; citation_title=Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance; citation_author=W Roh; citation_volume=9; citation_publication_date=2017; citation_pages=eaah3560; citation_doi=10.1126/scitranslmed.aah3560; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy; citation_author=T Davoli; citation_volume=355; citation_publication_date=2017; citation_pages=eaaf8399; citation_doi=10.1126/science.aaf8399; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma; citation_author=W Hugo; citation_volume=165; citation_publication_date=2016; citation_pages=35-44; citation_doi=10.1016/j.cell.2016.02.065; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Molecular and genetic properties of tumors associated with local immune cytolytic activity; citation_author=MS Rooney, SA Shukla, CJ Wu, G Getz, N Hacohen; citation_volume=160; citation_publication_date=2015; citation_pages=48-61; citation_doi=10.1016/j.cell.2014.12.033; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial; citation_author=JS Weber; citation_volume=17; citation_publication_date=2016; citation_pages=943-955; citation_doi=10.1016/S1470-2045(16)30126-7; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine; citation_author=EM Allen; citation_volume=20; citation_publication_date=2014; citation_pages=682-688; citation_doi=10.1038/nm.3559; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Patterns of genomic evolution in advanced melanoma; citation_author=E Birkeland; citation_volume=9; citation_publication_date=2018; citation_doi=10.1038/s41467-018-05063-1; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Signatures of mutational processes in human cancer; citation_author=LB Alexandrov; citation_volume=500; citation_publication_date=2013; citation_pages=415-421; citation_doi=10.1038/nature12477; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Whole-genome landscapes of major melanoma subtypes; citation_author=NK Hayward; citation_volume=545; citation_publication_date=2017; citation_pages=175-180; citation_doi=10.1038/nature22071; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors; citation_author=D Miao; citation_volume=50; citation_publication_date=2018; citation_pages=1271-1281; citation_doi=10.1038/s41588-018-0200-2; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Allele-specific HLA loss and immune escape in lung cancer evolution; citation_author=N McGranahan; citation_volume=171; citation_publication_date=2017; citation_pages=1259-1271; citation_doi=10.1016/j.cell.2017.10.001; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=Recurrent SERPINB3 and SERPINB4 mutations in patients that respond to anti-CTLA4 immunotherapy; citation_author=N Riaz; citation_volume=48; citation_publication_date=2016; citation_pages=1327-1329; citation_doi=10.1038/ng.3677; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Primary resistance to PD-1 blockade mediated by JAK1/2 mutations; citation_author=DS Shin; citation_volume=7; citation_publication_date=2017; citation_pages=188-201; citation_doi=10.1158/2159-8290.CD-16-1223; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Acquired IFN-γ resistance impairs anti-tumor immunity and gives rise to T cell-resistant melanoma lesions; citation_author=A Sucker; citation_volume=8; citation_publication_date=2017; citation_doi=10.1038/ncomms15440; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles; citation_author=A Subramanian; citation_volume=102; citation_publication_date=2005; citation_pages=15545-15550; citation_doi=10.1073/pnas.0506580102; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Cell Syst.; citation_title=The molecular signatures database hallmark gene-set collection; citation_author=A Liberzon; citation_volume=1; citation_publication_date=2015; citation_pages=417-425; citation_doi=10.1016/j.cels.2015.12.004; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma; citation_author=N Auslander; citation_volume=24; citation_publication_date=2018; citation_pages=1545-1549; citation_doi=10.1038/s41591-018-0157-9; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial; citation_author=L Fehrenbacher; citation_volume=387; citation_publication_date=2016; citation_pages=1837-1846; citation_doi=10.1016/S0140-6736(16)00587-0; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma; citation_author=AC Huang; citation_volume=25; citation_publication_date=2019; citation_pages=454-461; citation_doi=10.1038/s41591-019-0357-y; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response; citation_author=P Jiang; citation_volume=24; citation_publication_date=2018; citation_pages=1550-1558; citation_doi=10.1038/s41591-018-0136-1; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Sci. Rep.; citation_title=12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?; citation_author=JL Messina; citation_volume=2; citation_publication_date=2012; citation_doi=10.1038/srep00765; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Invest.; citation_title=IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade; citation_author=M Ayers; citation_volume=127; citation_publication_date=2017; citation_pages=2930-2940; citation_doi=10.1172/JCI91190; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers; citation_author=C-Y Ock; citation_volume=8; citation_publication_date=2017; citation_doi=10.1038/s41467-017-01018-0; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=Nat. Methods; citation_title=Robust enumeration of cell subsets from tissue expression profiles; citation_author=AM Newman; citation_volume=12; citation_publication_date=2015; citation_pages=453-457; citation_doi=10.1038/nmeth.3337; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade; citation_author=L Jerby-Arnon; citation_volume=175; citation_publication_date=2018; citation_pages=984-997; citation_doi=10.1016/j.cell.2018.09.006; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1; citation_author=DA Barbie; citation_volume=462; citation_publication_date=2009; citation_pages=108-112; citation_doi=10.1038/nature08460; citation_id=CR43">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Tumor and microenvironment evolution during immunotherapy with nivolumab; citation_author=N Riaz; citation_volume=171; citation_publication_date=2017; citation_pages=934-949; citation_doi=10.1016/j.cell.2017.09.028; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab; citation_author=J Weber; citation_volume=27; citation_publication_date=2016; citation_pages=10470; citation_doi=10.1093/annonc/mdw378.01; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma; citation_author=RN Amaria; citation_volume=24; citation_publication_date=2018; citation_pages=1649-1654; citation_doi=10.1038/s41591-018-0197-1; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Sci. Transl. Med.; citation_title=MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma; citation_author=SJ Rodig; citation_volume=10; citation_publication_date=2018; citation_pages=eaar3342; citation_doi=10.1126/scitranslmed.aar3342; citation_id=CR47">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy; citation_author=DB Johnson; citation_volume=7; citation_publication_date=2016; citation_doi=10.1038/ncomms10582; citation_id=CR48">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade; citation_author=N McGranahan; citation_volume=351; citation_publication_date=2016; citation_pages=1463-1469; citation_doi=10.1126/science.aaf1490; citation_id=CR49">
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival; citation_author=LGT Morris; citation_volume=7; citation_publication_date=2016; citation_pages=10051-10063; citation_doi=10.18632/oncotarget.7067; citation_id=CR50">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer; citation_author=D Liu; citation_volume=8; citation_publication_date=2017; citation_doi=10.1038/s41467-017-02320-7; citation_id=CR51">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution; citation_author=SM Dewhurst; citation_volume=4; citation_publication_date=2014; citation_pages=175-185; citation_doi=10.1158/2159-8290.CD-13-0285; citation_id=CR52">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab; citation_author=B Weide; citation_volume=22; citation_publication_date=2016; citation_pages=5487-5496; citation_doi=10.1158/1078-0432.CCR-16-0127; citation_id=CR53">
    <meta name="citation_reference" content="citation_journal_title=JCI Insight; citation_title=Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy; citation_author=MF Fransen; citation_volume=3; citation_publication_date=2018; citation_pages=124507; citation_doi=10.1172/jci.insight.124507; citation_id=CR54">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma; citation_author=CU Blank; citation_volume=24; citation_publication_date=2018; citation_pages=1655-1661; citation_doi=10.1038/s41591-018-0198-0; citation_id=CR55">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother. Cancer; citation_title=nCounter PanCancer immune profiling panel (NanoString Technologies, Seattle, WA).; citation_author=A Cesano; citation_volume=3; citation_publication_date=2015; citation_pages=42; citation_doi=10.1186/s40425-015-0088-7; citation_id=CR56">
    <meta name="citation_reference" content="citation_journal_title=Genome Biol.; citation_title=A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries; citation_author=S Fisher; citation_volume=12; citation_publication_date=2011; citation_doi=10.1186/gb-2011-12-1-r1; citation_id=CR57">
    <meta name="citation_reference" content="citation_journal_title=Nat. Biotechnol.; citation_title=Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing; citation_author=A Gnirke; citation_volume=27; citation_publication_date=2009; citation_pages=182-189; citation_doi=10.1038/nbt.1523; citation_id=CR58">
    <meta name="citation_reference" content="citation_journal_title=Bioinformatics; citation_title=ContEst: estimating cross-contamination of human samples in next generation sequencing data; citation_author=K Cibulskis; citation_volume=27; citation_publication_date=2011; citation_pages=2601-2602; citation_doi=10.1093/bioinformatics/btr446; citation_id=CR59">
    <meta name="citation_reference" content="citation_journal_title=Nat. Biotechnol.; citation_title=Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples; citation_author=K Cibulskis; citation_volume=31; citation_publication_date=2013; citation_pages=213-219; citation_doi=10.1038/nbt.2514; citation_id=CR60">
    <meta name="citation_reference" content="citation_journal_title=Nucleic Acids Res.; citation_title=Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation; citation_author=M Costello; citation_volume=41; citation_publication_date=2013; citation_pages=e67; citation_doi=10.1093/nar/gks1443; citation_id=CR61">
    <meta name="citation_reference" content="citation_journal_title=Bioinformatics; citation_title=Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs; citation_author=CT Saunders; citation_volume=28; citation_publication_date=2012; citation_pages=1811-1817; citation_doi=10.1093/bioinformatics/bts271; citation_id=CR62">
    <meta name="citation_reference" content="citation_journal_title=Hum. Mutat.; citation_title=Oncotator: cancer variant annotation tool; citation_author=AH Ramos; citation_volume=36; citation_publication_date=2015; citation_pages=E2423-E2429; citation_doi=10.1002/humu.22771; citation_id=CR63">
    <meta name="citation_reference" content="citation_journal_title=Nat. Biotechnol.; citation_title=Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes; citation_author=SA Shukla; citation_volume=33; citation_publication_date=2015; citation_pages=1152; citation_doi=10.1038/nbt.3344; citation_id=CR64">
    <meta name="citation_reference" content="citation_journal_title=PloS ONE; citation_title=NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and HLA-B locus protein of known sequence; citation_author=M Nielsen; citation_volume=2; citation_publication_date=2007; citation_pages=e796; citation_doi=10.1371/journal.pone.0000796; citation_id=CR65">
    <meta name="citation_reference" content="citation_journal_title=Biostatistics; citation_title=Circular binary segmentation for the analysis of array-based DNA copy number data; citation_author=AB Olshen, ES Venkatraman, R Lucito, M Wigler; citation_volume=5; citation_publication_date=2004; citation_pages=557-572; citation_doi=10.1093/biostatistics/kxh008; citation_id=CR66">
    <meta name="citation_reference" content="citation_journal_title=Nat. Biotechnol.; citation_title=Absolute quantification of somatic DNA alterations in human cancer; citation_author=SL Carter; citation_volume=30; citation_publication_date=2012; citation_pages=413-421; citation_doi=10.1038/nbt.2203; citation_id=CR67">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov; citation_title=Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets; citation_author=PK Brastianos; citation_volume=5; citation_publication_date=2015; citation_pages=1164-1177; citation_doi=10.1158/2159-8290.CD-15-0369; citation_id=CR68">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Learning the parts of objects by non-negative matrix factorization; citation_author=DD Lee, HS Seung; citation_volume=401; citation_publication_date=1999; citation_pages=788-791; citation_doi=10.1038/44565; citation_id=CR69">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=Metagenes and molecular pattern discovery using matrix factorization; citation_author=JP Brunet; citation_volume=101; citation_publication_date=2004; citation_pages=4164-4169; citation_doi=10.1073/pnas.0308531101; citation_id=CR70">
    <meta name="citation_reference" content="citation_journal_title=Bioinformatics; citation_title=SomaticSignatures: inferring mutational signatures from single-nucleotide variants; citation_author=JS Gehring, B Fischer, M Lawrence, W Huber; citation_volume=31; citation_publication_date=2015; citation_pages=3673-3675; citation_id=CR71">
    <meta name="citation_reference" content="citation_journal_title=BMC Bioinformatics; citation_title=A flexible R package for nonnegative matrix factorization; citation_author=R Gaujoux, C Seoighe; citation_volume=11; citation_publication_date=2010; citation_doi=10.1186/1471-2105-11-367; citation_id=CR72">
    <meta name="citation_reference" content="citation_journal_title=Nucleic Acids Res.; citation_title=COSMIC: exploring the world’s knowledge of somatic mutations in human cancer; citation_author=SA Forbes; citation_volume=43; citation_publication_date=2015; citation_pages=D805-D811; citation_doi=10.1093/nar/gku1075; citation_id=CR73">
    <meta name="citation_reference" content="citation_journal_title=Bioinformatics; citation_title=STAR: ultrafast universal RNA-seq aligner; citation_author=A Dobin; citation_volume=29; citation_publication_date=2013; citation_pages=15-21; citation_doi=10.1093/bioinformatics/bts635; citation_id=CR74">
    <meta name="citation_reference" content="citation_journal_title=BMC Bioinformatics; citation_title=RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome; citation_author=B Li, CN Dewey; citation_volume=12; citation_publication_date=2011; citation_doi=10.1186/1471-2105-12-323; citation_id=CR75">
    <meta name="citation_reference" content="citation_journal_title=Bioinformatics; citation_title=BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis; citation_author=S Durinck; citation_volume=21; citation_publication_date=2005; citation_pages=3439-3440; citation_doi=10.1093/bioinformatics/bti525; citation_id=CR76">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=The immune landscape of cancer; citation_author=V Thorsson; citation_volume=48; citation_publication_date=2018; citation_pages=812-830; citation_doi=10.1016/j.immuni.2018.03.023; citation_id=CR77">
    <meta name="citation_reference" content="Davidson-Pilon C. et al. CamDavidsonPilon/lifelines v.0.18.5. Zenodo 
                  https://doi.org/10.5281/zenodo.2562267
                  
                 (2019).">
    <meta name="citation_reference" content="Waksom M. et al. mwaskom/seaborn v.0.8.1 Zenodo 
                  https://doi.org/10.5281/zenodo.883859
                  
                 (2017).">
    <meta name="citation_author" content="Liu, David">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Schilling, Bastian">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital Würzburg, Würzburg, Germany">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital, Essen, Germany">
    <meta name="citation_author_institution" content="German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany">
    <meta name="citation_author" content="Liu, Derek">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA">
    <meta name="citation_author" content="Sucker, Antje">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital, Essen, Germany">
    <meta name="citation_author_institution" content="German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany">
    <meta name="citation_author" content="Livingstone, Elisabeth">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital, Essen, Germany">
    <meta name="citation_author_institution" content="German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany">
    <meta name="citation_author" content="Jerby-Arnon, Livnat">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Zimmer, Lisa">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital, Essen, Germany">
    <meta name="citation_author_institution" content="German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany">
    <meta name="citation_author" content="Gutzmer, Ralf">
    <meta name="citation_author_institution" content="Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany">
    <meta name="citation_author" content="Satzger, Imke">
    <meta name="citation_author_institution" content="Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany">
    <meta name="citation_author" content="Loquai, Carmen">
    <meta name="citation_author_institution" content="Department of Dermatology, University Medical Center, Mainz, Germany">
    <meta name="citation_author" content="Grabbe, Stephan">
    <meta name="citation_author_institution" content="Department of Dermatology, University Medical Center, Mainz, Germany">
    <meta name="citation_author" content="Vokes, Natalie">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Margolis, Claire A.">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Conway, Jake">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA">
    <meta name="citation_author" content="He, Meng Xiao">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA">
    <meta name="citation_author_institution" content="Biophysics Program, Harvard University, Cambridge, USA">
    <meta name="citation_author" content="Elmarakeby, Haitham">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Dietlein, Felix">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Miao, Diana">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA">
    <meta name="citation_author" content="Tracy, Adam">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Gogas, Helen">
    <meta name="citation_author_institution" content="First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece">
    <meta name="citation_author" content="Goldinger, Simone M.">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital Zürich, Zürich, Switzerland">
    <meta name="citation_author" content="Utikal, Jochen">
    <meta name="citation_author_institution" content="Department of Dermatology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany">
    <meta name="citation_author_institution" content="Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany">
    <meta name="citation_author" content="Blank, Christian U.">
    <meta name="citation_author_institution" content="Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands">
    <meta name="citation_author" content="Rauschenberg, Ricarda">
    <meta name="citation_author_institution" content="Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany">
    <meta name="citation_author_institution" content="National Center for Tumor Diseases, Dresden, Germany">
    <meta name="citation_author_institution" content="German Cancer Research Centre, Heidelberg, Germany">
    <meta name="citation_author" content="von Bubnoff, Dagmar">
    <meta name="citation_author_institution" content="Department of Dermatology, Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany">
    <meta name="citation_author" content="Krackhardt, Angela">
    <meta name="citation_author_institution" content="German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany">
    <meta name="citation_author_institution" content="Medizinische Klinik III, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany">
    <meta name="citation_author" content="Weide, Benjamin">
    <meta name="citation_author_institution" content="Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany">
    <meta name="citation_author" content="Haferkamp, Sebastian">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital Regensburg, Regensburg, Germany">
    <meta name="citation_author" content="Kiecker, Felix">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital Berlin, Berlin, Germany">
    <meta name="citation_author" content="Izar, Ben">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Garraway, Levi">
    <meta name="citation_author_institution" content="Eli Lilly and Co., Indianapolis, USA">
    <meta name="citation_author" content="Regev, Aviv">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Flaherty, Keith">
    <meta name="citation_author_institution" content="Massachusetts General Hospital, Boston, USA">
    <meta name="citation_author" content="Paschen, Annette">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital, Essen, Germany">
    <meta name="citation_author_institution" content="German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany">
    <meta name="citation_author" content="Van Allen, Eliezer M.">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author_institution" content="Broad Institute of Harvard and MIT, Cambridge, USA">
    <meta name="citation_author" content="Schadendorf, Dirk">
    <meta name="citation_author_institution" content="Department of Dermatology, University Hospital, Essen, Germany">
    <meta name="citation_author_institution" content="German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma">
    <meta name="twitter:description" content="Nature Medicine - Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-019-0654-5">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma - Nature Medicine">
    <meta property="og:description" content="Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a strong predictor of response across melanoma subtypes.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-019-0654-5;doi=10.1038/s41591-019-0654-5;subjmeta=114,1634,1813,631,67,69;kwrd=Cancer+genomics,Computational+biology+and+bioinformatics,Melanoma">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-1590198645&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-019-0654-5%26doi%3D10.1038/s41591-019-0654-5%26subjmeta%3D114,1634,1813,631,67,69%26kwrd%3DCancer+genomics,Computational+biology+and+bioinformatics,Melanoma">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-1590198645&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-019-0654-5%26doi%3D10.1038/s41591-019-0654-5%26subjmeta%3D114,1634,1813,631,67,69%26kwrd%3DCancer+genomics,Computational+biology+and+bioinformatics,Melanoma"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-019-0654-5"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-019-0654-5.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-019-0654-5.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2019-12-02">02 December 2019</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma</h1>
                    <ul class="c-article-author-list c-article-author-list--long js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-David-Liu-Aff1-Aff2" data-author-popup="auth-David-Liu-Aff1-Aff2" data-author-search="Liu, David" data-track-context="researcher popup with no profile" data-track-index="1_36">David Liu</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Bastian-Schilling-Aff3-Aff4-Aff5" data-author-popup="auth-Bastian-Schilling-Aff3-Aff4-Aff5" data-author-search="Schilling, Bastian" data-track-context="researcher popup with no profile" data-track-index="2_36">Bastian Schilling</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-8859-4103"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-8859-4103</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a>,<a href="#Aff4" tabindex="-1">4</a>,<a href="#Aff5" tabindex="-1">5</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Derek-Liu-Aff1-Aff2-Aff6" data-author-popup="auth-Derek-Liu-Aff1-Aff2-Aff6" data-author-search="Liu, Derek" data-track-context="researcher popup with no profile" data-track-index="3_36">Derek Liu</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Antje-Sucker-Aff4-Aff5" data-author-popup="auth-Antje-Sucker-Aff4-Aff5" data-author-search="Sucker, Antje" data-track-context="researcher popup with no profile" data-track-index="4_36">Antje Sucker</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a>,<a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Elisabeth-Livingstone-Aff4-Aff5" data-author-popup="auth-Elisabeth-Livingstone-Aff4-Aff5" data-author-search="Livingstone, Elisabeth" data-track-context="researcher popup with no profile" data-track-index="5_36">Elisabeth Livingstone</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a>,<a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Livnat-Jerby_Arnon-Aff2" data-author-popup="auth-Livnat-Jerby_Arnon-Aff2" data-author-search="Jerby-Arnon, Livnat" data-track-context="researcher popup with no profile" data-track-index="6_36">Livnat Jerby-Arnon</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lisa-Zimmer-Aff4-Aff5" data-author-popup="auth-Lisa-Zimmer-Aff4-Aff5" data-author-search="Zimmer, Lisa" data-track-context="researcher popup with no profile" data-track-index="7_36">Lisa Zimmer</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a>,<a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ralf-Gutzmer-Aff7" data-author-popup="auth-Ralf-Gutzmer-Aff7" data-author-search="Gutzmer, Ralf" data-track-context="researcher popup with no profile" data-track-index="8_36">Ralf Gutzmer</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Imke-Satzger-Aff7" data-author-popup="auth-Imke-Satzger-Aff7" data-author-search="Satzger, Imke" data-track-context="researcher popup with no profile" data-track-index="9_36">Imke Satzger</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Carmen-Loquai-Aff8" data-author-popup="auth-Carmen-Loquai-Aff8" data-author-search="Loquai, Carmen" data-track-context="researcher popup with no profile" data-track-index="10_36">Carmen Loquai</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Stephan-Grabbe-Aff8" data-author-popup="auth-Stephan-Grabbe-Aff8" data-author-search="Grabbe, Stephan" data-track-context="researcher popup with no profile" data-track-index="11_36">Stephan Grabbe</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Natalie-Vokes-Aff1-Aff2" data-author-popup="auth-Natalie-Vokes-Aff1-Aff2" data-author-search="Vokes, Natalie" data-track-context="researcher popup with no profile" data-track-index="12_36">Natalie Vokes</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Claire_A_-Margolis-Aff1-Aff2" data-author-popup="auth-Claire_A_-Margolis-Aff1-Aff2" data-author-search="Margolis, Claire A." data-track-context="researcher popup with no profile" data-track-index="13_36">Claire A. Margolis</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jake-Conway-Aff2-Aff6" data-author-popup="auth-Jake-Conway-Aff2-Aff6" data-author-search="Conway, Jake" data-track-context="researcher popup with no profile" data-track-index="14_36">Jake Conway</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Meng_Xiao-He-Aff2-Aff6-Aff9" data-author-popup="auth-Meng_Xiao-He-Aff2-Aff6-Aff9" data-author-search="He, Meng Xiao" data-track-context="researcher popup with no profile" data-track-index="15_36">Meng Xiao He</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a>,<a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Haitham-Elmarakeby-Aff1-Aff2" data-author-popup="auth-Haitham-Elmarakeby-Aff1-Aff2" data-author-search="Elmarakeby, Haitham" data-track-context="researcher popup with no profile" data-track-index="16_36">Haitham Elmarakeby</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Felix-Dietlein-Aff1-Aff2" data-author-popup="auth-Felix-Dietlein-Aff1-Aff2" data-author-search="Dietlein, Felix" data-track-context="researcher popup with no profile" data-track-index="17_36">Felix Dietlein</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Diana-Miao-Aff1-Aff2-Aff6" data-author-popup="auth-Diana-Miao-Aff1-Aff2-Aff6" data-author-search="Miao, Diana" data-track-context="researcher popup with no profile" data-track-index="18_36">Diana Miao</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-1754-2319"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1754-2319</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Adam-Tracy-Aff2" data-author-popup="auth-Adam-Tracy-Aff2" data-author-search="Tracy, Adam" data-track-context="researcher popup with no profile" data-track-index="19_36">Adam Tracy</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Helen-Gogas-Aff10" data-author-popup="auth-Helen-Gogas-Aff10" data-author-search="Gogas, Helen" data-track-context="researcher popup with no profile" data-track-index="20_36">Helen Gogas</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Simone_M_-Goldinger-Aff11" data-author-popup="auth-Simone_M_-Goldinger-Aff11" data-author-search="Goldinger, Simone M." data-track-context="researcher popup with no profile" data-track-index="21_36">Simone M. Goldinger</a><sup class="u-js-hide"><a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jochen-Utikal-Aff12-Aff13" data-author-popup="auth-Jochen-Utikal-Aff12-Aff13" data-author-search="Utikal, Jochen" data-track-context="researcher popup with no profile" data-track-index="22_36">Jochen Utikal</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-5316-0241"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-5316-0241</a></span><sup class="u-js-hide"><a href="#Aff12" tabindex="-1">12</a>,<a href="#Aff13" tabindex="-1">13</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Christian_U_-Blank-Aff14" data-author-popup="auth-Christian_U_-Blank-Aff14" data-author-search="Blank, Christian U." data-track-context="researcher popup with no profile" data-track-index="23_36">Christian U. Blank</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-7945-5846"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7945-5846</a></span><sup class="u-js-hide"><a href="#Aff14" tabindex="-1">14</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ricarda-Rauschenberg-Aff15-Aff16-Aff17" data-author-popup="auth-Ricarda-Rauschenberg-Aff15-Aff16-Aff17" data-author-search="Rauschenberg, Ricarda" data-track-context="researcher popup with no profile" data-track-index="24_36">Ricarda Rauschenberg</a><sup class="u-js-hide"><a href="#Aff15" tabindex="-1">15</a>,<a href="#Aff16" tabindex="-1">16</a>,<a href="#Aff17" tabindex="-1">17</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Dagmar-Bubnoff-Aff18" data-author-popup="auth-Dagmar-Bubnoff-Aff18" data-author-search="von Bubnoff, Dagmar" data-track-context="researcher popup with no profile" data-track-index="25_36">Dagmar von Bubnoff</a><sup class="u-js-hide"><a href="#Aff18" tabindex="-1">18</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Angela-Krackhardt-Aff5-Aff19" data-author-popup="auth-Angela-Krackhardt-Aff5-Aff19" data-author-search="Krackhardt, Angela" data-track-context="researcher popup with no profile" data-track-index="26_36">Angela Krackhardt</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a>,<a href="#Aff19" tabindex="-1">19</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Benjamin-Weide-Aff20" data-author-popup="auth-Benjamin-Weide-Aff20" data-author-search="Weide, Benjamin" data-track-context="researcher popup with no profile" data-track-index="27_36">Benjamin Weide</a><sup class="u-js-hide"><a href="#Aff20" tabindex="-1">20</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sebastian-Haferkamp-Aff21" data-author-popup="auth-Sebastian-Haferkamp-Aff21" data-author-search="Haferkamp, Sebastian" data-track-context="researcher popup with no profile" data-track-index="28_36">Sebastian Haferkamp</a><sup class="u-js-hide"><a href="#Aff21" tabindex="-1">21</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Felix-Kiecker-Aff22" data-author-popup="auth-Felix-Kiecker-Aff22" data-author-search="Kiecker, Felix" data-track-context="researcher popup with no profile" data-track-index="29_36">Felix Kiecker</a><sup class="u-js-hide"><a href="#Aff22" tabindex="-1">22</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ben-Izar-Aff1-Aff2" data-author-popup="auth-Ben-Izar-Aff1-Aff2" data-author-search="Izar, Ben" data-track-context="researcher popup with no profile" data-track-index="30_36">Ben Izar</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Levi-Garraway-Aff23" data-author-popup="auth-Levi-Garraway-Aff23" data-author-search="Garraway, Levi" data-track-context="researcher popup with no profile" data-track-index="31_36">Levi Garraway</a><sup class="u-js-hide"><a href="#Aff23" tabindex="-1">23</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Aviv-Regev-Aff2" data-author-popup="auth-Aviv-Regev-Aff2" data-author-search="Regev, Aviv" data-track-context="researcher popup with no profile" data-track-index="32_36">Aviv Regev</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3293-3158"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3293-3158</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Keith-Flaherty-Aff24" data-author-popup="auth-Keith-Flaherty-Aff24" data-author-search="Flaherty, Keith" data-track-context="researcher popup with no profile" data-track-index="33_36">Keith Flaherty</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-3402-0478"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-3402-0478</a></span><sup class="u-js-hide"><a href="#Aff24" tabindex="-1">24</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Annette-Paschen-Aff4-Aff5" data-author-popup="auth-Annette-Paschen-Aff4-Aff5" data-author-search="Paschen, Annette" data-track-context="researcher popup with no profile" data-track-index="34_36">Annette Paschen</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a>,<a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Eliezer_M_-Allen-Aff1-Aff2" data-author-popup="auth-Eliezer_M_-Allen-Aff1-Aff2" data-author-search="Van Allen, Eliezer M." data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="35_36">Eliezer M. Van Allen<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-0201-4444"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-0201-4444</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 36 authors for this article" title="Show all 36 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Dirk-Schadendorf-Aff4-Aff5" data-author-popup="auth-Dirk-Schadendorf-Aff4-Aff5" data-author-search="Schadendorf, Dirk" data-corresp-id="c2" data-track-context="researcher popup with no profile" data-track-index="36_36">Dirk Schadendorf<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3524-7858"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3524-7858</a></span><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a>,<a href="#Aff5" tabindex="-1">5</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;25</b>,&nbsp;<span class="u-visually-hidden">pages </span>1916–1927 (<span data-test="article-publication-year">2019</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">61k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">638 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">138 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-019-0654-5/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            
                
                    <p class="u-mt-0">An <a href="https://doi.org/10.1038/s41591-020-0975-4" class="relation-link" data-track="click" data-track-action="view linked article" data-track-label="link">Author Correction</a> to this article was published on 19 June 2020</p>
                
            
        </div>
    

    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            <p class="u-mt-0">This article has been <a href="#change-history">updated</a></p>
        </div>
    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (<i>n</i> = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of response was confounded by melanoma subtype, whereas multiple novel genomic and transcriptomic features predicted selective response, including features associated with MHC-I and MHC-II antigen presentation. Furthermore, previous anti-CTLA4 ICB exposure was associated with different predictors of response compared to tumors that were naive to ICB, suggesting selective immune effects of previous exposure to anti-CTLA4 ICB. Finally, we developed parsimonious models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 ICB in individual tumors, with validation in smaller independent cohorts limited by the availability of comprehensive data. Broadly, we present a framework to discover predictive features and build models of ICB therapeutic response.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-022-32838-4/MediaObjects/41467_2022_32838_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-022-32838-4?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41467-022-32838-4">Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">19 September 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-022-15714-5/MediaObjects/41598_2022_15714_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41598-022-15714-5?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41598-022-15714-5">Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">07 July 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41525-021-00169-w/MediaObjects/41525_2021_169_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41525-021-00169-w?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41525-021-00169-w">Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">04 February 2021</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749521132,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>While ICB has resulted in durable clinical response in multiple tumor types<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010)." href="#ref-CR1" id="ref-link-section-d66811012e1253">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015)." href="#ref-CR2" id="ref-link-section-d66811012e1253_1">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017)." href="#ref-CR3" id="ref-link-section-d66811012e1253_2">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016)." href="#ref-CR4" id="ref-link-section-d66811012e1253_3">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016)." href="#ref-CR5" id="ref-link-section-d66811012e1253_4">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015)." href="#ref-CR6" id="ref-link-section-d66811012e1253_5">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956–965 (2016)." href="/articles/s41591-019-0654-5#ref-CR7" id="ref-link-section-d66811012e1256">7</a></sup>, only a subset of patients respond, and predictors of response are not fully characterized. Both tumor-intrinsic and tumor-extrinsic biomarkers of response and resistance to ICB in melanoma have been proposed, including tumor mutational burden (TMB) and neoantigen load<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124 (2015)." href="#ref-CR8" id="ref-link-section-d66811012e1260">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014)." href="#ref-CR9" id="ref-link-section-d66811012e1260_1">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015)." href="#ref-CR10" id="ref-link-section-d66811012e1260_2">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018)." href="/articles/s41591-019-0654-5#ref-CR11" id="ref-link-section-d66811012e1263">11</a></sup>, immunohistological detection of PD-L1 and CD8<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)." href="/articles/s41591-019-0654-5#ref-CR12" id="ref-link-section-d66811012e1267">12</a></sup> and genetic alterations affecting antigen presentation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016)." href="/articles/s41591-019-0654-5#ref-CR13" id="ref-link-section-d66811012e1271">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017)." href="/articles/s41591-019-0654-5#ref-CR14" id="ref-link-section-d66811012e1274">14</a></sup>, interferon (IFN)-γ signaling pathways<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 (2016)." href="/articles/s41591-019-0654-5#ref-CR15" id="ref-link-section-d66811012e1278">15</a></sup>, alternative survival and proliferation pathways<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016)." href="/articles/s41591-019-0654-5#ref-CR13" id="ref-link-section-d66811012e1283">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202–216 (2016)." href="/articles/s41591-019-0654-5#ref-CR16" id="ref-link-section-d66811012e1286">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="George, S. et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46, 197–204 (2017)." href="/articles/s41591-019-0654-5#ref-CR17" id="ref-link-section-d66811012e1289">17</a></sup> and aneuploidy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)." href="/articles/s41591-019-0654-5#ref-CR18" id="ref-link-section-d66811012e1293">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Davoli, T. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017)." href="/articles/s41591-019-0654-5#ref-CR19" id="ref-link-section-d66811012e1296">19</a></sup>. Gene expression signatures expressed in tumors<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016)." href="/articles/s41591-019-0654-5#ref-CR20" id="ref-link-section-d66811012e1300">20</a></sup> and the tumor immune microenvironment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. &amp; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015)." href="/articles/s41591-019-0654-5#ref-CR21" id="ref-link-section-d66811012e1304">21</a></sup> have also been implicated. However, these observations have often been made in preclinical models or in small clinical cohorts without validation in larger, independent cohorts of patients with melanoma. Furthermore, whether these observations are exclusive to a specific ICB regimen (that is, anti-PD1, anti-CTLA4 or a combination of these) is incompletely characterized. Broadly, the expanding suite of pathways that has been invoked to mediate selective ICB response in melanoma indicates that integrated systems biology models to predict response and survival are necessary, but these have yet to be well developed.</p><p>Clinically, the optimal role of anti-CTLA4 in conjunction<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017)." href="/articles/s41591-019-0654-5#ref-CR3" id="ref-link-section-d66811012e1311">3</a></sup> or sequentially<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Weber, J. S. et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 17, 943–955 (2016)." href="/articles/s41591-019-0654-5#ref-CR22" id="ref-link-section-d66811012e1315">22</a></sup> with anti-PD1 ICB is unclear. Understanding the differential biology underlying the response to anti-PD1 ICB in tumors with and without previous anti-CTLA4 therapy may inform the rational design of combination therapies and optimize therapy selection for individual patients.</p><p>Thus, we performed an integrative study employing genomic, transcriptomic and clinical data from a comprehensively clinically annotated and sequenced cohort of 144 patients with advanced melanoma undergoing anti-PD1 ICB with and without previous anti-CTLA4 ICB to discover biomarkers of response and resistance, and develop clinically applicable parsimonious predictive models.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Genomic and clinical cohort characteristics and melanoma subtypes</h3><p>We identified 206 patients diagnosed with advanced melanoma and treated with anti-PD1 ICB, and performed whole-exome sequencing (WES) on matched pretreatment tumor samples and normal tissue<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Van Allen, E. M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20, 682–688 (2014)." href="/articles/s41591-019-0654-5#ref-CR23" id="ref-link-section-d66811012e1334">23</a></sup>, and whole-transcriptome sequencing (RNA-seq) on available pretreatment tumor tissue. After quality control (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), WES data from 144 patients and RNA-seq data from 121 patients were available for final evaluation (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig6">1</a>). Best objective response (BOR) to anti-PD1 ICB using RECIST (v.1.1) criteria (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>) included 45% with progressive disease (PD), 14% with stable disease (SD), 3% with mixed response (MR), 26% with partial response (PR) and 12% with complete response (CR; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1a</a>), for an overall response rate of 38%. Overall, 73% were cutaneous melanomas, 13% were of occult origin, 7% were mucosal and 7% were acral in origin. A total of 44% (<i>n</i> = 64) of patients had previous treatment with ipilimumab, whereas 56% (<i>n</i> = 80) were naive to ipilimumab. The median follow-up for survival was 29.9 months. Other clinical characteristics are detailed in Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-019-0654-5#Tab1">1</a>.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Cohort genomic and clinical characteristics and association of TMB with response."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Cohort genomic and clinical characteristics and association of TMB with response.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="653"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>a</b>, CoMut plot showing association between clinical and genomic characteristics. Each column represents a tumor. Tumors are ordered by best RECIST criteria response (CR, PR, PD, SD or MR), and within each response subgroup by decreasing nonsynonymous (Nonsyn) mutational load (top row). Nonsynonymous mutational burden is further subdivided into clonal (purple) and subclonal (light purple) mutational load. Mutational signatures (sig) refer to the inferred relative contribution of UV-induced mutations, alkylating DNA damage process and other mutational signatures (aging+). The primary type of melanoma (skin, occult, acral or mucosal) is indicated. Tumor purity is the inferred proportion of the tumor sample that is from cancer cells compared to other cell types (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>). The dominant mutational signature (that is, the mutational signature associated with the highest proportion of mutations) is indicated. Mutations in <i>BRAF</i>, <i>NRAS</i> and <i>NF1</i> are shown for each tumor. <b>b</b>, Mutational load (mut load) in progressors (<i>n</i> = 65 patients), responders (<i>n</i> = 55 patients) and patients with SD and MR (<i>n</i> = 24 patients). Nonsynonymous mutational load is higher in responders (CR and PR) than in progressors (two-sided MWW, <i>P</i> = 0.026), but is not significantly different between responders and patients having SD or MR as the best RECIST response (two-sided MWW, <i>P</i> = 0.14). <b>c</b>, Mutational load by melanoma type. Different melanoma types have different mutational loads (Kruskal–Wallis, <i>P</i> = 2.4 × 10<sup>−</sup><sup>5</sup>): mutational load is higher in cutaneous and occult melanomas (<i>n</i> = 124 patients) than in acral and mucosal melanomas (<i>n</i> = 20 patients; median 297.5 versus 58; two-sided MWW, <i>P</i> = 1.1 × 10<sup>−6</sup>). <b>d</b>, Response to anti-PD1 ICB by melanoma type. Cutaneous and occult melanomas (<i>n</i> = 124 patients) have higher response rates (~40% CR and PR) versus acral and mucosal melanomas (<i>n</i> = 20 patients, 20%; two-sided Fisher’s exact test, <i>P</i> = 0.06). <b>e</b>, Mutational load in responders versus progressors stratified by melanoma type. There was no significant difference between responder and progressor mutational loads when melanomas were stratified by type (two-sided MWW; progressors versus responders (PD/R): skin (<i>n</i> = 42/43), <i>P</i> = 0.27; occult (<i>n</i> = 10/8), <i>P</i> = 0.35; acral (<i>n</i> = 7/2), <i>P</i> = 0.19; mucosal (<i>n</i> = 6/2), <i>P</i> = 0.40). Mutational load was also not a significant predictor of response in combined logistic regression after adjusting for melanoma type (<i>P</i> = 0.24). <b>f</b>, TMB in responders versus nonresponders, stratified by skin or occult melanomas versus mucosal or acral melanomas. Within each subgroup, responders trended toward having higher TMB than nonresponders (cutaneous/occult (<i>n</i> = 52 progressors and 51 responders): MWW, <i>P</i> = 0.14; mucosal/acral (<i>n</i> = 13 progressors and 4 responders): MWW, <i>P</i> = 0.08). Notably, responders with mucosal or acral melanoma (<i>n</i> = 4) had a lower mutational load than progressors with cutaneous or occult melanoma (<i>n</i> = 52; MWW, <i>P</i> = 0.03). Boxplots: box limits indicate the IQR (25th to 75th percentiles), with a center line indicating the median. Whiskers show the value ranges up to 1.5 × IQR above the 75th or below the 25th percentiles, with outliers beyond those ranges shown as individual points. *<i>P</i> &lt; 0.05, **<i>P</i> &lt; 0.01, ***<i>P</i> &lt; 0.001. NS, not significant.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Cohort clinical characteristics</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-019-0654-5/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Overall the median nonsynonymous TMB was 6.5 mutations per Mb (250.5 mutations per exome), with an interquartile range (IQR) of 2.0–14.4 mutations per Mb (77.75–578.5 mutations per exome). Overall, 39% of tumors had <i>BRAF</i> mutations, 30% had <i>NRAS</i> mutations and 17% had <i>NF1</i> mutations (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1a</a>). The median tumor purity (the proportion of sample DNA from tumor cells) was 0.67 (IQR 0.46–0.83) and the median tumor heterogeneity (the proportion of subclonal mutations) was 0.17 (IQR 0.12–0.25). The median purity-corrected tumor ploidy (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>) was 2.15 (IQR 2.01–3.12), with 38% of tumors inferred to have genome doubling, consistent with previous reports<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Birkeland, E. et al. Patterns of genomic evolution in advanced melanoma. Nat. Commun. 9, 2665 (2018)." href="/articles/s41591-019-0654-5#ref-CR24" id="ref-link-section-d66811012e2005">24</a></sup>. The predominant mutational signature in most tumors was related to ultraviolet (UV) exposure<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)." href="/articles/s41591-019-0654-5#ref-CR25" id="ref-link-section-d66811012e2009">25</a></sup> (69% related to UV, 3% related to alkylating chemotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)." href="/articles/s41591-019-0654-5#ref-CR25" id="ref-link-section-d66811012e2013">25</a></sup> and 28% related to another predominant mutational signature, mostly associated with aging<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)." href="/articles/s41591-019-0654-5#ref-CR25" id="ref-link-section-d66811012e2017">25</a></sup>; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1a</a>). Individual tumor characteristics are detailed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">1</a>.</p><p>To discover differential features associated with response, we compared clinical responders (<i>n</i> = 55) to progressors (<i>n</i> = 65), excluding patients with SD (<i>n</i> = 20) and MR (<i>n</i> = 4) as the BOR. Overall survival (OS) and progression-free survival (PFS) were significantly different between these groups (log-rank <i>P</i> &lt; 0.00001 for both comparisons; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig7">2a,b</a>).</p><p>TMB was higher in responders than in progressors (Mann–Whitney–Wilcoxon (MWW), <i>P</i> = 0.026; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1b</a>), but there was substantial overlap between responders and progressors. We hypothesized that the relationship between response and TMB might further be confounded by melanoma subtype. TMB was significantly different between different melanoma subtypes (Kruskal–Wallis, <i>P</i> = 2.4 × 10<sup>−5</sup>; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1c</a>), with cutaneous and occult melanomas having similar and higher TMB than acral and mucosal melanomas<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175–180 (2017)." href="/articles/s41591-019-0654-5#ref-CR26" id="ref-link-section-d66811012e2067">26</a></sup> (median of 297.5 versus 58, nonsynonymous mutations; MWW, <i>P</i> = 1.1 × 10<sup>−6</sup>), with a higher response rate (~40% versus ~20%; Fisher’s exact test, <i>P</i> = 0.06; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1d</a>). When stratified by melanoma subtype, responders did not have significantly higher TMB than nonresponders (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1e</a>), and, in multivariate logistic regression adjusting for melanoma subtype, TMB was not a significant predictor (<i>P</i> = 0.24). Strikingly, responders with mucosal or acral melanoma had a lower TMB than progressors with cutaneous or occult melanoma (MWW, <i>P</i> = 0.03; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig1">1f</a>), suggesting that disease subtype confounds the association between TMB and response to anti-PD1 therapy.</p><h3 class="c-article__sub-heading" id="Sec4">Genomic and transcriptomic features associated with response</h3><p>Higher tumor purity and heterogeneity were associated with progression (MWW, <i>P</i> = 0.04 and <i>P</i> = 0.02, respectively; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2a,c</a>), whereas ploidy was lower in progressors (MWW, <i>P</i> = 0.04; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2b</a>). The proportion of the tumor genome with copy number alterations (CNAs) trended toward being higher in patients with PD (MWW, <i>P</i> = 0.09; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig7">2c</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Genomic and transcriptomic features associated with response."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Genomic and transcriptomic features associated with response.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="852"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>All <i>P</i> values are unadjusted, unless otherwise indicated. <b>a</b>, Tumor heterogeneity, defined as the proportion of subclonal mutations in each tumor (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), in responders (CR or PR) versus progressors (PD). Progressors (<i>n</i> = 65 patients) had greater heterogeneity than responders (<i>n</i> = 55 patients; two-sided MWW, <i>P</i> = 0.02). <b>b</b>, Tumor ploidy, defined as the overall genomic copy number (a normal diploid cell has a copy number of 2; <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), in responders versus progressors. Responders (<i>n</i> = 55 patients) had higher tumor ploidy than progressors (<i>n</i> = 65 patients; two-sided MWW, <i>P</i> = 0.04). <b>c</b>, Tumor purity, defined as the proportion of DNA from tumor versus other cells in the sample (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), in responders versus progressors. Progressors (<i>n</i> = 65 patients) had higher tumor purity than responders (<i>n</i> = 55 patients; two-sided MWW, <i>P</i> = 0.04). <b>d</b>, Response versus progression in <i>TAP2-</i>amplified tumors versus other tumors. <i>TAP2</i> amplification (<i>n</i> = 6 patients) was associated with response (two-sided Fisher’s exact test, <i>P</i> = 0.008). <b>e</b>, Response versus progression in tumors with amplified MHC-I HLA genes (<i>HLA-A</i>, <i>HLA-B</i> or <i>HLA-C</i>) versus other tumors. MHC-I HLA amplification (<i>n</i> = 6 patients) was associated with response (two-sided Fisher’s exact test, <i>P</i> = 0.008). <b>f</b>, Venn diagram showing the overlap of <i>TAP2</i>-amplified tumors and tumors with amplification of MHC-I HLA genes. Four tumors had amplifications on chromosome 6, including the MHC-I genes <i>HLA-A</i>, <i>HLA-B</i>, <i>HLA-C</i> and <i>TAP2</i> and two tumors each had amplifications in one but not the other region, for a total of eight tumors with amplifications in either. <b>g</b>, Difference in the median expression and two-sided MWW <i>P</i> value of association between 938 immune-related genes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Cesano, A. nCounter PanCancer immune profiling panel (NanoString Technologies, Seattle, WA). J. Immunother. Cancer 3, 42 (2015)." href="/articles/s41591-019-0654-5#ref-CR56" id="ref-link-section-d66811012e2248">56</a></sup> and features in responders versus progressors. Expression levels of MHC-II HLA genes (red), MHC-I HLA genes and antigen-presentation machinery (APM)-related genes (orange) are shown. <b>h</b>, Hierarchical clustering of the correlation matrix between genomic, clinical and transcriptomic features associated with response. Color indicates the Pearson correlation between features, from perfect negative correlation (Pearson, <i>r</i> = −1, blue) to perfect positive correlation (Pearson, <i>r</i> = 1, red). An immune-related cluster of MHC-I- and MHC-II-related gene expression is observed, with subclusters of MHC-I and MHC-II genes. Mutational and neoantigen load are highly correlated and form a cluster independently from the immune cluster (for example, Pearson correlation, <i>r</i> = 0.15, <i>P</i> = 0.11 between ssGSEA of MHC-II HLA genes and nonsynonymous mutational load). Purity is negatively correlated with the immune cluster and is independent of ploidy and heterogeneity. The sample size for each correlation depended on the number of available data points: correlations involving exclusively genomic or clinical data had <i>n</i> = 144 tumor samples, whereas correlations involving transcriptomic features had <i>n</i> = 121 tumor samples with data available. Tx, treatment. Boxplots: box limits indicate the IQR (25th to 75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5 × IQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points. *<i>P</i> &lt; 0.05, **<i>P</i> &lt; 0.01, ***<i>P</i> &lt; 0.001; NS, not significant.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Given these observations, we performed an unbiased analysis for single-gene predictors of response to anti-PD1 ICB across all mutated genes detected in this cohort. After multiple-hypothesis test correction, no genes were significantly associated with response or resistance to therapy (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig8">3a</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">2</a>), highlighting the large sample sizes needed for adequate power to detect these associations<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271–1281 (2018)." href="/articles/s41591-019-0654-5#ref-CR27" id="ref-link-section-d66811012e2300">27</a></sup>. We observed only rare mutations in major histocompatibility complex class I (MHC-I) antigen-presentation genes (<i>TAP1</i>, <i>TAP2</i>, <i>B2M</i>, <i>HLA-A</i>, <i>HLA-B</i> and <i>HLA-C</i>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017)." href="/articles/s41591-019-0654-5#ref-CR14" id="ref-link-section-d66811012e2323">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017)." href="/articles/s41591-019-0654-5#ref-CR28" id="ref-link-section-d66811012e2326">28</a></sup>. Mutations in <i>SERPINB3</i> or <i>SERPINB4</i><sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Riaz, N. et al. Recurrent SERPINB3 and SERPINB4 mutations in patients that respond to anti-CTLA4 immunotherapy. Nat. Genet. 48, 1327–1329 (2016)." href="/articles/s41591-019-0654-5#ref-CR29" id="ref-link-section-d66811012e2336">29</a></sup> were not associated with response <i>(</i>Fisher’s exact test, <i>P</i> = 0.51 and <i>P</i> = 1.0, respectively). Loss of heterozygosity (LOH) in <i>B2M</i><sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017)." href="/articles/s41591-019-0654-5#ref-CR14" id="ref-link-section-d66811012e2351">14</a></sup> was found in 9 of 55 (16%) responders and 16 of 65 (25%) progressors (odds ratio (OR) = 0.6) but was not significantly associated with resistance (Fisher’s exact test, <i>P</i> = 0.37). LOH in <i>HLA-A</i>, <i>HLA-B</i> or <i>HLA-C</i><sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017)." href="/articles/s41591-019-0654-5#ref-CR28" id="ref-link-section-d66811012e2367">28</a></sup> was not associated with response or resistance to therapy (Fisher’s exact test, <i>P</i> = 0.52, <i>P</i> = 0.57 and <i>P</i> = 0.84, respectively). Confirming previous findings, LOH of <i>JAK1</i><sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016)." href="/articles/s41591-019-0654-5#ref-CR13" id="ref-link-section-d66811012e2383">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017)." href="/articles/s41591-019-0654-5#ref-CR30" id="ref-link-section-d66811012e2386">30</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Sucker, A. et al. Acquired IFN-γ resistance impairs anti-tumor immunity and gives rise to T cell-resistant melanoma lesions. Nat. Commun. 8, 15440 (2017)." href="/articles/s41591-019-0654-5#ref-CR31" id="ref-link-section-d66811012e2389">31</a></sup> was associated with resistance (OR = 0.33; Fisher’s exact test, <i>P</i> = 0.02). Biallelic <i>CDKN2A</i> alteration<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271–1281 (2018)." href="/articles/s41591-019-0654-5#ref-CR27" id="ref-link-section-d66811012e2400">27</a></sup> was found in 15 of 55 (27%) responders and 25 of 65 (38%) progressors (OR = 0.6), but was not significant (Fisher’s exact test, <i>P</i> = 0.24).</p><p>We also performed an unbiased analysis of the association between focal gene amplifications and response to therapy. While no gene amplification was significant after multiple-hypothesis test correction (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig8">3b</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">3</a>), amplification of <i>TAP2</i>, an integral part of the MHC-I antigen-loading pathway, was found exclusively in responders to therapy (<i>n</i> = 6; Fisher’s exact test, <i>P</i> = 0.008; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2d</a>). <i>TAP2</i> is located at 6p21 in a region encoding both MHC-I and MHC-II human leukocyte antigen (HLA) loci, and four out of six <i>TAP2</i> amplifications were associated with larger amplifications across the region, while two out of six amplifications were more focal (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig9">4</a>). Notably, tumors with amplifications in this region encompassing the MHC-I-related <i>HLA-A</i>, <i>HLA-B</i> and <i>HLA-C</i> genes (a region of approximately 1.5 Mb; <i>n</i> = 6) were also associated with response to therapy (Fisher’s exact test, <i>P</i> = 0.008; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2e</a>), with four out of six also having amplifications in <i>TAP2</i>. Altogether, eight patients had amplification of either <i>TAP2</i> or <i>HLA-A</i>, <i>HLA-B</i> or <i>HLA-C</i> amplification (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2f</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig9">4</a>), and were exclusively responders (Fisher’s exact test, <i>P</i> = 0.001).</p><p>We then examined the expression of antigen-presentation molecules and their association with response. Interestingly, expression of all 13 MHC-II-associated HLA genes was higher in responders (collective two-sided binomial test, <i>P</i> = 0.0002; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2g</a>), with four genes (<i>HLA-DMA</i>, <i>HLA-DMB</i>, <i>HLA-DOB</i> and <i>HLA-DOB</i>) individually passing a statistical significance threshold (MWW, <i>P</i> &lt; 0.05; Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">4</a>). MHC-I antigen-presentation genes all trended toward having higher expression in responders (collective two-sided binomial test, <i>P</i> = 0.02; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2g</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">4</a>), but none passed the statistical significance threshold.</p><p>To examine pathways differentially enriched in responders versus progressors, we next performed unbiased gene set enrichment analysis (GSEA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)." href="/articles/s41591-019-0654-5#ref-CR32" id="ref-link-section-d66811012e2523">32</a></sup>; <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>) using the Hallmark gene sets<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Liberzon, A. et al. The molecular signatures database hallmark gene-set collection. Cell Syst. 1, 417–425 (2015)." href="/articles/s41591-019-0654-5#ref-CR33" id="ref-link-section-d66811012e2530">33</a></sup>. A total of 24 pathways were enriched (false discovery rate (FDR), <i>q</i> &lt; 0.1) in responders, and 5 of the top 6 enriched pathways were immune related, including IFN-γ response, genes involved in allograft rejection, complement, the inflammatory response and interleukin (IL)-6–JAK–STAT3 signaling (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">5</a>). No pathways were significantly enriched in progressors.</p><p>We further evaluated various transcriptomic signatures<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)." href="/articles/s41591-019-0654-5#ref-CR18" id="ref-link-section-d66811012e2543">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Davoli, T. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017)." href="/articles/s41591-019-0654-5#ref-CR19" id="ref-link-section-d66811012e2546">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. &amp; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015)." href="/articles/s41591-019-0654-5#ref-CR21" id="ref-link-section-d66811012e2549">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545–1549 (2018)." href="#ref-CR34" id="ref-link-section-d66811012e2552">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016)." href="#ref-CR35" id="ref-link-section-d66811012e2552_1">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454–461 (2019)." href="#ref-CR36" id="ref-link-section-d66811012e2552_2">36</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018)." href="#ref-CR37" id="ref-link-section-d66811012e2552_3">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012)." href="#ref-CR38" id="ref-link-section-d66811012e2552_4">38</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017)." href="#ref-CR39" id="ref-link-section-d66811012e2552_5">39</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Ock, C.-Y. et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat. Commun. 8, 1050 (2017)." href="/articles/s41591-019-0654-5#ref-CR40" id="ref-link-section-d66811012e2555">40</a></sup> that had been proposed and demonstrated in various settings to be associated with response to immunotherapy (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), but we found no significant differences (<i>P</i> &lt; 0.05) in these signatures between responders and progressors within our cohort (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">6</a>).</p><p>Immune infiltrate has been associated with response to immunotherapy across multiple cancer types and immune therapies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)." href="/articles/s41591-019-0654-5#ref-CR12" id="ref-link-section-d66811012e2571">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545–1549 (2018)." href="/articles/s41591-019-0654-5#ref-CR34" id="ref-link-section-d66811012e2574">34</a></sup>. We inferred the absolute level of immune infiltrate within each sample using an immune deconvolution algorithm (CIBERSORT<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015)." href="/articles/s41591-019-0654-5#ref-CR41" id="ref-link-section-d66811012e2578">41</a></sup> using the LM22 signature matrix). We found no significant difference in the total immune infiltrate or abundance of individual immune cell subsets in responders versus progressors (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">7</a>). We also generated profiles of expression of immune cell subset signatures derived from single-cell analyses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997 (2018)." href="/articles/s41591-019-0654-5#ref-CR42" id="ref-link-section-d66811012e2585">42</a></sup> and found that the expression of multiple signatures was significantly higher (unadjusted MWW, <i>P</i> &lt; 0.05) in responders versus progressors, including for signatures of overall immune infiltrate, T cells, B cells, macrophages, CD8<sup>+</sup> cytotoxic exhausted T cells and CD4<sup>+</sup> exhausted T cells (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">7</a>). Although the strength of association differed by deconvolution method, both approaches generally agreed on the direction of association, providing evidence for a moderate association of immune infiltrate with the response to anti-PD1 ICB.</p><h3 class="c-article__sub-heading" id="Sec5">Correlations between molecular features</h3><p>To understand the relationship between predictors of response, we performed hierarchical clustering of the correlation coefficients between associated predictors (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig2">2h</a>). Clustered features are correlated and may reflect the same underlying biology, whereas separate clusters may reflect independent feature categories. A large immune-related cluster with MHC-II- and MHC-I-related subclusters was observed, with a separate independent cluster of mutation- and neoantigen-load-related features, suggesting independent feature categories. Tumor purity was negatively correlated with the immune cluster, suggesting that low tumor purity may be a proxy for higher immune infiltrates within the tumor sample. Other features, including tumor heterogeneity and ploidy, were independent from these two clusters. Extending this analysis to previously hypothesized signatures and Hallmark gene set signatures (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig10">5</a>), immune activity signatures, including signatures of cytolytic<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. &amp; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015)." href="/articles/s41591-019-0654-5#ref-CR21" id="ref-link-section-d66811012e2614">21</a></sup> and cytotoxic<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Davoli, T. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017)." href="/articles/s41591-019-0654-5#ref-CR19" id="ref-link-section-d66811012e2618">19</a></sup> activity, IFN-γ and T effector cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)." href="/articles/s41591-019-0654-5#ref-CR18" id="ref-link-section-d66811012e2622">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016)." href="/articles/s41591-019-0654-5#ref-CR35" id="ref-link-section-d66811012e2625">35</a></sup>, immune chemokines<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012)." href="/articles/s41591-019-0654-5#ref-CR38" id="ref-link-section-d66811012e2630">38</a></sup> and single-cell-derived immune cell signatures<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997 (2018)." href="/articles/s41591-019-0654-5#ref-CR42" id="ref-link-section-d66811012e2634">42</a></sup>, clustered together. A tumor-intrinsic resistance program signature<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997 (2018)." href="/articles/s41591-019-0654-5#ref-CR42" id="ref-link-section-d66811012e2638">42</a></sup>, signatures of T cell dysfunction and exclusion<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018)." href="/articles/s41591-019-0654-5#ref-CR37" id="ref-link-section-d66811012e2642">37</a></sup> and comparative immune-checkpoint gene expression<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545–1549 (2018)." href="/articles/s41591-019-0654-5#ref-CR34" id="ref-link-section-d66811012e2646">34</a></sup> were distinct from the immune cluster. Overall, these findings suggested that multiple previously hypothesized predictors of ICB response reflect the same underlying biological state and additional independent classes of predictors exist that may provide additional predictive power.</p><h3 class="c-article__sub-heading" id="Sec6">Previous exposure to anti-CTLA4 ICB</h3><p>Our cohort contained patients with previous exposure to ipilimumab in anti-CTLA4 ICB (<i>n</i> = 60) and patients who were naive to ipilimumab (<i>n</i> = 84; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig3">3a</a>). Despite the groups having similar response rates (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig3">3b</a>), we hypothesized that these two groups might have differential predictors of response and resistance to anti-PD1 ICB. We performed a focused analysis of patients who were treated with ipilimumab and biopsied after treatment (<i>n</i> = 44 with WES and <i>n</i> = 34 with RNA-seq) versus patients who were naive to ipilimumab (<i>n</i> = 84 with WES and <i>n</i> = 71 with RNA-seq). A composite, rank-based score of MHC-II HLA expression (single-sample GSEA (ssGSEA)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009)." href="/articles/s41591-019-0654-5#ref-CR43" id="ref-link-section-d66811012e2683">43</a></sup>; <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>) was higher in responders than in progressors in the overall cohort and the subgroup treated with ipilimumab, but was not significantly different in the subgroup that was naive to ipilimumab (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig3">3c–e</a>; MWW, <i>P</i> = 0.03, <i>P</i> = 0.03 and <i>P</i> = 0.31, respectively). We found very similar results in the largest available independent validation cohort<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017)." href="/articles/s41591-019-0654-5#ref-CR44" id="ref-link-section-d66811012e2703">44</a></sup> with information on previous ipilimumab treatment (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig3">3f–h</a>), although the difference was not significant in this smaller cohort (<i>n</i> = 32 patients, 15 of whom were treated with ipilimumab and 17 of whom were naive for ipilimumab).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Differential predictors of response and progression in ipilimumab-treated tumors versus ipilimumab-naive tumors."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Differential predictors of response and progression in ipilimumab-treated tumors versus ipilimumab-naive tumors.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="1021"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, Timeline showing when sequenced biopsies were obtained from tumors that were treated with ipilimumab or naive to ipilimumab in the course of therapy. Subsequent analyses focused on comparing tumor biopsies obtained after ipilimumab treatment (<i>n</i> = 45 WES, <i>n</i> = 34 RNA-seq) to ipilimumab-naive tumor biopsies (<i>n</i> = 84 WES, <i>n</i> = 74 RNA-seq). <b>b</b>, Best RECIST response by ipilimumab pretreatment status. There was no difference between the distribution of responses in naive (<i>n</i> = 84) and pretreated (<i>n</i> = 60) patients (two-sided chi-squared test, <i>P</i> = 0.44; degrees of freedom (d.f.) = 3). <b>c</b>, ssGSEA of MHC-II HLA genes (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>) in responders (<i>n</i> = 47 patients) versus progressors (<i>n</i> = 56 patients) in the overall cohort. MHC-II scores were higher in responders than in progressors (two-sided MWW, <i>P</i> = 0.03). <b>d</b>, ssGSEA of MHC-II HLA genes in responders versus progressors in the post-ipilimumab-treatment subgroup. MHC-II scores were higher in responders (<i>n</i> = 11 patients) than in progressors (<i>n</i> = 16 patients; two-sided MWW, <i>P</i> = 0.03). <b>e</b>, ssGSEA of MHC-II HLA genes in responders (<i>n</i> = 31 patients) versus progressors (<i>n</i> = 34 patients) in the ipilimumab-naive subgroup. There was no significant difference in MHC-II scores between responders and progressors (two-sided MWW, <i>P</i> = 0.31). <b>f</b>, MHC-II HLA gene set scores (ssGSEA) in responders (<i>n</i> = 10 patients) versus progressors (<i>n</i> = 22 patients) in a validation cohort (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>; two-sided MWW, <i>P</i> = 0.34). <b>g</b>, MHC-II HLA gene set scores (ssGSEA) in responders (<i>n</i> = 4 patients) versus progressors (<i>n</i> = 11 patients) in the ipilimumab-treated subgroup of a validation cohort (two-sided MWW, <i>P</i> = 0.10). <b>h</b>, MHC-II HLA gene set scores (ssGSEA) in responders (<i>n</i> = 6 patients) versus progressors (<i>n</i> = 11 patients) in the ipilimumab-naive subgroup of a validation cohort (two-sided MWW, <i>P</i> = 0.80). <b>i</b>, Selected Cancer Hallmark gene sets (GSEA) enriched in responders versus progressors in the overall (<i>n</i> = 47 responders and 56 progressors), post-ipilimumab-treatment (<i>n</i> = 11 responders and 16 progressors), and ipilimumab-naive (<i>n</i> = 31 responders and 34 progressors) subgroups of our discovery cohort. IFN-γ and IFN-α response pathways were enriched in responders in the overall (FDR, <i>q</i> &lt; 0.001 and <i>q</i> = 0.02, respectively) and ipilimumab-treated (<i>q</i> &lt; 0.001, both) subgroups but not in the ipilimumab-naive subgroups (<i>q</i> = 0.13 and <i>q</i> = 0.997, respectively) in the discovery cohort (empiric, <i>P</i> = 0.183 and <i>P</i> = 0.18, respectively for the difference in <i>q</i> values between the subgroups; <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>). <b>j</b>, Selected Cancer Hallmark gene sets (GSEA) enriched in responders versus progressors in the overall, post-ipilimumab-treatment and ipilimumab-naive subgroups in an independent validation cohort. IFN-γ and IFN-α response pathways were enriched in responders in the overall (FDR, <i>q</i> &lt; 0.0001 and <i>q</i> = 0.0034, respectively) and ipilimumab-treated (<i>q</i> &lt; 0.0001, both) subgroups but not in the ipilimumab-naive subgroup (<i>q</i> = 0.87 and <i>q</i> = 0.03 (enriched in progressors), respectively) in the discovery cohort. Pathways favoring enrichment in progressors (as opposed to responders) are visualized here with an FDR <i>q</i> value of 1. All Hallmark pathways and their GSEA enrichment scores are shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">5</a>. Boxplots: box limits indicate the IQR (25th to 75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5 × IQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points. *<i>P</i> &lt; 0.05, **<i>P</i> &lt; 0.01, ***<i>P</i> &lt; 0.001. NS, not significant.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>We next examined the association of TMB, purity, ploidy and heterogeneity with response stratified by previous ipilimumab therapy (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig11">6a</a>). Unlike previous studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017)." href="/articles/s41591-019-0654-5#ref-CR44" id="ref-link-section-d66811012e2925">44</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Weber, J. et al. Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab. Ann. Oncol. 27, 10470 (2016)." href="/articles/s41591-019-0654-5#ref-CR45" id="ref-link-section-d66811012e2928">45</a></sup>, we found no specific association of a higher TMB with response in the ipilimumab-naive versus ipilimumab-treated subgroup (MWW, <i>P</i> = 0.15, both). However, higher heterogeneity and lower ploidy were associated with progressors only in the ipilimumab-naive subgroup (MWW, <i>P</i> = 0.06 and <i>P</i> = 0.004, respectively).</p><p>We analyzed the differential expression of specific immune-related genes in responders versus progressors in ipilimumab-treated and ipilimumab-naive subgroups and found that higher expression of various immune-related pathways distinguished responders from progressors in ipilimumab-treated but not ipilimumab-naive subgroups (all <i>P</i> values are unadjusted). Examples included the leukocyte chemoattractants <i>CXCL9</i> and <i>CXCL10</i> and their receptor <i>CXCR3</i> (MWW, <i>P</i> = 0.05, <i>P</i> = 0.08 and <i>P</i> = 0.02, respectively, in the ipilimumab-treated subgroup), <i>CD3D</i> (MWW, <i>P</i> = 0.02), B cell markers <i>CD19</i> (MWW, <i>P</i> = 0.04) and <i>CD20</i> (<i>MS4A1</i>; MWW, <i>P</i> = 0.002) and macrophage marker <i>CD163</i> (MWW, <i>P</i> = 0.03). Interestingly, <i>CD4</i>, <i>FOXP3</i> <i>and CTLA4</i> also followed this pattern of higher expression in responders in the ipilimumab-treated subgroup <i>(</i>MWW, <i>P</i> = 0.06, <i>P</i> <i>=</i> 0.06 and <i>P</i> = 0.008, respectively), but <i>CD8A</i> and <i>CD8B</i> had less evidence of association with response in either ipilimumab-treated (MWW, <i>P</i> = 0.17 and <i>P</i> <i>=</i> 0.27, respectively) or ipilimumab-naive (MWW, <i>P</i> = 0.93 and <i>P</i> <i>=</i> 0.49, respectively) subgroups. Expression of <i>TAP2</i> was higher (MWW, <i>P</i> = 0.02) in responders than in progressors in the ipilimumab-treated subgroup but not in the ipilimumab-naive subgroup (MWW, <i>P</i> = 0.98). In contrast, <i>TGFB2</i> expression was higher in progressors in the ipilimumab-naive subgroup (MWW, <i>P</i> = 0.002) but not in the ipilimumab-treated subgroup (MWW, <i>P</i> = 0.43). The complete set of gene expression comparisons in the overall, ipilimumab-treated and ipilimumab-naive cohorts is in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">4</a>.</p><p>We then repeated GSEA to examine the pathways differentially enriched in responders versus progressors between ipilimumab-treated and ipilimumab-naive subgroups. The most differentially enriched pathways were related to immune response: the IFN-γ and IFN-α responses were significantly enriched in responders in the ipilimumab-treated subgroup (FDR, <i>q</i> &lt; 0.0001, both), but not in the ipilimumab-naive subgroup (FDR, <i>q</i> = 0.13 and <i>q</i> = 0.996, respectively; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig3">3i</a>). Using permutation testing (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), we found a nonsignificant empiric <i>P</i> value of 0.183 and 0.18, respectively, for this difference in enriched pathways in these subgroups in our discovery cohort. However, we repeated the analysis in an independent validation cohort<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649–1654 (2018)." href="/articles/s41591-019-0654-5#ref-CR46" id="ref-link-section-d66811012e3089">46</a></sup> and found similar results (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig3">3j</a>). Complete GSEA results are provided in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">5</a>.</p><p>To further dissect the impact of MHC-II expression on patient response, we stratified the cohort into patients with high and low MHC-II expression (ssGSEA, median split). In the overall cohort, low MHC-II expression was associated with primary resistance (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig4">4a</a>; Fisher’s exact test, <i>P</i> = 0.01; OR = 2.9, 95% confidence interval (CI) 1.3–6.5), but this association was largely driven by the ipilimumab-treated subgroup (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig4">4b</a>; Fisher’s exact test, <i>P</i> = 0.02; OR = 9.9, 95% CI 1.5–63.7), with a nonsignificant association in the ipilimumab-naive subgroup (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig4">4c</a>; Fisher’s exact test, <i>P</i> = 0.32; OR = 1.9, 95% CI 0.7–5.1). A formal interaction test of previous ipilimumab treatment status with MHC-II expression for predicting response was consistent with a subgroup-specific effect of low MHC-II expression on the ipilimumab-experienced subgroup (OR = 0.20, 95% CI 0.02–1.64), although this was nonsignificant (<i>P</i> = 0.13) in this small cohort.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Progression versus response by immune infiltrate and MHC-II HLA expression stratified by ipilimumab treatment."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Progression versus response by immune infiltrate and MHC-II HLA expression stratified by ipilimumab treatment.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="718"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>a</b>, Proportion of responders versus progressors in subgroups with high and low MHC-II HLA score (ssGSEA; divided by the median). Overall, a high MHC-II HLA score was associated with higher response (MHC-II high: <i>n</i> = 29 responders and 20 progressors; MHC-II low: <i>n</i> = 18 responders and 36 progressors; two-sided Fisher’s exact test, <i>P</i> = 0.01; OR = 2.9, 95% CI 1.3–6.5). <b>b</b>, As in <b>a</b> but in the ipilimumab-treated subgroup. Tumors with low MHC-II HLA score (ssGSEA) were associated with PD (MHC-II high: <i>n</i> = 9 responders and 5 progressors; MHC-II low: <i>n</i> = 2 responders and 11 progressors; two-sided Fisher’s exact test, <i>P</i> = 0.02; OR = 9.9, 95% CI 1.5–63.7). <b>c</b>, As in <b>a</b> but in the ipilimumab-naive subgroup. There was no significant difference between tumors with high and low MHC-II HLA scores (ssGSEA; MHC-II high: <i>n</i> = 18 responders and 14 progressors; MHC-II low: <i>n</i> = 13 responders and 19 progressors; two-sided Fisher’s exact <i>test, P</i> = 0.32; OR = 1.9, 95% CI 0.7–5.1). <b>d</b>, Proportion of responders versus progressors in subgroups with high and low immune infiltrate scores (divided by the median). Overall, there was no statistically significant difference in the proportion of responders versus progressors in tumors with high versus low immune infiltrate (infiltrate high: <i>n</i> = 27 responders and 24 progressors; infiltrate low: <i>n</i> = 20 responders and 32 progressors; two-sided Fisher’s exact test, <i>P</i> = 0.17; OR = 1.8, 95% CI 0.8–3.9). <b>e</b>, As in <b>d</b> but in the ipilimumab-treated subgroup. Tumors with low immune infiltrate scores were strongly associated with PD (infiltrate high: <i>n</i> = 10 responders and 7 progressors; infiltrate low: <i>n</i> = 1 responder and 9 progressors; two-sided Fisher’s exact test, <i>P</i> = 0.02; OR = 12.9, 95% CI 1.3–125.8). <b>f</b>, As in <b>d</b> but in the ipilimumab-naive subgroup. There was no statistically significant difference between tumors with high and low immune infiltrate scores (infiltrate high: <i>n</i> = 14 responders and 15 progressors; infiltrate low: <i>n</i> = 17 responders and 18 progressors; two-sided Fisher’s exact test, <i>P</i> = 1.0; OR = 0.99, 95% CI 0.4–2.6). <b>g</b>, Schematic of the hypothesized effect of ipilimumab treatment on immune response as a predictor of subsequent response to anti-PD1 ICB. Tumors that were treated with ipilimumab but failed to have an immune response or infiltrate in the tumor microenvironment were strongly predicted to have intrinsic resistance to anti-PD1 ICB. However, having an immune response did not guarantee a subsequent response to anti-PD1 ICB. In ipilimumab-naive tumors, neither the presence nor the absence of immune infiltrate was a good predictor of anti-PD1 ICB response.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>A similar analysis of estimated total immune infiltrate levels<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015)." href="/articles/s41591-019-0654-5#ref-CR41" id="ref-link-section-d66811012e3238">41</a></sup> (with tumors split by the median into high and low groups) showed that low immune infiltrate was significantly associated with intrinsic resistance in the ipilimumab-treated subgroup (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig4">4e</a>; Fisher’s exact test, <i>P</i> = 0.02; OR = 12.9, 95% CI 1.3–125.8), but not in the ipilimumab-naive subgroup (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig4">4f</a>; Fisher’s exact test, <i>P</i> = 1.00; OR = 0.99, 95% CI 0.4–2.6) or overall cohort (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig4">4d</a>; Fisher’s exact test, <i>P</i> = 0.17; OR = 1.8, 95% CI 0.8–3.9), indicating a subgroup-specific association in the ipilimumab-experienced subgroup of low immune infiltrate with resistance to therapy (OR = 0.08, 95% CI 0.007–0.97; <i>P</i> = 0.047).</p><p>Taken together, these findings suggest that evidence of immune response in the tumor microenvironment at the time of progression following anti-CTLA4 ICB is a necessary but not sufficient marker for response to anti-PD1 ICB therapy; patients without immune response to anti-CTLA4 ICB are very likely to also be intrinsically resistant to anti-PD1 ICB, highlighting a high-risk and poor-prognosis subgroup of patients (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig4">4g</a>).</p><h3 class="c-article__sub-heading" id="Sec7">Integrative predictive modeling of primary resistance</h3><p>Patients with primary resistance to anti-PD1 ICB have poor survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig12">7</a>), and the ability to predict these patients would enable individualized management regimens (for example combination ICB) to improve outcomes. Thus, we set out to develop parsimonious predictive models integrating clinical, genomic and transcriptomic features to predict PD (primary resistance) versus non-PD (CR, PR, SD and MR) and developed separate predictive models in ipilimumab-treated and ipilimumab-naive subgroups.</p><p>In the ipilimumab-treated group (<i>n</i> = 34 with WES and RNA-seq), there were 16 patients who had PD and 18 who had non-PD. Using a forward-selection approach to choose the features of a parsimonious predictive model (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), low MHC-II HLA expression was most strongly predictive of PD (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig5">5a</a>) and was correlated with MHC-I HLA, IFN-α and IFN-γ response pathway scores. In the final multivariate model, high MHC-II expression, low lactate dehydrogenase (LDH; below the median of 247 U l<sup>−1</sup>) and the presence of lymph node metastases were independent predictors of non-PD (<i>P</i> = 0.03, <i>P</i> = 0.02 and <i>P</i> = 0.04, respectively, Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">8</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig13">8a,c</a>), and the model had an area under the curve (AUC) of 0.90 in our discovery cohort (fivefold cross-validation mean AUC = 0.83; empiric <i>P</i> &lt; 0.001; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig5">5b</a>, Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig13">8f</a> and <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>). Notably, TMB did not significantly improve model fit (log-likelihood ratio, <i>P</i> = 0.10), was not an independently predictive feature (<i>P</i> = 0.18) and did not meet Bayesian information criteria (BIC; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig13">8c</a>) when added to the model.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Integrative predictive modeling of intrinsic resistance to anti-PD1 ICB."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: Integrative predictive modeling of intrinsic resistance to anti-PD1 ICB.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="719"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p><b>a</b>, CoMut plot showing the relationship between response and predictive features in the ipilimumab-treated subgroup. Each column represents a patient, and the top row indicates whether the patient had PD (intrinsic resistance) or non-PD (CR, PR, SD or MR) as the best response. Patients are sorted by MHC-II HLA score, which was the most predictive feature and was correlated with MHC-I and IFN response pathway scores. MHC-II HLA, LDH at treatment initiation and the presence of lymph node metastases (LN met) were features used for our logistic regression model, chosen using forward selection (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>). <b>b</b>, A receiver–operator characteristic (ROC) curve for our predictive model for ipilimumab-treated tumors (<i>n</i> = 34 patients) using MHC-II HLA, LDH and lymph node metastases as features. The AUC was 0.9, and the log-likelihood ratio was <i>P</i> = 0.0003. The fivefold cross-validation mean AUC was 0.83. <b>c</b>, CoMut plot showing the relationship between response and predictive features in the ipilimumab-naive subgroup. Each column represents a patient, and the top row indicates whether the patient had PD (intrinsic resistance) or non-PD as the best response. Patients are sorted by tumor heterogeneity (top), tumor ploidy (middle) and tumor purity (bottom), which were the three features chosen in our predictive model (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>). Purity, ploidy and heterogeneity were independent predictors in the multivariate model (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">9</a>). <b>d</b>, The ROC curve for our predictive model for ipilimumab-naive tumors (<i>n</i> = 84 tumors) using heterogeneity, purity and ploidy as features. The AUC was 0.77, and the log-likelihood ratio was <i>P</i> = 0.0003. The average tenfold cross-validation mean AUC was 0.73. <b>e</b>, Survival (PFS and OS as indicated) stratified by high versus low predictive model score (split by the median) in ipilimumab-treated tumors in our discovery cohort. Tumors with high scores had worse PFS and OS (two-sided KM log-rank test, <i>P</i> = 0.0001 and <i>P</i> = 0.001, respectively). <b>f</b>, Survival (PFS and OS as indicated) stratified by high versus low predictive model score (split by the median) in ipilimumab-naive tumors in our discovery cohort. Tumors with high scores had worse PFS and OS (two-sided KM log-rank test, <i>P</i> = 0.003 and <i>P</i> = 6.3 × 10<sup>−5</sup>, respectively).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-019-0654-5/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>In the ipilimumab-naive group, there were 34 patients with PD and 41 with non-PD. In the multivariate predictive model, higher heterogeneity, lower ploidy and higher purity were independently predictive of PD (<i>P</i> = 0.025, <i>P</i> = 0.014 and <i>P</i> = 0.046, respectively; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig5">5c</a>, Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">9</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig13">8b,d</a>), with an AUC of 0.77 (tenfold cross-validation mean AUC of 0.73; empiric <i>P</i> = 0.036; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig5">5d</a>, Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig13">8e</a> and <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>). TMB did not significantly improve the model fit (log-likelihood ratio test, <i>P</i> = 0.63), was not an independently predictive feature (<i>P</i> = 0.63) and did not meet BIC criteria (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig13">8d</a>) when added to this multivariate model. Further, each model’s performance was specific to its subgroup (<i>P</i> = 0.004 and <i>P</i> = 0.018 for the interaction between ipilimumab-experienced and ipilimumab-naive model scores, respectively, and previous ipilimumab therapy). Each model had poor performance when applied to the opposing subgroup (AUC = 0.49 and AUC = 0.54, respectively; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig14">9a,b</a>), suggesting that previous ipilimumab treatment status may stratify the appropriate predictors and predictive models to be applied in these subgroups.</p><p>We attempted to validate our models in independent cohorts but were limited by a lack of publicly available cohorts with all the molecular features and relevant clinical data on previous ipilimumab therapy and biopsy timing used in our integrated model. In a limited validation, we tested predictive models incorporating individual features where data were available in an independent validation cohort<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017)." href="/articles/s41591-019-0654-5#ref-CR44" id="ref-link-section-d66811012e3464">44</a></sup> (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>), and found concordant predictions of primary resistance with low MHC-II HLA expression in ipilimumab-treated tumors and higher heterogeneity in ipilimumab-naive tumors (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig15">10</a>), although neither of these predictors was significant in this small cohort (empiric <i>P</i> = 0.21 and <i>P</i> = 0.066, respectively; <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>).</p><p>In an exploratory analysis, we predicted PD in response to anti-PD1 ICB in tumors where the tumor biopsy was taken before ipilimumab treatment (<i>n</i> = 15; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig3">3a</a>) using our ipilimumab-naive predictive model. Of the eight tumors with PD in response to anti-PD1 ICB, five had the highest model scores (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig14">9c</a>), with an overall AUC of 0.71. Interestingly, of the three poorly discriminated tumors with low model scores but PD responses, one (patient 82) was from a brain metastasis and one (patient 80) was an acral melanoma.</p><p>Finally, splitting the cohort into subsets with high and low model scores (split by the median), we found large differences in OS and PFS in both the ipilimumab-treated subgroup (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig5">5e</a>; median PFS: 38.1 months versus 2.8 months, log-rank <i>P</i> = 0.0001; median OS: unreached versus 9.0 months, log-rank <i>P</i> = 0.001) and ipilimumab-naive subgroup (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig5">5f</a>; median PFS: 24.7 months versus 3.1 months, log-rank <i>P</i> = 0.005; median OS: unreached versus 15.0 months, log-rank <i>P</i> &lt; 0.0001).</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec8-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec8">Discussion</h2><div class="c-article-section__content" id="Sec8-content"><p>In this study, we analyzed a uniformly clinically annotated cohort of patients with advanced melanoma treated with anti-PD1 ICB monotherapy for whom WES and RNA-seq data were available. While we observed an association between response and TMB, this observation was confounded by disease subtype, strongly suggesting that TMB cannot be applied generically across melanoma subtypes as a predictive biomarker for anti-PD1 ICB.</p><p>Beyond TMB, we found that MHC-II expression, tumor heterogeneity, purity and ploidy were associated with ICB response. In two previous studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, eaar3342 (2018)." href="/articles/s41591-019-0654-5#ref-CR47" id="ref-link-section-d66811012e3531">47</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat. Commun. 7, 10582 (2016)." href="/articles/s41591-019-0654-5#ref-CR48" id="ref-link-section-d66811012e3534">48</a></sup>, MHC-II expression on tumor cells by immunohistochemistry was found to be predictive for response to anti-PD1 ICB and was hypothesized to represent a subset of tumors that could stimulate CD4<sup>+</sup> helper T cell or cytotoxic activity. Consistent with this hypothesis, we found that MHC-II transcriptomic expression was correlated with expression of <i>CD4</i> and the cytolytic molecules <i>PRF1</i> and <i>GZMA</i> in our cohort. However, whether MHC-II expression represents expression on tumor cells or antigen-presenting cells within the tumor microenvironment cannot be determined from our bulk transcriptome data, and whether the association of PD1 ICB response with MHC-II expression is limited to tumor-cell-specific MHC-II expression is unclear. Notably, CD8<sup>+</sup> T cell markers were not higher in responders versus progressors in our cohort, and although MHC-II, MHC-I, IFN-γ and IFN-α response pathway expression was correlated, MHC-II expression was the best predictor of response in our cohort. Further, we found evidence for the involvement of other immune compartments (for example, B cell markers enriched in ipilimumab-experienced responders) in ICB response, consistent with data from a recent trial demonstrating higher B cell infiltrate in responders to neoadjuvant immunotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649–1654 (2018)." href="/articles/s41591-019-0654-5#ref-CR46" id="ref-link-section-d66811012e3552">46</a></sup>, although the specific cell types, functional states and tumor immune interactions are not yet well characterized.</p><p>Tumor heterogeneity (the proportion of subclonal mutations) has previously been associated with poor prognosis across multiple tumor types and therapies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016)." href="#ref-CR49" id="ref-link-section-d66811012e3559">49</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Morris, L. G. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051–10063 (2016)." href="#ref-CR50" id="ref-link-section-d66811012e3559_1">50</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat. Commun. 8, 2193 (2017)." href="/articles/s41591-019-0654-5#ref-CR51" id="ref-link-section-d66811012e3562">51</a></sup>. High heterogeneity suggests a highly mutagenic disease and a high degree of subclonality, with a higher likelihood of preexisting or rapidly evolving resistant clones. Interestingly, in our cohort, four patients had a very high TMB with an alkylating chemotherapy mutational signature (and known previous alkylating chemotherapy); low tumor heterogeneity distinguished the two responders from the two nonresponders (with SD and PD as the best response), who had high tumor heterogeneity with a majority of subclonal mutations. This association has also been observed in dacarbazine-experienced patients with melanoma treated with anti-CTLA4 ICB<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016)." href="/articles/s41591-019-0654-5#ref-CR49" id="ref-link-section-d66811012e3566">49</a></sup>, suggesting that tumor heterogeneity may be significantly correlated with ICB resistance.</p><p>In our cohort, higher ploidy and lower purity were associated with ICB response, but the biological basis of these relationships is unclear. Genome doubling events are common in cancer and may accelerate genome evolution by increasing the tolerance of genome instability<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175–185 (2014)." href="/articles/s41591-019-0654-5#ref-CR52" id="ref-link-section-d66811012e3573">52</a></sup>, and higher aneuploidy has been associated with a worse response to ICB<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)." href="/articles/s41591-019-0654-5#ref-CR18" id="ref-link-section-d66811012e3577">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Davoli, T. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017)." href="/articles/s41591-019-0654-5#ref-CR19" id="ref-link-section-d66811012e3580">19</a></sup>. However, whether genome doubling (and higher ploidy) is also associated with increased immunogenicity is unclear. Purity is negatively correlated with expression of markers of immune response and may be a proxy for the level of immune response in the tumor microenvironment in this setting rather than an artifact of tumor sample processing. However, tumor purity may also reflect differences in tumor biology leading to intrinsic resistance.</p><p>Notably, we found that previous exposure to anti-CTLA4 ICB affected the predictors of response to anti-PD1 ICB, although patients with and without exposure had similar response rates to anti-PD1 ICB. Immune-related markers are strongly enriched in responders compared to progressors with previous ipilimumab exposure, but this relationship is less clear in ipilimumab-naive patients. Specifically, post-ipilimumab tumors with poor immune response at progression were resistant to further anti-PD1 ICB, whereas ipilimumab-naive immune-poor and immune-infiltrated tumors were similarly likely to respond to anti-PD1 ICB. Whether anti-CTLA4 ICB induces or, alternatively, reveals an immune-resistant state in a subset of melanomas is an important question that deserves further evaluation. Further, cross-resistance to sequential ICB may also predict resistance to simultaneous combination ICB; this hypothesis should be evaluated in an appropriate cohort.</p><p>Building on these findings, we constructed predictive models integrating clinical, genomic and transcriptomic characteristics to identify patients with melanoma with intrinsic resistance to anti-PD1 ICB. Integrating multiple clinical and molecular features resulted in superior discrimination compared to models with any single feature or modality. In patients treated with ipilimumab, low MHC-II expression and high LDH predicted intrinsic resistance, whereas lymph node metastasis predicted improved response to therapy. MHC-II<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, eaar3342 (2018)." href="/articles/s41591-019-0654-5#ref-CR47" id="ref-link-section-d66811012e3591">47</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat. Commun. 7, 10582 (2016)." href="/articles/s41591-019-0654-5#ref-CR48" id="ref-link-section-d66811012e3594">48</a></sup> and LDH<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="Weide, B. et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin. Cancer Res. 22, 5487–5496 (2016)." href="/articles/s41591-019-0654-5#ref-CR53" id="ref-link-section-d66811012e3598">53</a></sup> have previously been implicated in predicting anti-PD1 responsiveness. Lymph node metastases might provide a reservoir of tumor-specific immune cells, facilitating their activation by physiologic lymph node function; recent experimental data in a murine model suggests that lymph node metastases are necessary for PD1 response<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight 3, 124507 (2018)." href="/articles/s41591-019-0654-5#ref-CR54" id="ref-link-section-d66811012e3602">54</a></sup>, and recent clinical data showing greater tumor-resident T cell clone response to neoadjuvant compared to adjuvant immunotherapy further supports this hypothesis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018)." href="/articles/s41591-019-0654-5#ref-CR55" id="ref-link-section-d66811012e3606">55</a></sup>. Similarly, integrating tumor heterogeneity, ploidy and purity for ipilimumab-naive disease resulted in a higher AUC than was obtained with any single-feature model alone. Beyond predicting response, these parsimonious models strongly stratified patients by PFS and OS, suggesting potential clinical applicability in identifying patients at high and low risk.</p><p>These findings will require validation in independent and larger cohorts; at the time of our study, limited data were publicly available where molecularly sequenced tumors with previous treatment data and all relevant clinical parameters were available for validation. Further, heterogeneity in sequencing approaches and data normalization between cohorts hindered our ability to develop standardized features to create and validate models. However, our results highlight the value of integrating rich clinical data with molecular tumor characterization and the need to generate such multimodal data.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec9-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec9">Methods</h2><div class="c-article-section__content" id="Sec9-content"><h3 class="c-article__sub-heading" id="Sec10">Patient cohort and clinical end points</h3><p>Patients were identified in databases of participating sites. For enrollment, patients were required to have advanced melanoma and to have received PD1 blockade as a palliative treatment. Tissue obtained before PD1 blockade was required for enrollment and was collected during routine medical care. Clinicopathological and demographic data were collected from patient records locally and are shown in Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-019-0654-5#Tab1">1</a>. Age, stage and ECOG performance status were documented before the first application of anti-PD1 ICB. LDH was measured within 28 d of the first application of nivolumab or pembrolizumab. OS was defined as the time between the first application of anti-PD1 ICB and the date of death (any cause). For subjects without documentation of death, OS was censored on the last date the patient was known to be alive. BOR to anti-PD1 ICB was assessed according to RECIST criteria v.1.1 by the participating sites. Patients achieving CR or PR as BOR were grouped as responders, whereas patients showing PD as the best response were referred to as progressors. Patients were classified as MR when achieving unequivocal responses in individual existing lesions but also progression in others or new lesions. PFS was defined as the time between the first application of anti-PD1 ICB and the date of documented disease progression. For patients without documentation of progression, PFS was censored on the last date the patient was known to be without progression.</p><p>This retrospective study and associated informed consent procedures were approved by the central Ethics Committee (EC) of the University Hospital Essen (12-5152-BO and 11-4715). Approval by the local EC was obtained by investigators if required by local regulations.</p><h3 class="c-article__sub-heading" id="Sec11">Samples</h3><p>Samples were collected retrospectively and obtained by excision or biopsy of melanoma tissue, collected locally at the participating sites and provided formalin-fixed and paraffin-embedded (FFPE). Samples were collected between January 2013 and June 2016. The median time from biopsy to initiation of anti-PD1 blockade was 2.1 months with 90% of samples being collected 6 months before the first application of nivolumab or pembrolizumab. All biopsies were from metastatic sites, with the exception of eight biopsies; seven were from a primary lesion and one was from a recurrence at a primary site, representing less than 6% of the overall cohort.</p><h3 class="c-article__sub-heading" id="Sec12">Whole-exome and whole-transcriptome sequencing</h3><p>DNA extraction, whole exome library preparation and sequencing were performed for samples as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015)." href="/articles/s41591-019-0654-5#ref-CR10" id="ref-link-section-d66811012e3647">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Van Allen, E. M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20, 682–688 (2014)." href="/articles/s41591-019-0654-5#ref-CR23" id="ref-link-section-d66811012e3650">23</a></sup>. Slides were cut from FFPE blocks and macrodissected for tumor-enriched tissue. Paraffin was removed from FFPE sections and cores using CitriSolv (Fisher Scientific), followed by ethanol washes and tissue lysis overnight at 56 °C. Samples were then incubated at 90 °C to remove DNA cross links. Extraction of DNA, and, when possible, RNA was performed using the QIAGEN AllPrep DNA/RNA mini kit (51306). Germline DNA was obtained from peripheral blood mononuclear cells and adjacent normal tissue.</p><p>Whole-exome capture libraries were constructed from 100 ng of DNA from tumor and normal tissue after sample shearing, end repair and phosphorylation and ligation to barcoded sequencing adaptors. Ligated DNA was size selected for lengths of 200–350 bp and subjected to exonic hybrid capture using Illumina library preps. The sample was multiplexed and sequenced using Illumina HiSeq technology. The Illumina exome sequencing approach uses Illumina’s in-solution DNA-probe-based hybrid selection method that applies principles similar to those of Broad Institute–Agilent Technologies’ in-solution RNA-probe-based hybrid selection method<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011)." href="/articles/s41591-019-0654-5#ref-CR57" id="ref-link-section-d66811012e3657">57</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182–189 (2009)." href="/articles/s41591-019-0654-5#ref-CR58" id="ref-link-section-d66811012e3660">58</a></sup> to generate Illumina exome sequencing libraries.</p><p>Total RNA was assessed for quality using the Caliper LabChip GX2. The percentage of fragments with a size greater than 200 nucleotides (DV200) was calculated using software. An aliquot of 200 ng of RNA was used as the input for first-strand cDNA synthesis using Illumina’s TruSeq RNA Access Library Prep kit. Synthesis of the second strand of cDNA was followed by indexed adaptor ligation. Subsequent PCR amplification enriched for adaptor-ligated fragments. The amplified libraries were quantified using an automated PicoGreen assay.</p><p>A total of 200 ng of each cDNA library, not including controls, was combined into four-plex pools. Capture probes that target the exome were added and hybridized for the recommended time. Following hybridization, streptavidin magnetic beads were used to capture the library-bound probes from the previous step. Two wash steps effectively removed any nonspecifically bound products. These same hybridization, capture and wash steps were repeated to assure high specificity. A second round of amplification enriched the captured libraries. After enrichment the libraries were quantified with qPCR using the KAPA Library Quantification kit for Illumina sequencing platforms and were then pooled at an equimolar ratio. The entire process was in a 96-well format and all pipetting was performed using Agilent Bravo or Hamilton Starlet.</p><p>Pooled libraries were normalized to 2 nM and denatured using 0.2 N NaOH before sequencing. Flowcell cluster amplification and sequencing were performed according to the manufacturer’s protocols using either the HiSeq 2000 v.3 or HiSeq 2500. Each run generated 76-bp paired-end reads with a dual eight-base index barcode. Data were analyzed using the Broad Picard Pipeline, which includes demultiplexing and data aggregation.</p><h3 class="c-article__sub-heading" id="Sec13">Quality control and variant calling</h3><p>Initial exome sequence data processing and analysis were performed using pipelines at the Broad Institute. After alignment from the Broad Picard Pipeline, BAM files were uploaded into the Firehose infrastructure (<a href="https://software.broadinstitute.org/cancer/cga/Firehose">https://software.broadinstitute.org/cancer/cga/Firehose</a>), which managed intermediate analysis files executed by analysis pipelines. Sequencing data were incorporated into quality-control modules in Firehose to compare the tumor and normal genotypes and ensure concordance between samples. Quality-control cutoffs were as follows: mean target coverage &gt;50× (tumor) and &gt;20× (matched normal), cross-contamination of samples estimation (ContEst<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next generation sequencing data. Bioinformatics 27, 2601–2602 (2011)." href="/articles/s41591-019-0654-5#ref-CR59" id="ref-link-section-d66811012e3689">59</a></sup>) &lt;5% and tumor purity ≥10% (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM1">1</a>).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec14">Power calculation quality control</h4><p>To limit our analysis to samples where we had adequate power to call somatic variants, we performed a downstream per-sample power calculation. For each sample, we performed a Monte Carlo simulation of 1,000 true clonal mutations using the following procedures:</p><ul class="u-list-style-bullet">
                    <li>
                      <p>Sample the number of reads from the sample-specific coverage distribution</p>
                    </li>
                    <li>
                      <p>Draw the number of tumor reads from a binomial distribution using the estimated tumor purity</p>
                    </li>
                    <li>
                      <p>Draw the number of mutation reads from a binomial distribution given the assumption of a heterozygous mutation and no copy number variation</p>
                    </li>
                    <li>
                      <p>Characterize the mutation as detected or not on the basis of a log odds threshold of 6.3 (consistent with the MuTect<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013)." href="/articles/s41591-019-0654-5#ref-CR60" id="ref-link-section-d66811012e3727">60</a></sup> implementation).</p>
                    </li>
                  </ul><p>The estimated power to detect clonal mutations is the proportion of simulated mutations detected (for example, 800 detected out of 1,000 simulated clonal mutations is 80% power), which is a function of both sample-specific sequencing depth of coverage and tumor purity. Three tumors were excluded using this threshold (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig6">1</a>).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec15">Variant calling</h4><p>The MuTect algorithm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013)." href="/articles/s41591-019-0654-5#ref-CR60" id="ref-link-section-d66811012e3747">60</a></sup> was applied to identify somatic single-nucleotide variants in targeted exons, with computational filtering of artifacts introduced by DNA oxidation during sequencing<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013)." href="/articles/s41591-019-0654-5#ref-CR61" id="ref-link-section-d66811012e3751">61</a></sup> or FFPE-based DNA extraction using a filter-based method. Strelka<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 62" title="Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–1817 (2012)." href="/articles/s41591-019-0654-5#ref-CR62" id="ref-link-section-d66811012e3755">62</a></sup> was applied to identify small insertions or deletions. Identified alterations were annotated using Oncotator<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423–E2429 (2015)." href="/articles/s41591-019-0654-5#ref-CR63" id="ref-link-section-d66811012e3759">63</a></sup>.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec16">TMB and neoantigen load</h4><p>For purposes of analysis, the TMB was calculated as the log of the number of nonsynonymous mutations detected from WES. Mutations per Mb was calculated by dividing the total number of nonsynonymous mutations by the number of bases with sufficient coverage in the tumor and normal samples (≥14× and ≥8×, respectively) to call mutations (<a href="https://software.broadinstitute.org/cancer/cga/mutect">https://software.broadinstitute.org/cancer/cga/mutect</a>). Neoantigen prediction was performed as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015)." href="/articles/s41591-019-0654-5#ref-CR10" id="ref-link-section-d66811012e3778">10</a></sup>. Briefly, HLA type was inferred using POLYSOLVER<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64" title="Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152 (2015)." href="/articles/s41591-019-0654-5#ref-CR64" id="ref-link-section-d66811012e3782">64</a></sup>, which uses a Bayesian classifier to determine the genotype of each patient. Neoantigens were predicted for each patient by defining all novel nine and ten amino-acid sequences resulting from mutations and determining whether the predicted binding affinity to the patient’s germline HLA alleles was &lt;500 nM using NetMHCpan (v.2.4)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Nielsen, M. et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and HLA-B locus protein of known sequence. PloS ONE 2, e796 (2007)." href="/articles/s41591-019-0654-5#ref-CR65" id="ref-link-section-d66811012e3786">65</a></sup>.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec17">Copy number variants</h4><p>The total number of copy number alterations for individual tumors was inferred using adaptations of a binary segmentation algorithm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66" title="Olshen, A. B., Venkatraman, E. S., Lucito, R. &amp; Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004)." href="/articles/s41591-019-0654-5#ref-CR66" id="ref-link-section-d66811012e3799">66</a></sup> (CapSeg) comparing fractional exon coverage for tumor segments to a panel of normal samples, generating exomic segments and segment copy number. Copy number data were inspected visually and manually for focal amplifications and deletions and genes were annotated with Oncotator<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423–E2429 (2015)." href="/articles/s41591-019-0654-5#ref-CR63" id="ref-link-section-d66811012e3803">63</a></sup>. For allelic copy number alterations, heterozygous single-nucleotide polymorphisms were identified and integrated into the binary segmentation algorithm (Allelic CapSeg) and allelic segments were further adjusted for tumor purity and ploidy using estimates derived from ABSOLUTE<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012)." href="/articles/s41591-019-0654-5#ref-CR67" id="ref-link-section-d66811012e3807">67</a></sup>. We then called allelic amplifications and deletions, following previously described methodology and criteria<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68" title="Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164–1177 (2015)." href="/articles/s41591-019-0654-5#ref-CR68" id="ref-link-section-d66811012e3811">68</a></sup> integrating segment focality and the purity- and ploidy-corrected allelic copy number.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec18">Purity and ploidy</h4><p>Purity and ploidy were estimated using the ABSOLUTE algorithm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012)." href="/articles/s41591-019-0654-5#ref-CR67" id="ref-link-section-d66811012e3823">67</a></sup>, which integrates variant allele frequency distributions and copy number variants to estimate absolute tumor purity and ploidy and infer the cancer cell fraction, the proportion of cancer cells in the sample that contain each mutation. Allelic segments following purity and ploidy correction were used to estimate allelic copy number.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec19">Heterogeneity and aneuploidy</h4><p>Heterogeneity was estimated as the proportion of mutations in each sample that were inferred to be subclonal. Clonal mutations were defined as having a cancer cell fraction ≥0.8, while other mutations were defined as subclonal; we chose this definition as a simple conservative approach with high specificity.</p><p>To estimate aneuploidy, we used the proportion of the genome inferred to have an allelic amplification or deletion, using the allelic segmentation described above.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec20">Mutational signatures</h4><p>De novo mutational signatures were generated in this cohort using an adaptation of non-negative matrix factorization<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69" title="Lee, D. D. &amp; Seung, H. S. Learning the parts of objects by non-negative matrix factorization. Nature 401, 788–791 (1999)." href="/articles/s41591-019-0654-5#ref-CR69" id="ref-link-section-d66811012e3846">69</a></sup> via the Brunet update method<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 70" title="Brunet, J. P. et al. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl Acad. Sci. USA 101, 4164–4169 (2004)." href="/articles/s41591-019-0654-5#ref-CR70" id="ref-link-section-d66811012e3850">70</a></sup>, as previously described in detail<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat. Commun. 8, 2193 (2017)." href="/articles/s41591-019-0654-5#ref-CR51" id="ref-link-section-d66811012e3854">51</a></sup>, with the R package SomaticSignatures<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 71" title="Gehring, J. S., Fischer, B., Lawrence, M. &amp; Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics 31, 3673–3675 (2015)." href="/articles/s41591-019-0654-5#ref-CR71" id="ref-link-section-d66811012e3858">71</a></sup> and non-negative matrix factorization<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 72" title="Gaujoux, R. &amp; Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 11, 367 (2010)." href="/articles/s41591-019-0654-5#ref-CR72" id="ref-link-section-d66811012e3862">72</a></sup>. Cosine similarity was used to compare the discovered signatures to the 30 existing discovered and validated signatures in COSMIC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)." href="/articles/s41591-019-0654-5#ref-CR25" id="ref-link-section-d66811012e3867">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 73" title="Forbes, S. A. et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805–D811 (2015)." href="/articles/s41591-019-0654-5#ref-CR73" id="ref-link-section-d66811012e3870">73</a></sup>, with a threshold of 0.85, and we also manually visualized and inspected similarities in mutational motifs between our signatures and COSMIC signatures.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec21">Transcriptomic analysis</h4><p>Whole-transcriptome sequencing data from FFPE tissues were aligned using STAR<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 74" title="Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013)." href="/articles/s41591-019-0654-5#ref-CR74" id="ref-link-section-d66811012e3882">74</a></sup> and quantified with RSEM<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 75" title="Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011)." href="/articles/s41591-019-0654-5#ref-CR75" id="ref-link-section-d66811012e3886">75</a></sup> to yield gene-level expression in transcripts per million (TPM). For RNA-seq quality control, sequencing- and alignment-specific metrics were considered for each sample. The following alignment metrics (output by the STAR alignment method) were considered: percentage of uniquely mapped reads, average mapped read length, number of splices, mismatch rate per base, percentage of multimapped reads, percentage of reads mapped to too many locations, percentage of unmapped reads due to too many mismatches, percentage of unmapped reads due to reads being too short and percentage of unmapped reads due to other reasons. Additionally, we considered the raw number of reads, the average read length, the read duplication rate and DV200 for each sample. Samples were clustered across quality-control metrics using principal-component analysis, and outlier samples were manually evaluated and discarded. Three samples were removed owing to poor quality: patient 143 was excluded owing to an abnormally low absolute number of reads (number of reads &lt;1 million); patient 107 was excluded owing to an abnormally high percentage of reads mapped to too many locations (&gt;10% of reads), likely indicating high numbers of short or degraded reads; and patient 61 was excluded owing to multiple aberrant quality-control metrics resulting in overall poor quality when considering all metrics in aggregate as well as an aberrant expression profile compared to all other samples. Only transcriptomes from tumors whose WES also passed quality control were included; the final patient cohort for RNA-seq analysis included <i>n</i> = 121 transcriptomes.</p><p>We excluded certain classes of noncoding genes that constituted a large (&gt;10%) proportion of TPM in the majority of samples. Specifically we excluded genes characterized as snoRNA, using biomaRt<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76" title="Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21, 3439–3440 (2005)." href="/articles/s41591-019-0654-5#ref-CR76" id="ref-link-section-d66811012e3896">76</a></sup> to download Ensembl biotype annotations (using the dataset ‘hsapiens_gene_ensembl’ and version ‘GRCh38.p10’) and excluding genes whose biotype was ‘snoRNA’ (<i>n</i> = 380 genes). We then regenerated a new TPM metric for each sample to normalize the total transcriptome sum to 1 million.</p><p>For analysis, only genes with TPM &gt; 0 in 25% or more of the samples were included. This excluded 6,158 genes, with 20,848 genes passing this threshold.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec22">GSEA and ssGSEA</h4><p>GSEA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)." href="/articles/s41591-019-0654-5#ref-CR32" id="ref-link-section-d66811012e3914">32</a></sup> was performed using the Cancer Hallmarks gene sets<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Liberzon, A. et al. The molecular signatures database hallmark gene-set collection. Cell Syst. 1, 417–425 (2015)." href="/articles/s41591-019-0654-5#ref-CR33" id="ref-link-section-d66811012e3918">33</a></sup> from MSigDB at <a href="https://cloud.genepattern.org/">https://cloud.genepattern.org/</a>. We used default settings with 10,000 gene set permutations to generate <i>P</i> and <i>q</i> values, and we compared progressors and responders in the overall cohort, the ipilimumab-treated subgroup and the ipilimumab-naive subgroup separately.</p><p>To generate nonparametric gene set scores in individual samples, we generated ssGSEA projections<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009)." href="/articles/s41591-019-0654-5#ref-CR43" id="ref-link-section-d66811012e3938">43</a></sup> for gene sets using rank normalization, including the MHC-II HLA genes (<i>HLA-DMA</i>, <i>HLA-DMB</i>, <i>HLA-DOA</i>, <i>HLA-DOB</i>, <i>HLA-DPA1</i>, <i>HLA-DPB1</i>, <i>HLA-DQA1</i>, <i>HLA-DQA2</i>, <i>HLA-DQB1</i>, <i>HLA-DQB2</i>, <i>HLA-DRA</i>, <i>HLA-DRB1</i> and <i>HLA-DRB5</i>) and MHC-I HLA genes (<i>HLA-A</i>, <i>HLA-B</i>, <i>HLA-C</i>, <i>HLA-E</i>, <i>HLA-F</i>, <i>TAP1</i>, <i>TAP2</i> and <i>B2M</i>). ssGSEA scores were also generated for Cancer Hallmarks gene sets.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec23">Absolute immune infiltrate and immune subsets</h4><p>Estimation of the total immune infiltrate in each sample and immune cell subsets was performed using CIBERSORT with the LM22 gene set<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015)." href="/articles/s41591-019-0654-5#ref-CR41" id="ref-link-section-d66811012e4017">41</a></sup> on the CIBERSORT website (<a href="http://cibersort.stanford.edu">http://cibersort.stanford.edu</a>). The absolute mode was enabled and quantile normalization was disabled using the RNA-seq TPM matrix for the cohort.</p><p>A separate immune infiltrate and immune cell subsets score analysis was performed using single-cell-derived signatures, and the methodology used for generating normalized signature scores was as described by Jerby-Arnon and colleagues<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997 (2018)." href="/articles/s41591-019-0654-5#ref-CR42" id="ref-link-section-d66811012e4031">42</a></sup>.</p><p>As there is no gold standard for inferring immune infiltrate from bulk RNA-seq data, we chose to use CIBERSORT-inferred values throughout the analysis to allow comparisons with other studies, as CIBERSORT has been widely used (for example, in a pan-TCGA immune landscape analysis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 77" title="Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018)." href="/articles/s41591-019-0654-5#ref-CR77" id="ref-link-section-d66811012e4038">77</a></sup>).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec24">Gene expression signatures</h4><p>Published gene expression signatures related to immune-checkpoint response were collected from the literature and validated in our cohort<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)." href="/articles/s41591-019-0654-5#ref-CR18" id="ref-link-section-d66811012e4050">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Davoli, T. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017)." href="/articles/s41591-019-0654-5#ref-CR19" id="ref-link-section-d66811012e4053">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. &amp; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015)." href="/articles/s41591-019-0654-5#ref-CR21" id="ref-link-section-d66811012e4056">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545–1549 (2018)." href="#ref-CR34" id="ref-link-section-d66811012e4059">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016)." href="#ref-CR35" id="ref-link-section-d66811012e4059_1">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454–461 (2019)." href="#ref-CR36" id="ref-link-section-d66811012e4059_2">36</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018)." href="#ref-CR37" id="ref-link-section-d66811012e4059_3">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012)." href="#ref-CR38" id="ref-link-section-d66811012e4059_4">38</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017)." href="#ref-CR39" id="ref-link-section-d66811012e4059_5">39</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Ock, C.-Y. et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat. Commun. 8, 1050 (2017)." href="/articles/s41591-019-0654-5#ref-CR40" id="ref-link-section-d66811012e4062">40</a></sup>. Sample-wise scores for these gene signatures were calculated from RNA-seq data using TPM values and following the methodology described in corresponding studies. Genes with unavailable expression data were excluded from calculations of gene signature scores. In two gene signatures<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017)." href="/articles/s41591-019-0654-5#ref-CR39" id="ref-link-section-d66811012e4066">39</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Ock, C.-Y. et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat. Commun. 8, 1050 (2017)." href="/articles/s41591-019-0654-5#ref-CR40" id="ref-link-section-d66811012e4069">40</a></sup>, genes were incorporated independently (that is, weighted) into the published model, but neither the direction nor the coefficient was available, so these signatures were excluded from evaluation. Differences in immune signature scores between responders (CR and PR) and progressors (PD) across all samples, in the ipilimumab-naive subset and in the ipilimumab-treated subset were tested using the Mann–Whitney <i>U</i>-test. The predictive utility of these immune signatures was evaluated with AUC values derived from ROC curves of gene signature scores in the complete cohort, ipilimumab-naive subset and the ipilimumab-treated subset. Results and detailed descriptions of evaluated gene signatures are provided in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">6</a>.</p><h3 class="c-article__sub-heading" id="Sec25">Analysis</h3><p>Two primary response comparisons were made: (1) responders (defined as having CR or PR as the best RECIST response) versus progressors (defined as having PD as the best RECIST response) and (2) progressors (defined as having non-PD as the best RECIST response) versus non-progressors.</p><p>Statistical tests were performed utilizing the Python <i>scipy.stats</i> package. To compare numeric features between response categories, including transcriptome expression, a nonparametric MWW rank-sum test (<i>mannwhitneyu</i>() function) was used to minimize the effects of outliers. For comparison of the proportion between response categories, a chi-squared test (<i>chi2_contingency</i>() function) was utilized. For association of binary variables (for example, association of gene alteration with responders versus progressors), a Fisher’s exact test (<i>fisher_exact</i>() function) was utilized to generate a <i>P</i> value. A conservative adjusted OR was generated by repeating the Fisher’s exact test, adding one to both the number of gene-mutant responders and progressors. All tests were two sided unless otherwise indicated.</p><p>Survival analyses were performed utilizing the Python <i>lifelines</i> package<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 78" title="Davidson-Pilon C. et al. CamDavidsonPilon/lifelines v.0.18.5. Zenodo 
                  https://doi.org/10.5281/zenodo.2562267
                  
                 (2019)." href="/articles/s41591-019-0654-5#ref-CR78" id="ref-link-section-d66811012e4113">78</a></sup>. For Kaplan–Meier curve survival analysis, a log-rank test (<i>logrank_test()</i> function) was used to compare survival curves.</p><p>Hierarchical clustering was performed using the <i>clustermap()</i> function from the Python <i>seaborn</i> package<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 79" title="Waksom M. et al. mwaskom/seaborn v.0.8.1 Zenodo 
                  https://doi.org/10.5281/zenodo.883859
                  
                 (2017)." href="/articles/s41591-019-0654-5#ref-CR79" id="ref-link-section-d66811012e4129">79</a></sup>, with default settings including a Euclidean distance metric and the ‘single’ method of calculating cluster distance (minimization of the nearest point between clusters).</p><h3 class="c-article__sub-heading" id="Sec26">Validation</h3><p>For validation, we reviewed the literature and found three studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)." href="/articles/s41591-019-0654-5#ref-CR18" id="ref-link-section-d66811012e4141">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016)." href="/articles/s41591-019-0654-5#ref-CR20" id="ref-link-section-d66811012e4144">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017)." href="/articles/s41591-019-0654-5#ref-CR44" id="ref-link-section-d66811012e4147">44</a></sup> of advanced melanoma treated with anti-PD1 ICB with response, WES and RNA-seq data. However, one did not have information on previous ipilimumab treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016)." href="/articles/s41591-019-0654-5#ref-CR20" id="ref-link-section-d66811012e4151">20</a></sup>, and another<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)." href="/articles/s41591-019-0654-5#ref-CR18" id="ref-link-section-d66811012e4155">18</a></sup> had only two patients who were naive to ipilimumab and nine who were treated with ipilimumab with post-ipilimumab tumor biopsies and available WES and NanoString data; thus, we used the remaining cohort<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017)." href="/articles/s41591-019-0654-5#ref-CR44" id="ref-link-section-d66811012e4159">44</a></sup> as our primary validation cohort.</p><p>To allow appropriate validation, only cutaneous, occult, acral and mucosal samples were included from validation cohorts; specifically, uveal and ocular melanomas were excluded (Riaz cohort, <i>n</i> = 5 excluded). Only patients with evaluable response criteria were included (Riaz cohort, <i>n</i> = 2 excluded). WES, transcriptomic and heterogeneity data were obtained from <a href="https://github.com/riazn/bms038_analysis">https://github.com/riazn/bms038_analysis</a>. Fragments per kilobase of transcript per million mapped reads values were converted to TPM to be consistent with our cohort normalization.</p><h3 class="c-article__sub-heading" id="Sec27">Predictive model generation and cross-validation</h3><p>We used logistic regression for our model to predict PD as the best RECIST response versus non-PD rather than responder versus progressor to better reflect the real-world setting where all outcomes (PD, SD, MR, PR and CR) are possible. We evaluated genomic, transcriptomic and clinical features. Categorical features were converted to binary features for each categorical value. To be conservative, no gene-level mutations or expression values were individually considered. Global genomic tumor characteristics such as TMB, purity, ploidy, heterogeneity and aneuploidy were considered. Features were generated from the transcriptome, including ssGSEA values for gene sets representing Cancer Hallmarks pathways, and MHC-II and MHC-I antigen-presentation genes, as well as gene expression signatures following the methodology in the respective publications, as described above and in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">6</a>. Clinical characteristics including LDH and ECOG at the start of anti-PD1 ICB, the number of metastatic organs, sex, M stage, the number of different metastatic sites, metastatic sites and melanoma subtype were evaluated (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM4">1</a>). Features were chosen in a forward-selection-based process, where features that were significantly predictive (<i>P</i> &lt; 0.05) when added to the base model were ranked on the basis of the ability of the combined model to discriminate outcomes (using ROC curve AUC as the metric), and the best feature was chosen to be added to the base model. Potential features were evaluated on the basis of a manual review considering biological interpretability and clinical applicability. This process was iterated with the new base model and stopped when no features under consideration were significantly predictive.</p><p>The set of tumors with both WES and RNA-seq data was smaller than the set of tumors with only WES data; when the features chosen in model development for ipilimumab-naive tumors resulted in only WES features being chosen, model development was repeated in the superset of tumors requiring only clinical and WES data, and this model in the larger set is reported in the main text.</p><p>To estimate the ‘out-of-bag’ AUC, we used <i>k</i>-fold cross-validation (splitting the dataset into <i>k-</i>subsets, training on <i>k</i> − 1 subsets and calculating AUC on the holdout subset) and calculated the mean cross-validation AUC. Given the partially manual review of features, feature selection was not included in cross-validation. For the ipilimumab-treated subset (<i>n</i> = 34), we chose <i>k</i> = 5 folds, and for the larger ipilimumab-naive subset (<i>n</i> = 85), we chose <i>k</i> = 10 folds, to maintain a cross-validation holdout set of &gt;5 tumors. Cross-validation scores were calculated using the <i>cross_val_score</i> function from the Python <i>sklearn</i> package.</p><p>To further evaluate the statistical support for our models, we calculated the Akaike information criteria and BIC of each subsequent model after adding an additional feature in forward selection in the ipilimumab-experienced and ipilimumab-naive subgroups (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-019-0654-5#Fig13">8c,d</a>), and we also evaluated the addition of TMB as an additional feature to the selected models.</p><h3 class="c-article__sub-heading" id="Sec28">Permutation testing</h3><p>To test the statistical significance of differences in FDR <i>q</i> values of enriched pathways between ipilimumab-naive versus ipilimumab-experienced subgroups, we performed a permutation analysis. Briefly, we shuffled the ipilimumab-experienced and ipilimumab-naive labels for each tumor, keeping each subgroup size the same and keeping the same number of responders and progressors in each subgroup, and we reran GSEA on each new simulated subgroup. We repeated this 1,000 times to generate a distribution of enriched pathways in each subgroup under the null hypothesis of no relationship between subgroup and pathway enrichment. We then compared our observed outcome within this null distribution to generate an empiric <i>P</i> value. For example, for each pathway enriched in ipilimumab-experienced patients, the proportion of simulations with a difference in log <i>q</i> value between ipilimumab-experienced and ipilimumab-naive subgroups (equivalent to the ratio of <i>q</i> values) greater than or equal to our observed difference, and with an FDR <i>q</i> value in the ipilimumab-experienced subgroup equal to or more extreme than our observed ipilimumab-experienced <i>q</i> value would represent the empiric <i>P</i> value.</p><p>We performed a similar permutation test to generate an empiric <i>P</i> value for the predictive models for ipilimumab-experienced and ipilimumab-naive subgroups. Briefly, we permuted the outcome labels (progressors and non-progressors) within each subgroup, and generated an AUC and cross-validation AUC for the predictive model with the specified features (that is, MHC-II, LDH and lymph node metastasis for ipilimumab-experienced tumors; purity, ploidy and heterogeneity for ipilimumab-naive tumors) to generate a null distribution of AUCs and cross-validation AUCs under the null hypothesis that these predictors are not associated with outcomes. By permuting the phenotype rather than the predictors, we preserved the inter-predictor structure. Then, the proportion of simulations with AUC and cross-validation AUC greater than our observed AUC represented an empiric <i>P</i> value.</p><h3 class="c-article__sub-heading" id="Sec29">Reporting Summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-019-0654-5#MOESM1">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>All reasonable requests for raw and analyzed data and materials will be promptly reviewed by the senior authors to determine whether the request is subject to any intellectual property or confidentiality obligations. Patient-related data not included in the paper may be subject to patient confidentiality. Any data and materials that can be shared will be released via a material transfer agreement. All analyzed sequencing data are in supplementary tables or data available online. Raw sequencing data are available in dbGaP (accession number <a href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000452.v3.p1">phs000452.v3.p1</a>).</p>
            </div></div></section><section data-title="Code availability"><div class="c-article-section" id="code-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="code-availability">Code availability</h2><div class="c-article-section__content" id="code-availability-content">
              
              <p>Python code is available in packages as described in the manuscript. Code to regenerate figures using supplementary data and tables is available at GitHub at <a href="https://github.com/vanallenlab/schadendorf-pd1">https://github.com/vanallenlab/schadendorf-pd1</a>. Additional reasonable requests for code will be promptly reviewed by the senior authors to verify whether the request is subject to any intellectual property or confidentiality obligations, and shared to the extent permissible by these obligations.</p>
            </div></div></section><section data-title="Change history"><div class="c-article-section" id="change-history-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="change-history">Change history</h2><div class="c-article-section__content" id="change-history-content"><ul class="c-article-change-list"><li class="c-article-change-list__item u-mb-24" id="chg1"><ins datetime="2020-06-19"><h3 class="c-article-change-list__heading u-h3 u-pr-8 u-display-inline">19 June 2020</h3><div class="c-article-change-list__details"><p>An amendment to this paper has been published and can be accessed via a link at the top of the paper.</p></div></ins></li></ul></div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. <i>N. Engl. J. Med.</i> <b>363</b>, 711–723 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1003466" data-track-item_id="10.1056/NEJMoa1003466" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1003466" aria-label="Article reference 1" data-doi="10.1056/NEJMoa1003466">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVCrtrbN" aria-label="CAS reference 1">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20525992" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297" aria-label="PubMed Central reference 1">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1003466&amp;volume=363&amp;pages=711-723&amp;publication_year=2010&amp;author=Hodi%2CFS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>372</b>, 2521–2532 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1503093" data-track-item_id="10.1056/NEJMoa1503093" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1503093" aria-label="Article reference 2" data-doi="10.1056/NEJMoa1503093">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFyrsbrF" aria-label="CAS reference 2">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25891173" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20versus%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1503093&amp;volume=372&amp;pages=2521-2532&amp;publication_year=2015&amp;author=Robert%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>377</b>, 1345–1356 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1709684" data-track-item_id="10.1056/NEJMoa1709684" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1709684" aria-label="Article reference 3" data-doi="10.1056/NEJMoa1709684">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1Git73I" aria-label="CAS reference 3">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28889792" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778" aria-label="PubMed Central reference 3">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709684&amp;volume=377&amp;pages=1345-1356&amp;publication_year=2017&amp;author=Wolchok%2CJD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. <i>N. Engl. J. Med.</i> <b>375</b>, 1823–1833 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1606774" data-track-item_id="10.1056/NEJMoa1606774" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1606774" aria-label="Article reference 4" data-doi="10.1056/NEJMoa1606774">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhvF2ks77I" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27718847" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20versus%20chemotherapy%20for%20PD-L1-positive%20non-small%20cell%20lung%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1606774&amp;volume=375&amp;pages=1823-1833&amp;publication_year=2016&amp;author=Reck%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> <b>387</b>, 1909–1920 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(16)00561-4" data-track-item_id="10.1016/S0140-6736(16)00561-4" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2816%2900561-4" aria-label="Article reference 5" data-doi="10.1016/S0140-6736(16)00561-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XjslGmu7w%3D" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26952546" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480242" aria-label="PubMed Central reference 5">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy%3A%20a%20single-arm%2C%20multicentre%2C%20phase%202%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2816%2900561-4&amp;volume=387&amp;pages=1909-1920&amp;publication_year=2016&amp;author=Rosenberg%2CJE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. <i>N. Engl. J. Med.</i> <b>373</b>, 1803–1813 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1510665" data-track-item_id="10.1056/NEJMoa1510665" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1510665" aria-label="Article reference 6" data-doi="10.1056/NEJMoa1510665">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XjsFyhsrg%3D" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26406148" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487" aria-label="PubMed Central reference 6">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20versus%20everolimus%20in%20advanced%20renal-cell%20carcinoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1510665&amp;volume=373&amp;pages=1803-1813&amp;publication_year=2015&amp;author=Motzer%2CRJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <i>Lancet Oncol.</i> <b>17</b>, 956–965 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(16)30066-3" data-track-item_id="10.1016/S1470-2045(16)30066-3" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2816%2930066-3" aria-label="Article reference 7" data-doi="10.1016/S1470-2045(16)30066-3">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XptFerurg%3D" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27247226" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20clinical%20activity%20of%20pembrolizumab%20for%20treatment%20of%20recurrent%20or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20%28KEYNOTE-012%29%3A%20an%20open-label%2C%20multicentre%2C%20phase%201b%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2816%2930066-3&amp;volume=17&amp;pages=956-965&amp;publication_year=2016&amp;author=Seiwert%2CTY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> <b>348</b>, 124 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aaa1348" data-track-item_id="10.1126/science.aaa1348" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aaa1348" aria-label="Article reference 8" data-doi="10.1126/science.aaa1348">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXls1Wmtbg%3D" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25765070" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993154" aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Mutational%20landscape%20determines%20sensitivity%20to%20PD-1%20blockade%20in%20non-small%20cell%20lung%20cancer&amp;journal=Science&amp;doi=10.1126%2Fscience.aaa1348&amp;volume=348&amp;publication_year=2015&amp;author=Rizvi%2CNA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. <i>N. Engl. J. Med.</i> <b>371</b>, 2189–2199 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1406498" data-track-item_id="10.1056/NEJMoa1406498" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1406498" aria-label="Article reference 9" data-doi="10.1056/NEJMoa1406498">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25409260" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315319" aria-label="PubMed Central reference 9">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXht1ekt7o%3D" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Genetic%20basis%20for%20clinical%20response%20to%20CTLA-4%20blockade%20in%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1406498&amp;volume=371&amp;pages=2189-2199&amp;publication_year=2014&amp;author=Snyder%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> <b>350</b>, 207–211 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aad0095" data-track-item_id="10.1126/science.aad0095" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aad0095" aria-label="Article reference 10" data-doi="10.1126/science.aad0095">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26359337" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054517" aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1antLnJ" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20correlates%20of%20response%20to%20CTLA-4%20blockade%20in%20metastatic%20melanoma&amp;journal=Science&amp;doi=10.1126%2Fscience.aad0095&amp;volume=350&amp;pages=207-211&amp;publication_year=2015&amp;author=Allen%2CEM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> <b>362</b>, eaar3593 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aar3593" data-track-item_id="10.1126/science.aar3593" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aar3593" aria-label="Article reference 11" data-doi="10.1126/science.aar3593">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30309915" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718162" aria-label="PubMed Central reference 11">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVKqtLzP" aria-label="CAS reference 11">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Pan-tumor%20genomic%20biomarkers%20for%20PD-1%20checkpoint%20blockade-based%20immunotherapy&amp;journal=Science&amp;doi=10.1126%2Fscience.aar3593&amp;volume=362&amp;publication_year=2018&amp;author=Cristescu%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> <b>515</b>, 568–571 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature13954" data-track-item_id="10.1038/nature13954" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature13954" aria-label="Article reference 12" data-doi="10.1038/nature13954">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFanu7jL" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25428505" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418" aria-label="PubMed Central reference 12">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-1%20blockade%20induces%20responses%20by%20inhibiting%20adaptive%20immune%20resistance&amp;journal=Nature&amp;doi=10.1038%2Fnature13954&amp;volume=515&amp;pages=568-571&amp;publication_year=2014&amp;author=Tumeh%2CPC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. <i>N. Engl. J. Med.</i> <b>375</b>, 819–829 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1604958" data-track-item_id="10.1056/NEJMoa1604958" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1604958" aria-label="Article reference 13" data-doi="10.1056/NEJMoa1604958">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhvF2ks7%2FP" aria-label="CAS reference 13">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27433843" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007206" aria-label="PubMed Central reference 13">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Mutations%20associated%20with%20acquired%20resistance%20to%20PD-1%20blockade%20in%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1604958&amp;volume=375&amp;pages=819-829&amp;publication_year=2016&amp;author=Zaretsky%2CJM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nat. Commun.</i> <b>8</b>, 1136 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-017-01062-w" data-track-item_id="10.1038/s41467-017-01062-w" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-017-01062-w" aria-label="Article reference 14" data-doi="10.1038/s41467-017-01062-w">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29070816" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656607" aria-label="PubMed Central reference 14">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXovFyhtL8%3D" aria-label="CAS reference 14">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Resistance%20to%20checkpoint%20blockade%20therapy%20through%20inactivation%20of%20antigen%20presentation&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-01062-w&amp;volume=8&amp;publication_year=2017&amp;author=Sade-Feldman%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. <i>Cell</i> <b>167</b>, 397–404 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2016.08.069" data-track-item_id="10.1016/j.cell.2016.08.069" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2016.08.069" aria-label="Article reference 15" data-doi="10.1016/j.cell.2016.08.069">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhsFGrurbJ" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27667683" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088716" aria-label="PubMed Central reference 15">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Loss%20of%20IFN-%CE%B3%20pathway%20genes%20in%20tumor%20cells%20as%20a%20mechanism%20of%20resistance%20to%20anti-CTLA-4%20therapy&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2016.08.069&amp;volume=167&amp;pages=397-404&amp;publication_year=2016&amp;author=Gao%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. <i>Cancer Discov.</i> <b>6</b>, 202–216 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-15-0283" data-track-item_id="10.1158/2159-8290.CD-15-0283" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-15-0283" aria-label="Article reference 16" data-doi="10.1158/2159-8290.CD-15-0283">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XisVyjtbo%3D" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26645196" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Loss%20of%20PTEN%20promotes%20resistance%20to%20T%20cell-mediated%20immunotherapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-15-0283&amp;volume=6&amp;pages=202-216&amp;publication_year=2016&amp;author=Peng%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">George, S. et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. <i>Immunity</i> <b>46</b>, 197–204 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2017.02.001" data-track-item_id="10.1016/j.immuni.2017.02.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2017.02.001" aria-label="Article reference 17" data-doi="10.1016/j.immuni.2017.02.001">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXjtlertbk%3D" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28228279" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408320" aria-label="PubMed Central reference 17">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Loss%20of%20PTEN%20is%20associated%20with%20resistance%20to%20anti-PD-1%20checkpoint%20blockade%20therapy%20in%20metastatic%20uterine%20leiomyosarcoma&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2017.02.001&amp;volume=46&amp;pages=197-204&amp;publication_year=2017&amp;author=George%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Sci. Transl. Med.</i> <b>9</b>, eaah3560 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.aah3560" data-track-item_id="10.1126/scitranslmed.aah3560" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.aah3560" aria-label="Article reference 18" data-doi="10.1126/scitranslmed.aah3560">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28251903" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819607" aria-label="PubMed Central reference 18">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXjsVSktrk%3D" aria-label="CAS reference 18">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Integrated%20molecular%20analysis%20of%20tumor%20biopsies%20on%20sequential%20CTLA-4%20and%20PD-1%20blockade%20reveals%20markers%20of%20response%20and%20resistance&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.aah3560&amp;volume=9&amp;publication_year=2017&amp;author=Roh%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Davoli, T. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. <i>Science</i> <b>355</b>, eaaf8399 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aaf8399" data-track-item_id="10.1126/science.aaf8399" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aaf8399" aria-label="Article reference 19" data-doi="10.1126/science.aaf8399">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28104840" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592794" aria-label="PubMed Central reference 19">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtVehur8%3D" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20aneuploidy%20correlates%20with%20markers%20of%20immune%20evasion%20and%20with%20reduced%20response%20to%20immunotherapy&amp;journal=Science&amp;doi=10.1126%2Fscience.aaf8399&amp;volume=355&amp;publication_year=2017&amp;author=Davoli%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. <i>Cell</i> <b>165</b>, 35–44 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2016.02.065" data-track-item_id="10.1016/j.cell.2016.02.065" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2016.02.065" aria-label="Article reference 20" data-doi="10.1016/j.cell.2016.02.065">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XksVKrsbw%3D" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26997480" aria-label="PubMed reference 20">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808437" aria-label="PubMed Central reference 20">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20and%20transcriptomic%20features%20of%20response%20to%20anti-PD-1%20therapy%20in%20metastatic%20melanoma&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2016.02.065&amp;volume=165&amp;pages=35-44&amp;publication_year=2016&amp;author=Hugo%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. &amp; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. <i>Cell</i> <b>160</b>, 48–61 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2014.12.033" data-track-item_id="10.1016/j.cell.2014.12.033" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2014.12.033" aria-label="Article reference 21" data-doi="10.1016/j.cell.2014.12.033">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtF2lsbo%3D" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25594174" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856474" aria-label="PubMed Central reference 21">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Molecular%20and%20genetic%20properties%20of%20tumors%20associated%20with%20local%20immune%20cytolytic%20activity&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2014.12.033&amp;volume=160&amp;pages=48-61&amp;publication_year=2015&amp;author=Rooney%2CMS&amp;author=Shukla%2CSA&amp;author=Wu%2CCJ&amp;author=Getz%2CG&amp;author=Hacohen%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Weber, J. S. et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncol.</i> <b>17</b>, 943–955 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(16)30126-7" data-track-item_id="10.1016/S1470-2045(16)30126-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2816%2930126-7" aria-label="Article reference 22" data-doi="10.1016/S1470-2045(16)30126-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xpslyjs7w%3D" aria-label="CAS reference 22">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27269740" aria-label="PubMed reference 22">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474305" aria-label="PubMed Central reference 22">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Sequential%20administration%20of%20nivolumab%20and%20ipilimumab%20with%20a%20planned%20switch%20in%20patients%20with%20advanced%20melanoma%20%28CheckMate%20064%29%3A%20an%20open-label%2C%20randomised%2C%20phase%202%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2816%2930126-7&amp;volume=17&amp;pages=943-955&amp;publication_year=2016&amp;author=Weber%2CJS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Van Allen, E. M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. <i>Nat. Med.</i> <b>20</b>, 682–688 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nm.3559" data-track-item_id="10.1038/nm.3559" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnm.3559" aria-label="Article reference 23" data-doi="10.1038/nm.3559">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24836576" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048335" aria-label="PubMed Central reference 23">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXotFeqsLg%3D" aria-label="CAS reference 23">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Whole-exome%20sequencing%20and%20clinical%20interpretation%20of%20formalin-fixed%2C%20paraffin-embedded%20tumor%20samples%20to%20guide%20precision%20cancer%20medicine&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.3559&amp;volume=20&amp;pages=682-688&amp;publication_year=2014&amp;author=Allen%2CEM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Birkeland, E. et al. Patterns of genomic evolution in advanced melanoma. <i>Nat. Commun.</i> <b>9</b>, 2665 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-018-05063-1" data-track-item_id="10.1038/s41467-018-05063-1" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-018-05063-1" aria-label="Article reference 24" data-doi="10.1038/s41467-018-05063-1">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BB3c%2Fms12ntw%3D%3D" aria-label="CAS reference 24">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29991680" aria-label="PubMed reference 24">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039447" aria-label="PubMed Central reference 24">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Patterns%20of%20genomic%20evolution%20in%20advanced%20melanoma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-018-05063-1&amp;volume=9&amp;publication_year=2018&amp;author=Birkeland%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. <i>Nature</i> <b>500</b>, 415–421 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature12477" data-track-item_id="10.1038/nature12477" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature12477" aria-label="Article reference 25" data-doi="10.1038/nature12477">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtlWjur7M" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23945592" aria-label="PubMed reference 25">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776390" aria-label="PubMed Central reference 25">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Signatures%20of%20mutational%20processes%20in%20human%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature12477&amp;volume=500&amp;pages=415-421&amp;publication_year=2013&amp;author=Alexandrov%2CLB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> <b>545</b>, 175–180 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature22071" data-track-item_id="10.1038/nature22071" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature22071" aria-label="Article reference 26" data-doi="10.1038/nature22071">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXntVKms7w%3D" aria-label="CAS reference 26">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28467829" aria-label="PubMed reference 26">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Whole-genome%20landscapes%20of%20major%20melanoma%20subtypes&amp;journal=Nature&amp;doi=10.1038%2Fnature22071&amp;volume=545&amp;pages=175-180&amp;publication_year=2017&amp;author=Hayward%2CNK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nat. Genet.</i> <b>50</b>, 1271–1281 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41588-018-0200-2" data-track-item_id="10.1038/s41588-018-0200-2" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41588-018-0200-2" aria-label="Article reference 27" data-doi="10.1038/s41588-018-0200-2">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsF2nsrvM" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30150660" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119118" aria-label="PubMed Central reference 27">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20correlates%20of%20response%20to%20immune%20checkpoint%20blockade%20in%20microsatellite-stable%20solid%20tumors&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fs41588-018-0200-2&amp;volume=50&amp;pages=1271-1281&amp;publication_year=2018&amp;author=Miao%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. <i>Cell</i> <b>171</b>, 1259–1271 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2017.10.001" data-track-item_id="10.1016/j.cell.2017.10.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2017.10.001" aria-label="Article reference 28" data-doi="10.1016/j.cell.2017.10.001">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslehs7nL" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29107330" aria-label="PubMed reference 28">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720478" aria-label="PubMed Central reference 28">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Allele-specific%20HLA%20loss%20and%20immune%20escape%20in%20lung%20cancer%20evolution&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.10.001&amp;volume=171&amp;pages=1259-1271&amp;publication_year=2017&amp;author=McGranahan%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Riaz, N. et al. Recurrent SERPINB3 and SERPINB4 mutations in patients that respond to anti-CTLA4 immunotherapy. <i>Nat. Genet.</i> <b>48</b>, 1327–1329 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ng.3677" data-track-item_id="10.1038/ng.3677" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fng.3677" aria-label="Article reference 29" data-doi="10.1038/ng.3677">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1SltL3P" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27668655" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553281" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Recurrent%20SERPINB3%20and%20SERPINB4%20mutations%20in%20patients%20that%20respond%20to%20anti-CTLA4%20immunotherapy&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.3677&amp;volume=48&amp;pages=1327-1329&amp;publication_year=2016&amp;author=Riaz%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. <i>Cancer Discov.</i> <b>7</b>, 188–201 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-16-1223" data-track-item_id="10.1158/2159-8290.CD-16-1223" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-16-1223" aria-label="Article reference 30" data-doi="10.1158/2159-8290.CD-16-1223">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXitVCjsr0%3D" aria-label="CAS reference 30">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27903500" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Primary%20resistance%20to%20PD-1%20blockade%20mediated%20by%20JAK1%2F2%20mutations&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-16-1223&amp;volume=7&amp;pages=188-201&amp;publication_year=2017&amp;author=Shin%2CDS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Sucker, A. et al. Acquired IFN-γ resistance impairs anti-tumor immunity and gives rise to T cell-resistant melanoma lesions. <i>Nat. Commun.</i> <b>8</b>, 15440 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ncomms15440" data-track-item_id="10.1038/ncomms15440" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms15440" aria-label="Article reference 31" data-doi="10.1038/ncomms15440">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXovFCmu7k%3D" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28561041" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460020" aria-label="PubMed Central reference 31">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Acquired%20IFN-%CE%B3%20resistance%20impairs%20anti-tumor%20immunity%20and%20gives%20rise%20to%20T%20cell-resistant%20melanoma%20lesions&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms15440&amp;volume=8&amp;publication_year=2017&amp;author=Sucker%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. <i>Proc. Natl Acad. Sci. USA</i> <b>102</b>, 15545–15550 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.0506580102" data-track-item_id="10.1073/pnas.0506580102" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.0506580102" aria-label="Article reference 32" data-doi="10.1073/pnas.0506580102">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXht1ShtrnO" aria-label="CAS reference 32">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16199517" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1239896" aria-label="PubMed Central reference 32">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Gene%20set%20enrichment%20analysis%3A%20a%20knowledge-based%20approach%20for%20interpreting%20genome-wide%20expression%20profiles&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0506580102&amp;volume=102&amp;pages=15545-15550&amp;publication_year=2005&amp;author=Subramanian%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Liberzon, A. et al. The molecular signatures database hallmark gene-set collection. <i>Cell Syst.</i> <b>1</b>, 417–425 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cels.2015.12.004" data-track-item_id="10.1016/j.cels.2015.12.004" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cels.2015.12.004" aria-label="Article reference 33" data-doi="10.1016/j.cels.2015.12.004">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFaltLc%3D" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26771021" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707969" aria-label="PubMed Central reference 33">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20molecular%20signatures%20database%20hallmark%20gene-set%20collection&amp;journal=Cell%20Syst.&amp;doi=10.1016%2Fj.cels.2015.12.004&amp;volume=1&amp;pages=417-425&amp;publication_year=2015&amp;author=Liberzon%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nat. Med.</i> <b>24</b>, 1545–1549 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0157-9" data-track-item_id="10.1038/s41591-018-0157-9" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0157-9" aria-label="Article reference 34" data-doi="10.1038/s41591-018-0157-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFGjurzF" aria-label="CAS reference 34">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30127394" aria-label="PubMed reference 34">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693632" aria-label="PubMed Central reference 34">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Robust%20prediction%20of%20response%20to%20immune%20checkpoint%20blockade%20therapy%20in%20metastatic%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0157-9&amp;volume=24&amp;pages=1545-1549&amp;publication_year=2018&amp;author=Auslander%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> <b>387</b>, 1837–1846 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(16)00587-0" data-track-item_id="10.1016/S0140-6736(16)00587-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2816%2900587-0" aria-label="Article reference 35" data-doi="10.1016/S0140-6736(16)00587-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XktVOltrs%3D" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26970723" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small%20cell%20lung%20cancer%20%28POPLAR%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%202%20randomised%20controlled%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2816%2900587-0&amp;volume=387&amp;pages=1837-1846&amp;publication_year=2016&amp;author=Fehrenbacher%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nat. Med.</i> <b>25</b>, 454–461 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-019-0357-y" data-track-item_id="10.1038/s41591-019-0357-y" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-019-0357-y" aria-label="Article reference 36" data-doi="10.1038/s41591-019-0357-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXmsVyruro%3D" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30804515" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699626" aria-label="PubMed Central reference 36">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20single%20dose%20of%20neoadjuvant%20PD-1%20blockade%20predicts%20clinical%20outcomes%20in%20resectable%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0357-y&amp;volume=25&amp;pages=454-461&amp;publication_year=2019&amp;author=Huang%2CAC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. <i>Nat. Med.</i> <b>24</b>, 1550–1558 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0136-1" data-track-item_id="10.1038/s41591-018-0136-1" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0136-1" aria-label="Article reference 37" data-doi="10.1038/s41591-018-0136-1">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFGjur3N" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30127393" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487502" aria-label="PubMed Central reference 37">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Signatures%20of%20T%20cell%20dysfunction%20and%20exclusion%20predict%20cancer%20immunotherapy%20response&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0136-1&amp;volume=24&amp;pages=1550-1558&amp;publication_year=2018&amp;author=Jiang%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? <i>Sci. Rep.</i> <b>2</b>, 765 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/srep00765" data-track-item_id="10.1038/srep00765" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fsrep00765" aria-label="Article reference 38" data-doi="10.1038/srep00765">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23097687" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479449" aria-label="PubMed Central reference 38">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38Xhs1WhtLrE" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=12-Chemokine%20gene%20signature%20identifies%20lymph%20node-like%20structures%20in%20melanoma%3A%20potential%20for%20patient%20selection%20for%20immunotherapy%3F&amp;journal=Sci.%20Rep.&amp;doi=10.1038%2Fsrep00765&amp;volume=2&amp;publication_year=2012&amp;author=Messina%2CJL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. <i>J. Clin. Invest.</i> <b>127</b>, 2930–2940 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/JCI91190" data-track-item_id="10.1172/JCI91190" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI91190" aria-label="Article reference 39" data-doi="10.1172/JCI91190">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28650338" aria-label="PubMed reference 39">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531419" aria-label="PubMed Central reference 39">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=IFN-%CE%B3-related%20mRNA%20profile%20predicts%20clinical%20response%20to%20PD-1%20blockade&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI91190&amp;volume=127&amp;pages=2930-2940&amp;publication_year=2017&amp;author=Ayers%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Ock, C.-Y. et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nat. Commun.</i> <b>8</b>, 1050 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-017-01018-0" data-track-item_id="10.1038/s41467-017-01018-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-017-01018-0" aria-label="Article reference 40" data-doi="10.1038/s41467-017-01018-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29051489" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648801" aria-label="PubMed Central reference 40">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXos1Krurk%3D" aria-label="CAS reference 40">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20landscape%20associated%20with%20potential%20response%20to%20anti-CTLA-4%20treatment%20in%20cancers&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-01018-0&amp;volume=8&amp;publication_year=2017&amp;author=Ock%2CC-Y">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. <i>Nat. Methods</i> <b>12</b>, 453–457 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nmeth.3337" data-track-item_id="10.1038/nmeth.3337" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnmeth.3337" aria-label="Article reference 41" data-doi="10.1038/nmeth.3337">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXlsVOgu7Y%3D" aria-label="CAS reference 41">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25822800" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739640" aria-label="PubMed Central reference 41">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Robust%20enumeration%20of%20cell%20subsets%20from%20tissue%20expression%20profiles&amp;journal=Nat.%20Methods&amp;doi=10.1038%2Fnmeth.3337&amp;volume=12&amp;pages=453-457&amp;publication_year=2015&amp;author=Newman%2CAM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. <i>Cell</i> <b>175</b>, 984–997 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2018.09.006" data-track-item_id="10.1016/j.cell.2018.09.006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2018.09.006" aria-label="Article reference 42" data-doi="10.1016/j.cell.2018.09.006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVyhurvK" aria-label="CAS reference 42">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30388455" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410377" aria-label="PubMed Central reference 42">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20cancer%20cell%20program%20promotes%20T%20cell%20exclusion%20and%20resistance%20to%20checkpoint%20blockade&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2018.09.006&amp;volume=175&amp;pages=984-997&amp;publication_year=2018&amp;author=Jerby-Arnon%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. <i>Nature</i> <b>462</b>, 108–112 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature08460" data-track-item_id="10.1038/nature08460" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature08460" aria-label="Article reference 43" data-doi="10.1038/nature08460">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXht12gtrvL" aria-label="CAS reference 43">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19847166" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783335" aria-label="PubMed Central reference 43">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Systematic%20RNA%20interference%20reveals%20that%20oncogenic%20KRAS-driven%20cancers%20require%20TBK1&amp;journal=Nature&amp;doi=10.1038%2Fnature08460&amp;volume=462&amp;pages=108-112&amp;publication_year=2009&amp;author=Barbie%2CDA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. <i>Cell</i> <b>171</b>, 934–949 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2017.09.028" data-track-item_id="10.1016/j.cell.2017.09.028" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2017.09.028" aria-label="Article reference 44" data-doi="10.1016/j.cell.2017.09.028">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1GjsrjL" aria-label="CAS reference 44">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29033130" aria-label="PubMed reference 44">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685550" aria-label="PubMed Central reference 44">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20and%20microenvironment%20evolution%20during%20immunotherapy%20with%20nivolumab&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.09.028&amp;volume=171&amp;pages=934-949&amp;publication_year=2017&amp;author=Riaz%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Weber, J. et al. Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab. <i>Ann. Oncol.</i> <b>27</b>, 10470 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdw378.01" data-track-item_id="10.1093/annonc/mdw378.01" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdw378.01" aria-label="Article reference 45" data-doi="10.1093/annonc/mdw378.01">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Baseline%20tumor%20T%20cell%20receptor%20%28TcR%29%20sequencing%20analysis%20and%20neo%20antigen%20load%20is%20associated%20with%20benefit%20in%20melanoma%20patients%20receiving%20sequential%20nivolumab%20and%20ipilimumab&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdw378.01&amp;volume=27&amp;publication_year=2016&amp;author=Weber%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nat. Med.</i> <b>24</b>, 1649–1654 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0197-1" data-track-item_id="10.1038/s41591-018-0197-1" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0197-1" aria-label="Article reference 46" data-doi="10.1038/s41591-018-0197-1">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVWjtLjL" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30297909" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481682" aria-label="PubMed Central reference 46">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Neoadjuvant%20immune%20checkpoint%20blockade%20in%20high-risk%20resectable%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0197-1&amp;volume=24&amp;pages=1649-1654&amp;publication_year=2018&amp;author=Amaria%2CRN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Sci. Transl. Med.</i> <b>10</b>, eaar3342 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.aar3342" data-track-item_id="10.1126/scitranslmed.aar3342" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.aar3342" aria-label="Article reference 47" data-doi="10.1126/scitranslmed.aar3342">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30021886" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitVOgtr4%3D" aria-label="CAS reference 47">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=MHC%20proteins%20confer%20differential%20sensitivity%20to%20CTLA-4%20and%20PD-1%20blockade%20in%20untreated%20metastatic%20melanoma&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.aar3342&amp;volume=10&amp;publication_year=2018&amp;author=Rodig%2CSJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nat. Commun.</i> <b>7</b>, 10582 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ncomms10582" data-track-item_id="10.1038/ncomms10582" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms10582" aria-label="Article reference 48" data-doi="10.1038/ncomms10582">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhslOmur4%3D" aria-label="CAS reference 48">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26822383" aria-label="PubMed reference 48">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740184" aria-label="PubMed Central reference 48">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=Melanoma-specific%20MHC-II%20expression%20represents%20a%20tumour-autonomous%20phenotype%20and%20predicts%20response%20to%20anti-PD-1%2FPD-L1%20therapy&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms10582&amp;volume=7&amp;publication_year=2016&amp;author=Johnson%2CDB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> <b>351</b>, 1463–1469 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aaf1490" data-track-item_id="10.1126/science.aaf1490" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aaf1490" aria-label="Article reference 49" data-doi="10.1126/science.aaf1490">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XksFCht70%3D" aria-label="CAS reference 49">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26940869" aria-label="PubMed reference 49">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984254" aria-label="PubMed Central reference 49">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=Clonal%20neoantigens%20elicit%20T%20cell%20immunoreactivity%20and%20sensitivity%20to%20immune%20checkpoint%20blockade&amp;journal=Science&amp;doi=10.1126%2Fscience.aaf1490&amp;volume=351&amp;pages=1463-1469&amp;publication_year=2016&amp;author=McGranahan%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Morris, L. G. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> <b>7</b>, 10051–10063 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.18632/oncotarget.7067" data-track-item_id="10.18632/oncotarget.7067" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.18632%2Foncotarget.7067" aria-label="Article reference 50" data-doi="10.18632/oncotarget.7067">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26840267" aria-label="PubMed reference 50">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891103" aria-label="PubMed Central reference 50">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Pan-cancer%20analysis%20of%20intratumor%20heterogeneity%20as%20a%20prognostic%20determinant%20of%20survival&amp;journal=Oncotarget&amp;doi=10.18632%2Foncotarget.7067&amp;volume=7&amp;pages=10051-10063&amp;publication_year=2016&amp;author=Morris%2CLGT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nat. Commun.</i> <b>8</b>, 2193 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-017-02320-7" data-track-item_id="10.1038/s41467-017-02320-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-017-02320-7" aria-label="Article reference 51" data-doi="10.1038/s41467-017-02320-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXmtlaktrk%3D" aria-label="CAS reference 51">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29259186" aria-label="PubMed reference 51">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736752" aria-label="PubMed Central reference 51">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Mutational%20patterns%20in%20chemotherapy%20resistant%20muscle-invasive%20bladder%20cancer&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-02320-7&amp;volume=8&amp;publication_year=2017&amp;author=Liu%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. <i>Cancer Discov.</i> <b>4</b>, 175–185 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-13-0285" data-track-item_id="10.1158/2159-8290.CD-13-0285" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-13-0285" aria-label="Article reference 52" data-doi="10.1158/2159-8290.CD-13-0285">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFymtrw%3D" aria-label="CAS reference 52">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24436049" aria-label="PubMed reference 52">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293454" aria-label="PubMed Central reference 52">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Tolerance%20of%20whole-genome%20doubling%20propagates%20chromosomal%20instability%20and%20accelerates%20cancer%20genome%20evolution&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-13-0285&amp;volume=4&amp;pages=175-185&amp;publication_year=2014&amp;author=Dewhurst%2CSM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">Weide, B. et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. <i>Clin. Cancer Res.</i> <b>22</b>, 5487–5496 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-16-0127" data-track-item_id="10.1158/1078-0432.CCR-16-0127" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-16-0127" aria-label="Article reference 53" data-doi="10.1158/1078-0432.CCR-16-0127">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhvVCqur3K" aria-label="CAS reference 53">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27185375" aria-label="PubMed reference 53">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572569" aria-label="PubMed Central reference 53">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=Baseline%20biomarkers%20for%20outcome%20of%20melanoma%20patients%20treated%20with%20pembrolizumab&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-0127&amp;volume=22&amp;pages=5487-5496&amp;publication_year=2016&amp;author=Weide%2CB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. <i>JCI Insight</i> <b>3</b>, 124507 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/jci.insight.124507" data-track-item_id="10.1172/jci.insight.124507" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2Fjci.insight.124507" aria-label="Article reference 54" data-doi="10.1172/jci.insight.124507">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30518694" aria-label="PubMed reference 54">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor-draining%20lymph%20nodes%20are%20pivotal%20in%20PD-1%2FPD-L1%20checkpoint%20therapy&amp;journal=JCI%20Insight&amp;doi=10.1172%2Fjci.insight.124507&amp;volume=3&amp;publication_year=2018&amp;author=Fransen%2CMF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <i>Nat. Med.</i> <b>24</b>, 1655–1661 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0198-0" data-track-item_id="10.1038/s41591-018-0198-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0198-0" aria-label="Article reference 55" data-doi="10.1038/s41591-018-0198-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVCit7rM" aria-label="CAS reference 55">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30297911" aria-label="PubMed reference 55">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=Neoadjuvant%20versus%20adjuvant%20ipilimumab%20plus%20nivolumab%20in%20macroscopic%20stage%20III%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0198-0&amp;volume=24&amp;pages=1655-1661&amp;publication_year=2018&amp;author=Blank%2CCU">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Cesano, A. nCounter PanCancer immune profiling panel (NanoString Technologies, Seattle, WA). <i>J. Immunother. Cancer</i> <b>3</b>, 42 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s40425-015-0088-7" data-track-item_id="10.1186/s40425-015-0088-7" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s40425-015-0088-7" aria-label="Article reference 56" data-doi="10.1186/s40425-015-0088-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26674611" aria-label="PubMed reference 56">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678588" aria-label="PubMed Central reference 56">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=nCounter%20PanCancer%20immune%20profiling%20panel%20%28NanoString%20Technologies%2C%20Seattle%2C%20WA%29.&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-015-0088-7&amp;volume=3&amp;publication_year=2015&amp;author=Cesano%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. <i>Genome Biol.</i> <b>12</b>, R1 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/gb-2011-12-1-r1" data-track-item_id="10.1186/gb-2011-12-1-r1" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/gb-2011-12-1-r1" aria-label="Article reference 57" data-doi="10.1186/gb-2011-12-1-r1">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21205303" aria-label="PubMed reference 57">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091298" aria-label="PubMed Central reference 57">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20scalable%2C%20fully%20automated%20process%20for%20construction%20of%20sequence-ready%20human%20exome%20targeted%20capture%20libraries&amp;journal=Genome%20Biol.&amp;doi=10.1186%2Fgb-2011-12-1-r1&amp;volume=12&amp;publication_year=2011&amp;author=Fisher%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="58."><p class="c-article-references__text" id="ref-CR58">Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. <i>Nat. Biotechnol.</i> <b>27</b>, 182–189 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nbt.1523" data-track-item_id="10.1038/nbt.1523" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnbt.1523" aria-label="Article reference 58" data-doi="10.1038/nbt.1523">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXht1ehs7o%3D" aria-label="CAS reference 58">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19182786" aria-label="PubMed reference 58">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663421" aria-label="PubMed Central reference 58">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Solution%20hybrid%20selection%20with%20ultra-long%20oligonucleotides%20for%20massively%20parallel%20targeted%20sequencing&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.1523&amp;volume=27&amp;pages=182-189&amp;publication_year=2009&amp;author=Gnirke%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="59."><p class="c-article-references__text" id="ref-CR59">Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next generation sequencing data. <i>Bioinformatics</i> <b>27</b>, 2601–2602 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/bioinformatics/btr446" data-track-item_id="10.1093/bioinformatics/btr446" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbioinformatics%2Fbtr446" aria-label="Article reference 59" data-doi="10.1093/bioinformatics/btr446">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFKjt7%2FL" aria-label="CAS reference 59">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21803805" aria-label="PubMed reference 59">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167057" aria-label="PubMed Central reference 59">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=ContEst%3A%20estimating%20cross-contamination%20of%20human%20samples%20in%20next%20generation%20sequencing%20data&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbtr446&amp;volume=27&amp;pages=2601-2602&amp;publication_year=2011&amp;author=Cibulskis%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="60."><p class="c-article-references__text" id="ref-CR60">Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. <i>Nat. Biotechnol.</i> <b>31</b>, 213–219 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nbt.2514" data-track-item_id="10.1038/nbt.2514" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnbt.2514" aria-label="Article reference 60" data-doi="10.1038/nbt.2514">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXjsFCntbc%3D" aria-label="CAS reference 60">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23396013" aria-label="PubMed reference 60">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833702" aria-label="PubMed Central reference 60">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=Sensitive%20detection%20of%20somatic%20point%20mutations%20in%20impure%20and%20heterogeneous%20cancer%20samples&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.2514&amp;volume=31&amp;pages=213-219&amp;publication_year=2013&amp;author=Cibulskis%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="61."><p class="c-article-references__text" id="ref-CR61">Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. <i>Nucleic Acids Res.</i> <b>41</b>, e67 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/nar/gks1443" data-track-item_id="10.1093/nar/gks1443" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fnar%2Fgks1443" aria-label="Article reference 61" data-doi="10.1093/nar/gks1443">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXlsVCnu7Y%3D" aria-label="CAS reference 61">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23303777" aria-label="PubMed reference 61">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616734" aria-label="PubMed Central reference 61">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 61" href="http://scholar.google.com/scholar_lookup?&amp;title=Discovery%20and%20characterization%20of%20artifactual%20mutations%20in%20deep%20coverage%20targeted%20capture%20sequencing%20data%20due%20to%20oxidative%20DNA%20damage%20during%20sample%20preparation&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgks1443&amp;volume=41&amp;publication_year=2013&amp;author=Costello%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="62."><p class="c-article-references__text" id="ref-CR62">Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. <i>Bioinformatics</i> <b>28</b>, 1811–1817 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/bioinformatics/bts271" data-track-item_id="10.1093/bioinformatics/bts271" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbioinformatics%2Fbts271" aria-label="Article reference 62" data-doi="10.1093/bioinformatics/bts271">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVSgtr%2FM" aria-label="CAS reference 62">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22581179" aria-label="PubMed reference 62">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=Strelka%3A%20accurate%20somatic%20small-variant%20calling%20from%20sequenced%20tumor-normal%20sample%20pairs&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbts271&amp;volume=28&amp;pages=1811-1817&amp;publication_year=2012&amp;author=Saunders%2CCT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="63."><p class="c-article-references__text" id="ref-CR63">Ramos, A. H. et al. Oncotator: cancer variant annotation tool. <i>Hum. Mutat.</i> <b>36</b>, E2423–E2429 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/humu.22771" data-track-item_id="10.1002/humu.22771" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fhumu.22771" aria-label="Article reference 63" data-doi="10.1002/humu.22771">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25703262" aria-label="PubMed reference 63">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350419" aria-label="PubMed Central reference 63">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 63" href="http://scholar.google.com/scholar_lookup?&amp;title=Oncotator%3A%20cancer%20variant%20annotation%20tool&amp;journal=Hum.%20Mutat.&amp;doi=10.1002%2Fhumu.22771&amp;volume=36&amp;pages=E2423-E2429&amp;publication_year=2015&amp;author=Ramos%2CAH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="64."><p class="c-article-references__text" id="ref-CR64">Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. <i>Nat. Biotechnol.</i> <b>33</b>, 1152 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nbt.3344" data-track-item_id="10.1038/nbt.3344" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnbt.3344" aria-label="Article reference 64" data-doi="10.1038/nbt.3344">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFWht7nO" aria-label="CAS reference 64">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26372948" aria-label="PubMed reference 64">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747795" aria-label="PubMed Central reference 64">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20analysis%20of%20cancer-associated%20somatic%20mutations%20in%20class%20I%20HLA%20genes&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.3344&amp;volume=33&amp;publication_year=2015&amp;author=Shukla%2CSA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="65."><p class="c-article-references__text" id="ref-CR65">Nielsen, M. et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and HLA-B locus protein of known sequence. <i>PloS ONE</i> <b>2</b>, e796 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0000796" data-track-item_id="10.1371/journal.pone.0000796" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0000796" aria-label="Article reference 65" data-doi="10.1371/journal.pone.0000796">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17726526" aria-label="PubMed reference 65">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1949492" aria-label="PubMed Central reference 65">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtFGnsbjE" aria-label="CAS reference 65">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=NetMHCpan%2C%20a%20method%20for%20quantitative%20predictions%20of%20peptide%20binding%20to%20any%20HLA-A%20and%20HLA-B%20locus%20protein%20of%20known%20sequence&amp;journal=PloS%20ONE&amp;doi=10.1371%2Fjournal.pone.0000796&amp;volume=2&amp;publication_year=2007&amp;author=Nielsen%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="66."><p class="c-article-references__text" id="ref-CR66">Olshen, A. B., Venkatraman, E. S., Lucito, R. &amp; Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. <i>Biostatistics</i> <b>5</b>, 557–572 (2004).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/biostatistics/kxh008" data-track-item_id="10.1093/biostatistics/kxh008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbiostatistics%2Fkxh008" aria-label="Article reference 66" data-doi="10.1093/biostatistics/kxh008">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15475419" aria-label="PubMed reference 66">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=Circular%20binary%20segmentation%20for%20the%20analysis%20of%20array-based%20DNA%20copy%20number%20data&amp;journal=Biostatistics&amp;doi=10.1093%2Fbiostatistics%2Fkxh008&amp;volume=5&amp;pages=557-572&amp;publication_year=2004&amp;author=Olshen%2CAB&amp;author=Venkatraman%2CES&amp;author=Lucito%2CR&amp;author=Wigler%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="67."><p class="c-article-references__text" id="ref-CR67">Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. <i>Nat. Biotechnol.</i> <b>30</b>, 413–421 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nbt.2203" data-track-item_id="10.1038/nbt.2203" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnbt.2203" aria-label="Article reference 67" data-doi="10.1038/nbt.2203">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38Xmt1Gktb4%3D" aria-label="CAS reference 67">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22544022" aria-label="PubMed reference 67">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383288" aria-label="PubMed Central reference 67">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=Absolute%20quantification%20of%20somatic%20DNA%20alterations%20in%20human%20cancer&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.2203&amp;volume=30&amp;pages=413-421&amp;publication_year=2012&amp;author=Carter%2CSL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="68."><p class="c-article-references__text" id="ref-CR68">Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. <i>Cancer Discov</i>. <b>5</b>, 1164–1177 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-15-0369" data-track-item_id="10.1158/2159-8290.CD-15-0369" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-15-0369" aria-label="Article reference 68" data-doi="10.1158/2159-8290.CD-15-0369">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvVWqsr3O" aria-label="CAS reference 68">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26410082" aria-label="PubMed reference 68">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916970" aria-label="PubMed Central reference 68">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 68" href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20characterization%20of%20brain%20metastases%20reveals%20branched%20evolution%20and%20potential%20therapeutic%20targets&amp;journal=Cancer%20Discov&amp;doi=10.1158%2F2159-8290.CD-15-0369&amp;volume=5&amp;pages=1164-1177&amp;publication_year=2015&amp;author=Brastianos%2CPK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="69."><p class="c-article-references__text" id="ref-CR69">Lee, D. D. &amp; Seung, H. S. Learning the parts of objects by non-negative matrix factorization. <i>Nature</i> <b>401</b>, 788–791 (1999).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/44565" data-track-item_id="10.1038/44565" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2F44565" aria-label="Article reference 69" data-doi="10.1038/44565">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK1MXntFartrg%3D" aria-label="CAS reference 69">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10548103" aria-label="PubMed reference 69">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Learning%20the%20parts%20of%20objects%20by%20non-negative%20matrix%20factorization&amp;journal=Nature&amp;doi=10.1038%2F44565&amp;volume=401&amp;pages=788-791&amp;publication_year=1999&amp;author=Lee%2CDD&amp;author=Seung%2CHS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="70."><p class="c-article-references__text" id="ref-CR70">Brunet, J. P. et al. Metagenes and molecular pattern discovery using matrix factorization. <i>Proc. Natl Acad. Sci. USA</i> <b>101</b>, 4164–4169 (2004).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.0308531101" data-track-item_id="10.1073/pnas.0308531101" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.0308531101" aria-label="Article reference 70" data-doi="10.1073/pnas.0308531101">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2cXivFartrc%3D" aria-label="CAS reference 70">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15016911" aria-label="PubMed reference 70">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC384712" aria-label="PubMed Central reference 70">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 70" href="http://scholar.google.com/scholar_lookup?&amp;title=Metagenes%20and%20molecular%20pattern%20discovery%20using%20matrix%20factorization&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0308531101&amp;volume=101&amp;pages=4164-4169&amp;publication_year=2004&amp;author=Brunet%2CJP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="71."><p class="c-article-references__text" id="ref-CR71">Gehring, J. S., Fischer, B., Lawrence, M. &amp; Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. <i>Bioinformatics</i> <b>31</b>, 3673–3675 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xht1ensr7P" aria-label="CAS reference 71">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26163694" aria-label="PubMed reference 71">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817139" aria-label="PubMed Central reference 71">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 71" href="http://scholar.google.com/scholar_lookup?&amp;title=SomaticSignatures%3A%20inferring%20mutational%20signatures%20from%20single-nucleotide%20variants&amp;journal=Bioinformatics&amp;volume=31&amp;pages=3673-3675&amp;publication_year=2015&amp;author=Gehring%2CJS&amp;author=Fischer%2CB&amp;author=Lawrence%2CM&amp;author=Huber%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="72."><p class="c-article-references__text" id="ref-CR72">Gaujoux, R. &amp; Seoighe, C. A flexible R package for nonnegative matrix factorization. <i>BMC Bioinformatics</i> <b>11</b>, 367 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1471-2105-11-367" data-track-item_id="10.1186/1471-2105-11-367" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1471-2105-11-367" aria-label="Article reference 72" data-doi="10.1186/1471-2105-11-367">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20598126" aria-label="PubMed reference 72">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912887" aria-label="PubMed Central reference 72">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXoslGiurY%3D" aria-label="CAS reference 72">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 72" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20flexible%20R%20package%20for%20nonnegative%20matrix%20factorization&amp;journal=BMC%20Bioinformatics&amp;doi=10.1186%2F1471-2105-11-367&amp;volume=11&amp;publication_year=2010&amp;author=Gaujoux%2CR&amp;author=Seoighe%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="73."><p class="c-article-references__text" id="ref-CR73">Forbes, S. A. et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. <i>Nucleic Acids Res.</i> <b>43</b>, D805–D811 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/nar/gku1075" data-track-item_id="10.1093/nar/gku1075" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fnar%2Fgku1075" aria-label="Article reference 73" data-doi="10.1093/nar/gku1075">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtV2itr3F" aria-label="CAS reference 73">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25355519" aria-label="PubMed reference 73">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 73" href="http://scholar.google.com/scholar_lookup?&amp;title=COSMIC%3A%20exploring%20the%20world%E2%80%99s%20knowledge%20of%20somatic%20mutations%20in%20human%20cancer&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgku1075&amp;volume=43&amp;pages=D805-D811&amp;publication_year=2015&amp;author=Forbes%2CSA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="74."><p class="c-article-references__text" id="ref-CR74">Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> <b>29</b>, 15–21 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/bioinformatics/bts635" data-track-item_id="10.1093/bioinformatics/bts635" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbioinformatics%2Fbts635" aria-label="Article reference 74" data-doi="10.1093/bioinformatics/bts635">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhvV2gsbnF" aria-label="CAS reference 74">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23104886" aria-label="PubMed reference 74">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 74" href="http://scholar.google.com/scholar_lookup?&amp;title=STAR%3A%20ultrafast%20universal%20RNA-seq%20aligner&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbts635&amp;volume=29&amp;pages=15-21&amp;publication_year=2013&amp;author=Dobin%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="75."><p class="c-article-references__text" id="ref-CR75">Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. <i>BMC Bioinformatics</i> <b>12</b>, 323 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1471-2105-12-323" data-track-item_id="10.1186/1471-2105-12-323" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1471-2105-12-323" aria-label="Article reference 75" data-doi="10.1186/1471-2105-12-323">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFajtLvM" aria-label="CAS reference 75">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21816040" aria-label="PubMed reference 75">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163565" aria-label="PubMed Central reference 75">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 75" href="http://scholar.google.com/scholar_lookup?&amp;title=RSEM%3A%20accurate%20transcript%20quantification%20from%20RNA-seq%20data%20with%20or%20without%20a%20reference%20genome&amp;journal=BMC%20Bioinformatics&amp;doi=10.1186%2F1471-2105-12-323&amp;volume=12&amp;publication_year=2011&amp;author=Li%2CB&amp;author=Dewey%2CCN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="76."><p class="c-article-references__text" id="ref-CR76">Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. <i>Bioinformatics</i> <b>21</b>, 3439–3440 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/bioinformatics/bti525" data-track-item_id="10.1093/bioinformatics/bti525" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbioinformatics%2Fbti525" aria-label="Article reference 76" data-doi="10.1093/bioinformatics/bti525">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXovVKru74%3D" aria-label="CAS reference 76">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16082012" aria-label="PubMed reference 76">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 76" href="http://scholar.google.com/scholar_lookup?&amp;title=BioMart%20and%20Bioconductor%3A%20a%20powerful%20link%20between%20biological%20databases%20and%20microarray%20data%20analysis&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbti525&amp;volume=21&amp;pages=3439-3440&amp;publication_year=2005&amp;author=Durinck%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="77."><p class="c-article-references__text" id="ref-CR77">Thorsson, V. et al. The immune landscape of cancer. <i>Immunity</i> <b>48</b>, 812–830 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2018.03.023" data-track-item_id="10.1016/j.immuni.2018.03.023" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2018.03.023" aria-label="Article reference 77" data-doi="10.1016/j.immuni.2018.03.023">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXntFSjt7o%3D" aria-label="CAS reference 77">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29628290" aria-label="PubMed reference 77">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982584" aria-label="PubMed Central reference 77">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 77" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20landscape%20of%20cancer&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.03.023&amp;volume=48&amp;pages=812-830&amp;publication_year=2018&amp;author=Thorsson%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="78."><p class="c-article-references__text" id="ref-CR78">Davidson-Pilon C. et al. CamDavidsonPilon/lifelines v.0.18.5. <i>Zenodo</i> <a href="https://doi.org/10.5281/zenodo.2562267" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.5281/zenodo.2562267">https://doi.org/10.5281/zenodo.2562267</a> (2019).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="79."><p class="c-article-references__text" id="ref-CR79">Waksom M. et al. mwaskom/seaborn v.0.8.1 <i>Zenodo</i> <a href="https://doi.org/10.5281/zenodo.883859" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.5281/zenodo.883859">https://doi.org/10.5281/zenodo.883859</a> (2017).</p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-019-0654-5?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>The authors thank the active investigators A. Gesierich (University Hospital Würzburg), J.C. Hassel (NCT Heidelberg), C. Pföhler (Saarland University Medical Center), E. Dabrowski (Ludwigshafen Medical Center), L.A. Schneider (University Medical Center Ulm), C. Weishaupt (University Hospital of Münster), K.G. Griewank (University Hospital Essen), E. Hadaschik (University Hospital Essen), G. Kyriakakis (Laikon General Hospital), F. Meier (NCT Dresden), M.H. Geukes Foppen (The Netherlands Cancer Institute), R. Dummer (University Hospital Zürich), E. Bräunlein (Technical University Munich) and M. Boxberg (Technical University Munich) for providing additional patient samples and clinical data. The authors also thank A. Giobbie-Hurder (Dana-Farber Cancer Institute) and J. Weirather (Dana-Farber Cancer Institute) for useful discussions regarding statistical testing. This work was supported by the Adelson Medical Research Foundation (L.G.), the Conquer Cancer Foundation (David Liu), the Society for Immunotherapy of Cancers (David Liu), the Damon Runyon Cancer Research Foundation (David Liu), the BroadNext10 (E.M.V.), the National Institutes of Health (K08 CA234458 (David Liu), R01 CA227388 (E.M.V.), U01 CA233100 (E.M.V.), T32 GM008313 (M.X.H.)), the Deutsche Forschungsgemeinschaft (German Research Foundation), SCHA 422/17-1, PA 2376/1-1 and HO 6389/2-1 (KFO 337; D.S, A.P.) and National Science Foundation Graduate Research Fellowship Program DGE1144152 (M.X.H.).</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally: David Liu, Bastian Schilling.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Dana-Farber Cancer Institute, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">David Liu,&nbsp;Derek Liu,&nbsp;Natalie Vokes,&nbsp;Claire A. Margolis,&nbsp;Haitham Elmarakeby,&nbsp;Felix Dietlein,&nbsp;Diana Miao,&nbsp;Ben Izar&nbsp;&amp;&nbsp;Eliezer M. Van Allen</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Broad Institute of Harvard and MIT, Cambridge, MA, USA</p><p class="c-article-author-affiliation__authors-list">David Liu,&nbsp;Derek Liu,&nbsp;Livnat Jerby-Arnon,&nbsp;Natalie Vokes,&nbsp;Claire A. Margolis,&nbsp;Jake Conway,&nbsp;Meng Xiao He,&nbsp;Haitham Elmarakeby,&nbsp;Felix Dietlein,&nbsp;Diana Miao,&nbsp;Adam Tracy,&nbsp;Ben Izar,&nbsp;Aviv Regev&nbsp;&amp;&nbsp;Eliezer M. Van Allen</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Department of Dermatology, University Hospital Würzburg, Würzburg, Germany</p><p class="c-article-author-affiliation__authors-list">Bastian Schilling</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Department of Dermatology, University Hospital, Essen, Germany</p><p class="c-article-author-affiliation__authors-list">Bastian Schilling,&nbsp;Antje Sucker,&nbsp;Elisabeth Livingstone,&nbsp;Lisa Zimmer,&nbsp;Annette Paschen&nbsp;&amp;&nbsp;Dirk Schadendorf</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany</p><p class="c-article-author-affiliation__authors-list">Bastian Schilling,&nbsp;Antje Sucker,&nbsp;Elisabeth Livingstone,&nbsp;Lisa Zimmer,&nbsp;Angela Krackhardt,&nbsp;Annette Paschen&nbsp;&amp;&nbsp;Dirk Schadendorf</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Harvard Medical School, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Derek Liu,&nbsp;Jake Conway,&nbsp;Meng Xiao He&nbsp;&amp;&nbsp;Diana Miao</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany</p><p class="c-article-author-affiliation__authors-list">Ralf Gutzmer&nbsp;&amp;&nbsp;Imke Satzger</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Department of Dermatology, University Medical Center, Mainz, Germany</p><p class="c-article-author-affiliation__authors-list">Carmen Loquai&nbsp;&amp;&nbsp;Stephan Grabbe</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Biophysics Program, Harvard University, Cambridge, MA, USA</p><p class="c-article-author-affiliation__authors-list">Meng Xiao He</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece</p><p class="c-article-author-affiliation__authors-list">Helen Gogas</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Department of Dermatology, University Hospital Zürich, Zürich, Switzerland</p><p class="c-article-author-affiliation__authors-list">Simone M. Goldinger</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">Department of Dermatology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany</p><p class="c-article-author-affiliation__authors-list">Jochen Utikal</p></li><li id="Aff13"><p class="c-article-author-affiliation__address">Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany</p><p class="c-article-author-affiliation__authors-list">Jochen Utikal</p></li><li id="Aff14"><p class="c-article-author-affiliation__address">Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands</p><p class="c-article-author-affiliation__authors-list">Christian U. Blank</p></li><li id="Aff15"><p class="c-article-author-affiliation__address">Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany</p><p class="c-article-author-affiliation__authors-list">Ricarda Rauschenberg</p></li><li id="Aff16"><p class="c-article-author-affiliation__address">National Center for Tumor Diseases, Dresden, Germany</p><p class="c-article-author-affiliation__authors-list">Ricarda Rauschenberg</p></li><li id="Aff17"><p class="c-article-author-affiliation__address">German Cancer Research Centre, Heidelberg, Germany</p><p class="c-article-author-affiliation__authors-list">Ricarda Rauschenberg</p></li><li id="Aff18"><p class="c-article-author-affiliation__address">Department of Dermatology, Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany</p><p class="c-article-author-affiliation__authors-list">Dagmar von Bubnoff</p></li><li id="Aff19"><p class="c-article-author-affiliation__address">Medizinische Klinik III, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany</p><p class="c-article-author-affiliation__authors-list">Angela Krackhardt</p></li><li id="Aff20"><p class="c-article-author-affiliation__address">Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany</p><p class="c-article-author-affiliation__authors-list">Benjamin Weide</p></li><li id="Aff21"><p class="c-article-author-affiliation__address">Department of Dermatology, University Hospital Regensburg, Regensburg, Germany</p><p class="c-article-author-affiliation__authors-list">Sebastian Haferkamp</p></li><li id="Aff22"><p class="c-article-author-affiliation__address">Department of Dermatology, University Hospital Berlin, Berlin, Germany</p><p class="c-article-author-affiliation__authors-list">Felix Kiecker</p></li><li id="Aff23"><p class="c-article-author-affiliation__address">Eli Lilly and Co., Indianapolis, IN, USA</p><p class="c-article-author-affiliation__authors-list">Levi Garraway</p></li><li id="Aff24"><p class="c-article-author-affiliation__address">Massachusetts General Hospital, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Keith Flaherty</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-David-Liu-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">David Liu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=David%20Liu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=David%20Liu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22David%20Liu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Bastian-Schilling-Aff3-Aff4-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Bastian Schilling</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Bastian%20Schilling" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Bastian%20Schilling" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Bastian%20Schilling%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Derek-Liu-Aff1-Aff2-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Derek Liu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Derek%20Liu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Derek%20Liu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Derek%20Liu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Antje-Sucker-Aff4-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Antje Sucker</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Antje%20Sucker" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Antje%20Sucker" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Antje%20Sucker%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Elisabeth-Livingstone-Aff4-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Elisabeth Livingstone</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Elisabeth%20Livingstone" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Elisabeth%20Livingstone" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Elisabeth%20Livingstone%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Livnat-Jerby_Arnon-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Livnat Jerby-Arnon</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Livnat%20Jerby-Arnon" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Livnat%20Jerby-Arnon" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Livnat%20Jerby-Arnon%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lisa-Zimmer-Aff4-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Lisa Zimmer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lisa%20Zimmer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lisa%20Zimmer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lisa%20Zimmer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ralf-Gutzmer-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Ralf Gutzmer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ralf%20Gutzmer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ralf%20Gutzmer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ralf%20Gutzmer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Imke-Satzger-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Imke Satzger</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Imke%20Satzger" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Imke%20Satzger" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Imke%20Satzger%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Carmen-Loquai-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Carmen Loquai</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Carmen%20Loquai" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Carmen%20Loquai" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Carmen%20Loquai%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Stephan-Grabbe-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Stephan Grabbe</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Stephan%20Grabbe" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Stephan%20Grabbe" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Stephan%20Grabbe%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Natalie-Vokes-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Natalie Vokes</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Natalie%20Vokes" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Natalie%20Vokes" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Natalie%20Vokes%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Claire_A_-Margolis-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Claire A. Margolis</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Claire%20A.%20Margolis" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Claire%20A.%20Margolis" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Claire%20A.%20Margolis%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jake-Conway-Aff2-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Jake Conway</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jake%20Conway" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jake%20Conway" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jake%20Conway%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Meng_Xiao-He-Aff2-Aff6-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Meng Xiao He</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Meng%20Xiao%20He" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Meng%20Xiao%20He" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Meng%20Xiao%20He%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Haitham-Elmarakeby-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Haitham Elmarakeby</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Haitham%20Elmarakeby" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Haitham%20Elmarakeby" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Haitham%20Elmarakeby%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Felix-Dietlein-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Felix Dietlein</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Felix%20Dietlein" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Felix%20Dietlein" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Felix%20Dietlein%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Diana-Miao-Aff1-Aff2-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Diana Miao</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Diana%20Miao" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Diana%20Miao" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Diana%20Miao%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Adam-Tracy-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Adam Tracy</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Adam%20Tracy" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Adam%20Tracy" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Adam%20Tracy%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Helen-Gogas-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Helen Gogas</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Helen%20Gogas" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Helen%20Gogas" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Helen%20Gogas%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Simone_M_-Goldinger-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Simone M. Goldinger</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Simone%20M.%20Goldinger" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Simone%20M.%20Goldinger" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Simone%20M.%20Goldinger%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jochen-Utikal-Aff12-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Jochen Utikal</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jochen%20Utikal" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jochen%20Utikal" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jochen%20Utikal%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Christian_U_-Blank-Aff14"><span class="c-article-authors-search__title u-h3 js-search-name">Christian U. Blank</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Christian%20U.%20Blank" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Christian%20U.%20Blank" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Christian%20U.%20Blank%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ricarda-Rauschenberg-Aff15-Aff16-Aff17"><span class="c-article-authors-search__title u-h3 js-search-name">Ricarda Rauschenberg</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ricarda%20Rauschenberg" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ricarda%20Rauschenberg" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ricarda%20Rauschenberg%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Dagmar-Bubnoff-Aff18"><span class="c-article-authors-search__title u-h3 js-search-name">Dagmar von Bubnoff</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Dagmar%20von%20Bubnoff" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Dagmar%20von%20Bubnoff" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Dagmar%20von%20Bubnoff%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Angela-Krackhardt-Aff5-Aff19"><span class="c-article-authors-search__title u-h3 js-search-name">Angela Krackhardt</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Angela%20Krackhardt" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Angela%20Krackhardt" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Angela%20Krackhardt%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Benjamin-Weide-Aff20"><span class="c-article-authors-search__title u-h3 js-search-name">Benjamin Weide</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Benjamin%20Weide" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Benjamin%20Weide" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Benjamin%20Weide%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sebastian-Haferkamp-Aff21"><span class="c-article-authors-search__title u-h3 js-search-name">Sebastian Haferkamp</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sebastian%20Haferkamp" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sebastian%20Haferkamp" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sebastian%20Haferkamp%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Felix-Kiecker-Aff22"><span class="c-article-authors-search__title u-h3 js-search-name">Felix Kiecker</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Felix%20Kiecker" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Felix%20Kiecker" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Felix%20Kiecker%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ben-Izar-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Ben Izar</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ben%20Izar" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ben%20Izar" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ben%20Izar%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Levi-Garraway-Aff23"><span class="c-article-authors-search__title u-h3 js-search-name">Levi Garraway</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Levi%20Garraway" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Levi%20Garraway" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Levi%20Garraway%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Aviv-Regev-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Aviv Regev</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Aviv%20Regev" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Aviv%20Regev" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Aviv%20Regev%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Keith-Flaherty-Aff24"><span class="c-article-authors-search__title u-h3 js-search-name">Keith Flaherty</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Keith%20Flaherty" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Keith%20Flaherty" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Keith%20Flaherty%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Annette-Paschen-Aff4-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Annette Paschen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Annette%20Paschen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Annette%20Paschen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Annette%20Paschen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Eliezer_M_-Allen-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Eliezer M. Van Allen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Eliezer%20M.%20Van%20Allen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Eliezer%20M.%20Van%20Allen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Eliezer%20M.%20Van%20Allen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Dirk-Schadendorf-Aff4-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Dirk Schadendorf</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Dirk%20Schadendorf" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Dirk%20Schadendorf" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Dirk%20Schadendorf%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>David Liu, B.S., L.G., A.R., K.F., E.M.V.A. and D.S. conceived and designed the overall study. B.S. collected and reviewed all clinical data. A.S. performed sample processing and shipping. B.S., E.L., L.Z., R.G., I.S., C.L., S.G., H.G., S.M.G., J.U., C.U.B, R.R., D.v.B., A.K., B.W., S.H. and F.K. provided samples and clinical annotation. A.T. oversaw sample processing and sequencing. David Liu, C.A.M., N.V., J.C., D.M., F.D. and M.X.H. designed and performed the mutational and copy number analyses. David Liu, Derek Liu, C.A.M., M.X.H., D.M., L.J.-A. and B.I. designed and performed RNA-seq analysis, including quality control, normalization, signature analysis, CIBERSORT and GSEA. David Liu, H.E. and M.X.H. designed and constructed the predictive modeling. David Liu, B.S., A.P., E.M.V.A. and D.S. interpreted the data. David Liu, B.S., E.M.V.A. and D.S. wrote the manuscript, and all authors reviewed and approved the final manuscript.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding authors</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:eliezerm_vanallen@dfci.harvard.edu">Eliezer M. Van Allen</a> or <a id="corresp-c2" href="mailto:dirk.schadendorf@uk-essen.de">Dirk Schadendorf</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar3">Competing interests</h3>
                <p>David Liu reports funding by a postdoctoral fellowship from the Society for Immunotherapy of Cancers, which is funded in part by an educational grant from Bristol-Meyers Squibb (BMS). BMS has had no input into the conception, conduct or reporting of the submitted work. B.S. is on the advisory board or has received honoraria from Incyte, Novartis, Roche, BMS and Merck Sharp &amp; Dohme (MSD), research funding from Pierre-Fabre Pharmaceuticals, BMS and MSD and travel support from Novartis, Roche, BMS, Pierre-Fabre Pharmaceuticals, MSD and Amgen, outside the scope of the submitted work. D.S. reports grants, personal fees and nonfinancial support from BMS, personal fees and nonfinancial support from Roche, grants, personal fees and nonfinancial support from Novartis, nonfinancial support from Regeneron, personal fees from Sanofi, personal fees and nonfinancial support from MSD, personal fees and nonfinancial support from Amgen, personal fees and nonfinancial support from 4SC, personal fees and nonfinancial support from Merck-EMD, personal fees from Array, personal fees and nonfinancial support from Pierre-Fabre, personal fees and nonfinancial support from Philogen, personal fees and nonfinancial support from Incyte and personal fees from Pfizer, outside the scope of the submitted work. E.M.V.A. reports advisory relationships and consulting with Tango Therapeutics, Genome Medical, Invitae, Illumina and Ervaxx; research support from Novartis and BMS; equity in Tango Therapeutics, Genome Medical, Syapse, Ervaxx and Microsoft; and travel reimbursement from Roche and Genentech, outside the submitted work. S.G. reports personal fees from MSD, personal fees from BMS, personal fees from Novartis and personal fees from Roche, outside the scope of the submitted work. L.Z. reports personal fees and others from BMS, personal fees and others from Novartis, personal fees and others from Pierre-Fabre, personal fees and others from MSD, personal fees from Roche, other fees from Amgen and personal fees from Sanofi, outside the scope of the submitted work. F.K. reports personal fees from Amgen, personal fees from BMS, grants and personal fees from Novartis, personal fees from Roche, personal fees from MSD and personal fees from Merck, outside the submitted work. J.U. reports personal fees and nonfinancial support from Amgen, personal fees and nonfinancial support from BMS, personal fees and nonfinancial support from MSD, personal fees and nonfinancial support from Novartis, personal fees and nonfinancial support from Pierre-Fabre, and personal fees and nonfinancial support from Roche, outside the scope of the submitted work. H.G. reports grants and personal fees from BMS, grants and personal fees from Roche, grants and personal fees from MSD, grants and personal fees from Novartis, personal fees from Amgen and personal fees from Pierre-Fabre, outside the scope of the submitted work. R.G. reports personal fees and nonfinancial support from BMS, personal fees and nonfinancial support from Roche Pharma, personal fees and nonfinancial support from Merck Serono, grants, personal fees and nonfinancial support from Amgen, personal fees and nonfinancial support from Pierre-Fabre, personal fees and nonfinancial support from Sanofi Regeneron, personal fees from MSD, grants, personal fees and nonfinancial support from Novartis, personal fees and nonfinancial support from Almirall Hermal, grants and personal fees from Pfizer, personal fees from LEO, personal fees from AstraZeneca, personal fees from Sun Pharma, personal fees from 4SC and grants from Johnson &amp; Johnson, outside the scope of the submitted work. I.S. reports grants and personal fees from Novartis, grants from Pfizer, personal fees from Roche, personal fees BMS and personal fees from MSD, outside the scope of the submitted work. C.L. reports personal fees from Roche, personal fees from Novartis, personal fees from Pierre-Fabre, personal fees from BMS, personal fees from MSD, personal fees from Amgen and personal fees from Idera and Sun Pharma, outside the scope of the submitted work. S.G. reports personal fees from BMS, personal fees from MSD and personal fees from Merck KGaA, outside the scope of the submitted work. E.L. reports personal fees and others from Amgen, personal fees and others from BMS, personal fees and others from MSD, personal fees and others from Novartis, personal fees and others from Roche, personal fees from medac, personal fees from Janssen, other fees from Actelion and other fees from Pierre-Fabre, outside the scope of the submitted work. A.K. reports grants from BMS and Kiadis, personal fees from BMS, Sanofi, Novartis, Roche, Vaccibody and nonfinancial support from Sanofi and BMS, outside the scope of the submitted work. C.B. reports personal fees from BMS, MSD, Roche, Novartis, GSK, Pfizer, Lilly, Pierre-Fabre and GenMab and grants from BMS, Novartis and NanoString, outside the scope of the submitted work. S.H. reports personal fees from Novartis, personal fees from BMS, personal fees from Amgen, personal fees from Pierre-Fabre and personal fees from Roche, outside the scope of the submitted work. B.W. reports grants and personal fees from Philogen, personal fees from Curevac, grants and personal fees from MSD, grants and personal fees from BMS and personal fees from GSK, outside the scope of the submitted work. R.R. reports personal fees from Novartis, personal fees and nonfinancial support from Amgen and nonfinancial support from BMS, outside the scope of the submitted work. D.v.B., A.S. and A.P. have nothing to disclose.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Peer review information</b> Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.</p><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec31-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec31">Extended data</h2><div class="c-article-section__content" id="Sec31-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1" href="/articles/s41591-019-0654-5/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig6_ESM.jpg">Extended Data Fig. 1</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Consort Diagram showing inclusion, exclusion, and quality control criteria for patients/tumors included in analysis.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 survival and genomic copy num" href="/articles/s41591-019-0654-5/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig7_ESM.jpg">Extended Data Fig. 2 Survival and genomic copy number characteristics of responders (n = 55 patients) (defined as CR or PR as best response) vs. progressors (n = 65 patients) (defined as PD as best response).</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(a) PFS Kaplan Meier survival curves; two-sided log-rank p = 2.1e-28 (b) OS Kaplan Meier survival curves; two-sided log-rank p = 5.1e-18 (c) Proportion of tumor genome with copy number alterations (two-sided MWW p = 0.09). Boxplots: Box limits indicate the interquartile range (25th-75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5xIQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points. PD = progressive disease. CR = complete response. PR = partial response.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 association of genomic altera" href="/articles/s41591-019-0654-5/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig8_ESM.jpg">Extended Data Fig. 3 Association of Genomic Alterations in Genes with Response vs. Progression.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>For each gene, the association of a genomic alteration with response was tested using a two-sided Fisher’s Exact test, and the odds ratio (OR) and p-value calculated. The adjusted OR is a conservative estimate generated by adding 1 to both mutant gene responders and progressors, thus moving the OR estimate closer to 1. The x- and y-axis are on log scales, but labeled in the original units. (<b>a</b>) Association of gene mutations with response (n = 55 patients) vs. progression (n = 65 patients). (<b>b</b>) Association of gene amplifications with response (n = 55 patients) vs. progression (n = 65 patients).</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 amplification of chromosome 6" href="/articles/s41591-019-0654-5/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig9_ESM.jpg">Extended Data Fig. 4 Amplification of Chromosome 6 Regions in TAP2, HLA-A/B/C amplified tumors.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Patients with amplifications in TAP2 or HLA-A/B/C are shown, with inferred amplifications in the relevant section of Chromosome 6 shown. 6 patients had amplifications in TAP2, 6 patients had amplifications in HLA-A/B/C, and 4 patients had amplifications of a chromosomal region including all four genes.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 hierarchical clustering of th" href="/articles/s41591-019-0654-5/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig10_ESM.jpg">Extended Data Fig. 5 Hierarchical clustering of the correlation matrix between transcriptional signatures previously associated with immunotherapy response and hallmark gene-sets, genomic, clinical, and transcriptomic features associated with response in our cohort.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>The color indicates the Pearson correlation between features, from perfect negative correlation (Pearson r = -1, blue) to perfect positive correlation (Pearson r = 1, red). Most previously hypothesized signatures cluster within an immune-activity related group with immune-related gene-sets. Sample size for each correlation depends on the number of available data points: correlations involving exclusively genomic or clinical data had n = 144 tumor samples, while correlations involving transcriptomic features had n = 121 tumor samples with data available.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 expression of genomic feature" href="/articles/s41591-019-0654-5/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig11_ESM.jpg">Extended Data Fig. 6 Expression of Genomic Features in Responders vs. Progressors in ipilimumab-treated and -naive subsets.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Two-sided Mann-Whitney-Wilcoxon tests were used to compare responders to progressors (ipilimumab-treated: n = 16 responders/20 progressors; ipilimumab-naïve: n = 34 responders/37 progressors). All p-values are unadjusted. Log Nonsyn Mutload: Ipi-treated p = 0.15; Ipi-naïve p = 0.15. Log Clonal Mutload: Ipi-treated p = 0.17; Ipi-naïve p = 0.08. Heterogeneity: Ipi-treated p = 0.51; Ipi-naïve p = 0.057. Ploidy: Ipi-treated p = 0.45; Ipi-naïve p = 0.002. Boxplots: Box limits indicate the interquartile range (25th-75th percentile), with a center line indicating the median. Whiskers show the value ranges up to 1.5xIQR above the 75th or below the 25th percentile, with outliers beyond those ranges shown as individual points.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 survival of patients stratifi" href="/articles/s41591-019-0654-5/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig12_ESM.jpg">Extended Data Fig. 7 Survival of patients stratified by progressive disease (PD) or non-PD (SD, MR, PR, or CR) best response (RECIST 1.1) to PD-1 ICB.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) PFS (two-sided logrank p = 4.0e-38 (<b>b</b>) OS (two-sided logrank p = 1.2e-19).</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 model selection criteria with" href="/articles/s41591-019-0654-5/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig13_ESM.jpg">Extended Data Fig. 8 Model selection criteria with increasing number of features by forward selection; cross-validation AUC distribution of final models.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) Model AUC for the ipi-treated subgroup. Each point is labeled with the additional feature, and the final model includes MHC-II, Lymph node metastasis, and LDH below the median as features. (<b>b</b>) Model AUC for the ipi-naive subgroup. Each point is labeled with the additional feature, and the final model includes ploidy, heterogeneity, and purity as features. (<b>c</b>) Model AIC/BIC for the ipi-experienced subgroup. (<b>d</b>) Model AIC/BIC for the ipi-naïve subgroup. (<b>e</b>) Using 10-fold crossvalidation in the ipilimumab-naïve subset, mean crossvalidation AUC is 0.73, with a SD of 0.25. Each fold split the cohort into a training (n = 74 patients) and test set (n = 10 patients) ((<b>f</b>) In the ipi-experienced subset, mean crossvalidation AUC is 0.85, with a SD of 0.18. Each fold split the cohort into a training (n = 27 patients) and test set (n = 7 patients).</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig14"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 subgroup model roc curves app" href="/articles/s41591-019-0654-5/figures/14" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig14_ESM.jpg">Extended Data Fig. 9 Subgroup Model ROC curves applied to other subgroups.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) Ipilimumab-treated subgroup model applied to ipilimumab-naive (n = 74 patients) subgroup; (<b>b</b>) Ipilimumab-naive model applied to ipilimumab-treated (n = 45 patients) subgroup; (<b>c</b>) Ipi-naïve model predicting PD as best response to PD-1 ICB applied to pre-ipilimumab-treated (n = 15 patients) tumors. (top) Comut plot overlaying best response and the ipi-naïve model score. Each column is one of 15 ipilimumab-treated tumors biopsied prior to ipilimumab therapy, ordered by the predictive model score. The 5 highest scoring tumors were all PD. (bottom) Receiver-operator curve for our ipilimumab-naive predictive model applied to pre-ipilimumab tumors (n = 15), with an AUC of 0.71.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig15"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 10 limited validation testing s" href="/articles/s41591-019-0654-5/figures/15" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig15_ESM.jpg">Extended Data Fig. 10 Limited validation testing single feature models in validation cohort.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) Relationship between response and MHC-II HLA score in the ipilimumab-treated subgroup of a validation cohort. Each column is a patient, and patients are sorted by MHC-II HLA score. (<b>b</b>) Validation of Predictive Model for ipilimumab-treated tumors. In a validation cohort (n = 23), a model using the only common available feature (MHC-II HLA score) had an AUC of 0.65 (log likelihood ratio p = 0.09, empiric p = 0.21, <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>). (<b>c</b>) Relationship between response and MHC-II HLA score in the ipilimumab-treated subgroup of a validation cohort. Each column is a patient, and patients are sorted by MHC-II HLA score. (<b>d</b>) Validation of Predictive Model for ipilimumab-naive Tumors. In a validation cohort (n = 20), a model using the only common available feature (heterogeneity) had an AUC of 0.73 (log likelihood ratio p = 0.17, empiric p = 0.066, <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-019-0654-5#Sec9">Methods</a>).</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec32-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec32">Supplementary information</h2><div class="c-article-section__content" id="Sec32-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_MOESM1_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary data 1" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_MOESM2_ESM.xlsx" data-supp-info-image="">Supplementary Data 1</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Gene-level mutation calls; copy number alterations; immune cell signatures; mutational signatures; and ssGSEA signatures using Hallmarks gene sets.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary data 2" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_MOESM3_ESM.txt" data-supp-info-image="">Supplementary Data 2</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>RNA-seq TPM matrix.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM4"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary tables" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_MOESM4_ESM.xlsx" data-supp-info-image="">Supplementary Tables</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Tables 1–9.</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Integrative%20molecular%20and%20clinical%20modeling%20of%20clinical%20outcomes%20to%20PD1%20blockade%20in%20patients%20with%20metastatic%20melanoma&amp;author=David%20Liu%20et%20al&amp;contentID=10.1038%2Fs41591-019-0654-5&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2019-12-02&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-019-0654-5" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-019-0654-5" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Liu, D., Schilling, B., Liu, D. <i>et al.</i> Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
                    <i>Nat Med</i> <b>25</b>, 1916–1927 (2019). https://doi.org/10.1038/s41591-019-0654-5</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-019-0654-5?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2019-03-25">25 March 2019</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2019-10-17">17 October 2019</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2019-12-02">02 December 2019</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2019-12">December 2019</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-019-0654-5</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/cancer-genomics" data-track="click" data-track-action="view subject" data-track-label="link">Cancer genomics</a></li><li class="c-article-subject-list__subject"><a href="/subjects/computational-biology-and-bioinformatics" data-track="click" data-track-action="view subject" data-track-label="link">Computational biology and bioinformatics</a></li><li class="c-article-subject-list__subject"><a href="/subjects/melanoma" data-track="click" data-track-action="view subject" data-track-label="link">Melanoma</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade" href="https://doi.org/10.1186/s13046-025-03318-6">
                                        Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Zelin Li</li><li>Shuhan Liu</li><li>Ziling Fang</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Journal of Experimental &amp; Clinical Cancer Research</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Dual role of Cathepsin S in cutaneous melanoma: insights from mendelian randomization and bioinformatics analysis" href="https://doi.org/10.1186/s12885-025-13481-w">
                                        Dual role of Cathepsin S in cutaneous melanoma: insights from mendelian randomization and bioinformatics analysis
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Linsa Zhou</li><li>Qiang Zhou</li><li>Sen Lin</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>BMC Cancer</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates" href="https://doi.org/10.1186/s12943-025-02328-4">
                                        The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Liuyue Kan</li><li>Ying Yu</li><li>Chuanli Ren</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Molecular Cancer</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy" href="https://doi.org/10.1186/s12935-025-03729-7">
                                        Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Verena Schweihofer</li><li>Christina Bruss</li><li>Anja Kathrin Wege</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Cancer Cell International</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Genetic and transcriptional insights into immune checkpoint blockade response and survival: lessons from melanoma and beyond" href="https://doi.org/10.1186/s12967-025-06467-6">
                                        Genetic and transcriptional insights into immune checkpoint blockade response and survival: lessons from melanoma and beyond
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Jiaxin Wen</li><li>Yanfeng Wang</li><li>Youyu Wang</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Journal of Translational Medicine</i> (2025)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-019-0654-5.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: none;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec8" class="c-reading-companion__section-item"><a href="#Sec8" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec9" class="c-reading-companion__section-item"><a href="#Sec9" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-code-availability" class="c-reading-companion__section-item"><a href="#code-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Code availability">Code availability</a></li><li id="rc-sec-change-history" class="c-reading-companion__section-item"><a href="#change-history" data-track="click" data-track-action="section anchor" data-track-label="link:Change history">Change history</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec31" class="c-reading-companion__section-item"><a href="#Sec31" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec32" class="c-reading-companion__section-item"><a href="#Sec32" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-019-0654-5;doi=10.1038/s41591-019-0654-5;subjmeta=114,1634,1813,631,67,69;kwrd=Cancer+genomics,Computational+biology+and+bioinformatics,Melanoma">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-322397313&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-019-0654-5%26doi%3D10.1038/s41591-019-0654-5%26subjmeta%3D114,1634,1813,631,67,69%26kwrd%3DCancer+genomics,Computational+biology+and+bioinformatics,Melanoma">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-322397313&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-019-0654-5%26doi%3D10.1038/s41591-019-0654-5%26subjmeta%3D114,1634,1813,631,67,69%26kwrd%3DCancer+genomics,Computational+biology+and+bioinformatics,Melanoma"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: Cohort genomic and clinical characteristics and association of TMB with response.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Genomic and transcriptomic features associated with response.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Differential predictors of response and progression in ipilimumab-treated tumors versus ipilimumab-naive tumors.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: Progression versus response by immune infiltrate and MHC-II HLA expression stratified by ipilimumab treatment.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Fig. 5: Integrative predictive modeling of intrinsic resistance to anti-PD1 ICB.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig5_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig5_HTML.png" alt="figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 1</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 2 Survival and genomic copy number characteristics of responders (n = 55 patients) (defined as CR or PR as best response) vs. progressors (n = 65 patients) (defined as PD as best response).</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 3 Association of Genomic Alterations in Genes with Response vs. Progression.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 4 Amplification of Chromosome 6 Regions in TAP2, HLA-A/B/C amplified tumors.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 5 Hierarchical clustering of the correlation matrix between transcriptional signatures previously associated with immunotherapy response and hallmark gene-sets, genomic, clinical, and transcriptomic features associated with response in our cohort.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 6 Expression of Genomic Features in Responders vs. Progressors in ipilimumab-treated and -naive subsets.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 7 Survival of patients stratified by progressive disease (PD) or non-PD (SD, MR, PR, or CR) best response (RECIST 1.1) to PD-1 ICB.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 8 Model selection criteria with increasing number of features by forward selection; cross-validation AUC distribution of final models.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig14">Extended Data Fig. 9 Subgroup Model ROC curves applied to other subgroups.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig14_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig14_ESM.jpg" alt="extended data figure 14" aria-describedby="rc-Fig14"></picture><p class="c-reading-companion__figure-links"><a href="#Fig14" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/14" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig15">Extended Data Fig. 10 Limited validation testing single feature models in validation cohort.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig15_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_Fig15_ESM.jpg" alt="extended data figure 15" aria-describedby="rc-Fig15"></picture><p class="c-reading-companion__figure-links"><a href="#Fig15" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-019-0654-5/figures/15" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. <i>N. Engl. J. Med.</i> <b>363</b>, 711–723 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1003466" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1003466" data-track-item_id="10.1056/NEJMoa1003466">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVCrtrbN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20525992" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1003466&amp;volume=363&amp;pages=711-723&amp;publication_year=2010&amp;author=Hodi%2CFS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>372</b>, 2521–2532 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1503093" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1503093" data-track-item_id="10.1056/NEJMoa1503093">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFyrsbrF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25891173" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20versus%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1503093&amp;volume=372&amp;pages=2521-2532&amp;publication_year=2015&amp;author=Robert%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>377</b>, 1345–1356 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1709684" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1709684" data-track-item_id="10.1056/NEJMoa1709684">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1Git73I" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28889792" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709684&amp;volume=377&amp;pages=1345-1356&amp;publication_year=2017&amp;author=Wolchok%2CJD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. <i>N. Engl. J. Med.</i> <b>375</b>, 1823–1833 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1606774" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1606774" data-track-item_id="10.1056/NEJMoa1606774">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhvF2ks77I" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27718847" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20versus%20chemotherapy%20for%20PD-L1-positive%20non-small%20cell%20lung%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1606774&amp;volume=375&amp;pages=1823-1833&amp;publication_year=2016&amp;author=Reck%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> <b>387</b>, 1909–1920 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2816%2900561-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(16)00561-4" data-track-item_id="10.1016/S0140-6736(16)00561-4">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XjslGmu7w%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26952546" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480242" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy%3A%20a%20single-arm%2C%20multicentre%2C%20phase%202%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2816%2900561-4&amp;volume=387&amp;pages=1909-1920&amp;publication_year=2016&amp;author=Rosenberg%2CJE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. <i>N. Engl. J. Med.</i> <b>373</b>, 1803–1813 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1510665" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1510665" data-track-item_id="10.1056/NEJMoa1510665">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XjsFyhsrg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26406148" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20versus%20everolimus%20in%20advanced%20renal-cell%20carcinoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1510665&amp;volume=373&amp;pages=1803-1813&amp;publication_year=2015&amp;author=Motzer%2CRJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <i>Lancet Oncol.</i> <b>17</b>, 956–965 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2816%2930066-3" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(16)30066-3" data-track-item_id="10.1016/S1470-2045(16)30066-3">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XptFerurg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27247226" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20clinical%20activity%20of%20pembrolizumab%20for%20treatment%20of%20recurrent%20or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20%28KEYNOTE-012%29%3A%20an%20open-label%2C%20multicentre%2C%20phase%201b%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2816%2930066-3&amp;volume=17&amp;pages=956-965&amp;publication_year=2016&amp;author=Seiwert%2CTY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> <b>348</b>, 124 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aaa1348" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aaa1348" data-track-item_id="10.1126/science.aaa1348">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXls1Wmtbg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25765070" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993154" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mutational%20landscape%20determines%20sensitivity%20to%20PD-1%20blockade%20in%20non-small%20cell%20lung%20cancer&amp;journal=Science&amp;doi=10.1126%2Fscience.aaa1348&amp;volume=348&amp;publication_year=2015&amp;author=Rizvi%2CNA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. <i>N. Engl. J. Med.</i> <b>371</b>, 2189–2199 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1406498" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1406498" data-track-item_id="10.1056/NEJMoa1406498">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25409260" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315319" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXht1ekt7o%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Genetic%20basis%20for%20clinical%20response%20to%20CTLA-4%20blockade%20in%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1406498&amp;volume=371&amp;pages=2189-2199&amp;publication_year=2014&amp;author=Snyder%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> <b>350</b>, 207–211 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aad0095" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aad0095" data-track-item_id="10.1126/science.aad0095">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26359337" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054517" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1antLnJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20correlates%20of%20response%20to%20CTLA-4%20blockade%20in%20metastatic%20melanoma&amp;journal=Science&amp;doi=10.1126%2Fscience.aad0095&amp;volume=350&amp;pages=207-211&amp;publication_year=2015&amp;author=Allen%2CEM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> <b>362</b>, eaar3593 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aar3593" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aar3593" data-track-item_id="10.1126/science.aar3593">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30309915" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718162" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVKqtLzP" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pan-tumor%20genomic%20biomarkers%20for%20PD-1%20checkpoint%20blockade-based%20immunotherapy&amp;journal=Science&amp;doi=10.1126%2Fscience.aar3593&amp;volume=362&amp;publication_year=2018&amp;author=Cristescu%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> <b>515</b>, 568–571 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature13954" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature13954" data-track-item_id="10.1038/nature13954">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFanu7jL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25428505" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PD-1%20blockade%20induces%20responses%20by%20inhibiting%20adaptive%20immune%20resistance&amp;journal=Nature&amp;doi=10.1038%2Fnature13954&amp;volume=515&amp;pages=568-571&amp;publication_year=2014&amp;author=Tumeh%2CPC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. <i>N. Engl. J. Med.</i> <b>375</b>, 819–829 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1604958" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1604958" data-track-item_id="10.1056/NEJMoa1604958">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhvF2ks7%2FP" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27433843" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007206" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mutations%20associated%20with%20acquired%20resistance%20to%20PD-1%20blockade%20in%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1604958&amp;volume=375&amp;pages=819-829&amp;publication_year=2016&amp;author=Zaretsky%2CJM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nat. Commun.</i> <b>8</b>, 1136 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-017-01062-w" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-017-01062-w" data-track-item_id="10.1038/s41467-017-01062-w">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29070816" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656607" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXovFyhtL8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Resistance%20to%20checkpoint%20blockade%20therapy%20through%20inactivation%20of%20antigen%20presentation&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-01062-w&amp;volume=8&amp;publication_year=2017&amp;author=Sade-Feldman%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. <i>Cell</i> <b>167</b>, 397–404 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2016.08.069" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2016.08.069" data-track-item_id="10.1016/j.cell.2016.08.069">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhsFGrurbJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27667683" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088716" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Loss%20of%20IFN-%CE%B3%20pathway%20genes%20in%20tumor%20cells%20as%20a%20mechanism%20of%20resistance%20to%20anti-CTLA-4%20therapy&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2016.08.069&amp;volume=167&amp;pages=397-404&amp;publication_year=2016&amp;author=Gao%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. <i>Cancer Discov.</i> <b>6</b>, 202–216 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-15-0283" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-15-0283" data-track-item_id="10.1158/2159-8290.CD-15-0283">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XisVyjtbo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26645196" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Loss%20of%20PTEN%20promotes%20resistance%20to%20T%20cell-mediated%20immunotherapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-15-0283&amp;volume=6&amp;pages=202-216&amp;publication_year=2016&amp;author=Peng%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">George, S. et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. <i>Immunity</i> <b>46</b>, 197–204 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2017.02.001" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2017.02.001" data-track-item_id="10.1016/j.immuni.2017.02.001">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXjtlertbk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28228279" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408320" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Loss%20of%20PTEN%20is%20associated%20with%20resistance%20to%20anti-PD-1%20checkpoint%20blockade%20therapy%20in%20metastatic%20uterine%20leiomyosarcoma&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2017.02.001&amp;volume=46&amp;pages=197-204&amp;publication_year=2017&amp;author=George%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Sci. Transl. Med.</i> <b>9</b>, eaah3560 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscitranslmed.aah3560" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/scitranslmed.aah3560" data-track-item_id="10.1126/scitranslmed.aah3560">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28251903" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819607" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXjsVSktrk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Integrated%20molecular%20analysis%20of%20tumor%20biopsies%20on%20sequential%20CTLA-4%20and%20PD-1%20blockade%20reveals%20markers%20of%20response%20and%20resistance&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.aah3560&amp;volume=9&amp;publication_year=2017&amp;author=Roh%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Davoli, T. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. <i>Science</i> <b>355</b>, eaaf8399 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aaf8399" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aaf8399" data-track-item_id="10.1126/science.aaf8399">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28104840" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592794" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtVehur8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20aneuploidy%20correlates%20with%20markers%20of%20immune%20evasion%20and%20with%20reduced%20response%20to%20immunotherapy&amp;journal=Science&amp;doi=10.1126%2Fscience.aaf8399&amp;volume=355&amp;publication_year=2017&amp;author=Davoli%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. <i>Cell</i> <b>165</b>, 35–44 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2016.02.065" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2016.02.065" data-track-item_id="10.1016/j.cell.2016.02.065">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XksVKrsbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26997480" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808437" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20and%20transcriptomic%20features%20of%20response%20to%20anti-PD-1%20therapy%20in%20metastatic%20melanoma&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2016.02.065&amp;volume=165&amp;pages=35-44&amp;publication_year=2016&amp;author=Hugo%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. &amp; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. <i>Cell</i> <b>160</b>, 48–61 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2014.12.033" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2014.12.033" data-track-item_id="10.1016/j.cell.2014.12.033">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtF2lsbo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25594174" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856474" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Molecular%20and%20genetic%20properties%20of%20tumors%20associated%20with%20local%20immune%20cytolytic%20activity&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2014.12.033&amp;volume=160&amp;pages=48-61&amp;publication_year=2015&amp;author=Rooney%2CMS&amp;author=Shukla%2CSA&amp;author=Wu%2CCJ&amp;author=Getz%2CG&amp;author=Hacohen%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Weber, J. S. et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncol.</i> <b>17</b>, 943–955 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2816%2930126-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(16)30126-7" data-track-item_id="10.1016/S1470-2045(16)30126-7">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xpslyjs7w%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27269740" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474305" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Sequential%20administration%20of%20nivolumab%20and%20ipilimumab%20with%20a%20planned%20switch%20in%20patients%20with%20advanced%20melanoma%20%28CheckMate%20064%29%3A%20an%20open-label%2C%20randomised%2C%20phase%202%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2816%2930126-7&amp;volume=17&amp;pages=943-955&amp;publication_year=2016&amp;author=Weber%2CJS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Van Allen, E. M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. <i>Nat. Med.</i> <b>20</b>, 682–688 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnm.3559" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nm.3559" data-track-item_id="10.1038/nm.3559">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24836576" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048335" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXotFeqsLg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Whole-exome%20sequencing%20and%20clinical%20interpretation%20of%20formalin-fixed%2C%20paraffin-embedded%20tumor%20samples%20to%20guide%20precision%20cancer%20medicine&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.3559&amp;volume=20&amp;pages=682-688&amp;publication_year=2014&amp;author=Allen%2CEM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Birkeland, E. et al. Patterns of genomic evolution in advanced melanoma. <i>Nat. Commun.</i> <b>9</b>, 2665 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-018-05063-1" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-018-05063-1" data-track-item_id="10.1038/s41467-018-05063-1">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3c%2Fms12ntw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29991680" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039447" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Patterns%20of%20genomic%20evolution%20in%20advanced%20melanoma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-018-05063-1&amp;volume=9&amp;publication_year=2018&amp;author=Birkeland%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. <i>Nature</i> <b>500</b>, 415–421 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature12477" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature12477" data-track-item_id="10.1038/nature12477">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtlWjur7M" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23945592" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776390" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Signatures%20of%20mutational%20processes%20in%20human%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature12477&amp;volume=500&amp;pages=415-421&amp;publication_year=2013&amp;author=Alexandrov%2CLB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> <b>545</b>, 175–180 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature22071" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature22071" data-track-item_id="10.1038/nature22071">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXntVKms7w%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28467829" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Whole-genome%20landscapes%20of%20major%20melanoma%20subtypes&amp;journal=Nature&amp;doi=10.1038%2Fnature22071&amp;volume=545&amp;pages=175-180&amp;publication_year=2017&amp;author=Hayward%2CNK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nat. Genet.</i> <b>50</b>, 1271–1281 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41588-018-0200-2" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41588-018-0200-2" data-track-item_id="10.1038/s41588-018-0200-2">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsF2nsrvM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30150660" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119118" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20correlates%20of%20response%20to%20immune%20checkpoint%20blockade%20in%20microsatellite-stable%20solid%20tumors&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fs41588-018-0200-2&amp;volume=50&amp;pages=1271-1281&amp;publication_year=2018&amp;author=Miao%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. <i>Cell</i> <b>171</b>, 1259–1271 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2017.10.001" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2017.10.001" data-track-item_id="10.1016/j.cell.2017.10.001">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslehs7nL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29107330" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720478" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Allele-specific%20HLA%20loss%20and%20immune%20escape%20in%20lung%20cancer%20evolution&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.10.001&amp;volume=171&amp;pages=1259-1271&amp;publication_year=2017&amp;author=McGranahan%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Riaz, N. et al. Recurrent SERPINB3 and SERPINB4 mutations in patients that respond to anti-CTLA4 immunotherapy. <i>Nat. Genet.</i> <b>48</b>, 1327–1329 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fng.3677" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ng.3677" data-track-item_id="10.1038/ng.3677">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1SltL3P" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27668655" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553281" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Recurrent%20SERPINB3%20and%20SERPINB4%20mutations%20in%20patients%20that%20respond%20to%20anti-CTLA4%20immunotherapy&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.3677&amp;volume=48&amp;pages=1327-1329&amp;publication_year=2016&amp;author=Riaz%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. <i>Cancer Discov.</i> <b>7</b>, 188–201 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-16-1223" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-16-1223" data-track-item_id="10.1158/2159-8290.CD-16-1223">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXitVCjsr0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27903500" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Primary%20resistance%20to%20PD-1%20blockade%20mediated%20by%20JAK1%2F2%20mutations&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-16-1223&amp;volume=7&amp;pages=188-201&amp;publication_year=2017&amp;author=Shin%2CDS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Sucker, A. et al. Acquired IFN-γ resistance impairs anti-tumor immunity and gives rise to T cell-resistant melanoma lesions. <i>Nat. Commun.</i> <b>8</b>, 15440 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fncomms15440" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ncomms15440" data-track-item_id="10.1038/ncomms15440">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXovFCmu7k%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28561041" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460020" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Acquired%20IFN-%CE%B3%20resistance%20impairs%20anti-tumor%20immunity%20and%20gives%20rise%20to%20T%20cell-resistant%20melanoma%20lesions&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms15440&amp;volume=8&amp;publication_year=2017&amp;author=Sucker%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. <i>Proc. Natl Acad. Sci. USA</i> <b>102</b>, 15545–15550 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.0506580102" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.0506580102" data-track-item_id="10.1073/pnas.0506580102">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXht1ShtrnO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16199517" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1239896" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Gene%20set%20enrichment%20analysis%3A%20a%20knowledge-based%20approach%20for%20interpreting%20genome-wide%20expression%20profiles&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0506580102&amp;volume=102&amp;pages=15545-15550&amp;publication_year=2005&amp;author=Subramanian%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Liberzon, A. et al. The molecular signatures database hallmark gene-set collection. <i>Cell Syst.</i> <b>1</b>, 417–425 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cels.2015.12.004" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cels.2015.12.004" data-track-item_id="10.1016/j.cels.2015.12.004">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFaltLc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26771021" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707969" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20molecular%20signatures%20database%20hallmark%20gene-set%20collection&amp;journal=Cell%20Syst.&amp;doi=10.1016%2Fj.cels.2015.12.004&amp;volume=1&amp;pages=417-425&amp;publication_year=2015&amp;author=Liberzon%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nat. Med.</i> <b>24</b>, 1545–1549 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-018-0157-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-018-0157-9" data-track-item_id="10.1038/s41591-018-0157-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFGjurzF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30127394" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693632" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Robust%20prediction%20of%20response%20to%20immune%20checkpoint%20blockade%20therapy%20in%20metastatic%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0157-9&amp;volume=24&amp;pages=1545-1549&amp;publication_year=2018&amp;author=Auslander%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> <b>387</b>, 1837–1846 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2816%2900587-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(16)00587-0" data-track-item_id="10.1016/S0140-6736(16)00587-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XktVOltrs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26970723" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small%20cell%20lung%20cancer%20%28POPLAR%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%202%20randomised%20controlled%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2816%2900587-0&amp;volume=387&amp;pages=1837-1846&amp;publication_year=2016&amp;author=Fehrenbacher%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nat. Med.</i> <b>25</b>, 454–461 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-019-0357-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-019-0357-y" data-track-item_id="10.1038/s41591-019-0357-y">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXmsVyruro%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30804515" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699626" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20single%20dose%20of%20neoadjuvant%20PD-1%20blockade%20predicts%20clinical%20outcomes%20in%20resectable%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0357-y&amp;volume=25&amp;pages=454-461&amp;publication_year=2019&amp;author=Huang%2CAC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. <i>Nat. Med.</i> <b>24</b>, 1550–1558 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-018-0136-1" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-018-0136-1" data-track-item_id="10.1038/s41591-018-0136-1">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFGjur3N" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30127393" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487502" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Signatures%20of%20T%20cell%20dysfunction%20and%20exclusion%20predict%20cancer%20immunotherapy%20response&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0136-1&amp;volume=24&amp;pages=1550-1558&amp;publication_year=2018&amp;author=Jiang%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? <i>Sci. Rep.</i> <b>2</b>, 765 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fsrep00765" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/srep00765" data-track-item_id="10.1038/srep00765">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23097687" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479449" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xhs1WhtLrE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=12-Chemokine%20gene%20signature%20identifies%20lymph%20node-like%20structures%20in%20melanoma%3A%20potential%20for%20patient%20selection%20for%20immunotherapy%3F&amp;journal=Sci.%20Rep.&amp;doi=10.1038%2Fsrep00765&amp;volume=2&amp;publication_year=2012&amp;author=Messina%2CJL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. <i>J. Clin. Invest.</i> <b>127</b>, 2930–2940 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2FJCI91190" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/JCI91190" data-track-item_id="10.1172/JCI91190">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28650338" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531419" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=IFN-%CE%B3-related%20mRNA%20profile%20predicts%20clinical%20response%20to%20PD-1%20blockade&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI91190&amp;volume=127&amp;pages=2930-2940&amp;publication_year=2017&amp;author=Ayers%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Ock, C.-Y. et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nat. Commun.</i> <b>8</b>, 1050 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-017-01018-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-017-01018-0" data-track-item_id="10.1038/s41467-017-01018-0">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29051489" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648801" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXos1Krurk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20landscape%20associated%20with%20potential%20response%20to%20anti-CTLA-4%20treatment%20in%20cancers&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-01018-0&amp;volume=8&amp;publication_year=2017&amp;author=Ock%2CC-Y" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. <i>Nat. Methods</i> <b>12</b>, 453–457 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnmeth.3337" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nmeth.3337" data-track-item_id="10.1038/nmeth.3337">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXlsVOgu7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25822800" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739640" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Robust%20enumeration%20of%20cell%20subsets%20from%20tissue%20expression%20profiles&amp;journal=Nat.%20Methods&amp;doi=10.1038%2Fnmeth.3337&amp;volume=12&amp;pages=453-457&amp;publication_year=2015&amp;author=Newman%2CAM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. <i>Cell</i> <b>175</b>, 984–997 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2018.09.006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2018.09.006" data-track-item_id="10.1016/j.cell.2018.09.006">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVyhurvK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30388455" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410377" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20cancer%20cell%20program%20promotes%20T%20cell%20exclusion%20and%20resistance%20to%20checkpoint%20blockade&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2018.09.006&amp;volume=175&amp;pages=984-997&amp;publication_year=2018&amp;author=Jerby-Arnon%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. <i>Nature</i> <b>462</b>, 108–112 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature08460" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature08460" data-track-item_id="10.1038/nature08460">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXht12gtrvL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19847166" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783335" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Systematic%20RNA%20interference%20reveals%20that%20oncogenic%20KRAS-driven%20cancers%20require%20TBK1&amp;journal=Nature&amp;doi=10.1038%2Fnature08460&amp;volume=462&amp;pages=108-112&amp;publication_year=2009&amp;author=Barbie%2CDA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. <i>Cell</i> <b>171</b>, 934–949 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2017.09.028" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2017.09.028" data-track-item_id="10.1016/j.cell.2017.09.028">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1GjsrjL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29033130" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685550" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20and%20microenvironment%20evolution%20during%20immunotherapy%20with%20nivolumab&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.09.028&amp;volume=171&amp;pages=934-949&amp;publication_year=2017&amp;author=Riaz%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Weber, J. et al. Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab. <i>Ann. Oncol.</i> <b>27</b>, 10470 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdw378.01" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdw378.01" data-track-item_id="10.1093/annonc/mdw378.01">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Baseline%20tumor%20T%20cell%20receptor%20%28TcR%29%20sequencing%20analysis%20and%20neo%20antigen%20load%20is%20associated%20with%20benefit%20in%20melanoma%20patients%20receiving%20sequential%20nivolumab%20and%20ipilimumab&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdw378.01&amp;volume=27&amp;publication_year=2016&amp;author=Weber%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nat. Med.</i> <b>24</b>, 1649–1654 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-018-0197-1" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-018-0197-1" data-track-item_id="10.1038/s41591-018-0197-1">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVWjtLjL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30297909" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481682" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Neoadjuvant%20immune%20checkpoint%20blockade%20in%20high-risk%20resectable%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0197-1&amp;volume=24&amp;pages=1649-1654&amp;publication_year=2018&amp;author=Amaria%2CRN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Sci. Transl. Med.</i> <b>10</b>, eaar3342 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscitranslmed.aar3342" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/scitranslmed.aar3342" data-track-item_id="10.1126/scitranslmed.aar3342">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30021886" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitVOgtr4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=MHC%20proteins%20confer%20differential%20sensitivity%20to%20CTLA-4%20and%20PD-1%20blockade%20in%20untreated%20metastatic%20melanoma&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.aar3342&amp;volume=10&amp;publication_year=2018&amp;author=Rodig%2CSJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nat. Commun.</i> <b>7</b>, 10582 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fncomms10582" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ncomms10582" data-track-item_id="10.1038/ncomms10582">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhslOmur4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26822383" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740184" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Melanoma-specific%20MHC-II%20expression%20represents%20a%20tumour-autonomous%20phenotype%20and%20predicts%20response%20to%20anti-PD-1%2FPD-L1%20therapy&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms10582&amp;volume=7&amp;publication_year=2016&amp;author=Johnson%2CDB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> <b>351</b>, 1463–1469 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aaf1490" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aaf1490" data-track-item_id="10.1126/science.aaf1490">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XksFCht70%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26940869" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984254" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clonal%20neoantigens%20elicit%20T%20cell%20immunoreactivity%20and%20sensitivity%20to%20immune%20checkpoint%20blockade&amp;journal=Science&amp;doi=10.1126%2Fscience.aaf1490&amp;volume=351&amp;pages=1463-1469&amp;publication_year=2016&amp;author=McGranahan%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR50">Morris, L. G. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> <b>7</b>, 10051–10063 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.18632%2Foncotarget.7067" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.18632/oncotarget.7067" data-track-item_id="10.18632/oncotarget.7067">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26840267" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891103" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pan-cancer%20analysis%20of%20intratumor%20heterogeneity%20as%20a%20prognostic%20determinant%20of%20survival&amp;journal=Oncotarget&amp;doi=10.18632%2Foncotarget.7067&amp;volume=7&amp;pages=10051-10063&amp;publication_year=2016&amp;author=Morris%2CLGT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR51">Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nat. Commun.</i> <b>8</b>, 2193 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-017-02320-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-017-02320-7" data-track-item_id="10.1038/s41467-017-02320-7">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXmtlaktrk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29259186" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736752" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mutational%20patterns%20in%20chemotherapy%20resistant%20muscle-invasive%20bladder%20cancer&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-02320-7&amp;volume=8&amp;publication_year=2017&amp;author=Liu%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR52">Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. <i>Cancer Discov.</i> <b>4</b>, 175–185 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-13-0285" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-13-0285" data-track-item_id="10.1158/2159-8290.CD-13-0285">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFymtrw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24436049" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293454" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tolerance%20of%20whole-genome%20doubling%20propagates%20chromosomal%20instability%20and%20accelerates%20cancer%20genome%20evolution&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-13-0285&amp;volume=4&amp;pages=175-185&amp;publication_year=2014&amp;author=Dewhurst%2CSM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR53">Weide, B. et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. <i>Clin. Cancer Res.</i> <b>22</b>, 5487–5496 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-16-0127" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-16-0127" data-track-item_id="10.1158/1078-0432.CCR-16-0127">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhvVCqur3K" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27185375" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572569" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Baseline%20biomarkers%20for%20outcome%20of%20melanoma%20patients%20treated%20with%20pembrolizumab&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-0127&amp;volume=22&amp;pages=5487-5496&amp;publication_year=2016&amp;author=Weide%2CB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR54">Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. <i>JCI Insight</i> <b>3</b>, 124507 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2Fjci.insight.124507" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/jci.insight.124507" data-track-item_id="10.1172/jci.insight.124507">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30518694" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor-draining%20lymph%20nodes%20are%20pivotal%20in%20PD-1%2FPD-L1%20checkpoint%20therapy&amp;journal=JCI%20Insight&amp;doi=10.1172%2Fjci.insight.124507&amp;volume=3&amp;publication_year=2018&amp;author=Fransen%2CMF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR55">Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <i>Nat. Med.</i> <b>24</b>, 1655–1661 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-018-0198-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-018-0198-0" data-track-item_id="10.1038/s41591-018-0198-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVCit7rM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30297911" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Neoadjuvant%20versus%20adjuvant%20ipilimumab%20plus%20nivolumab%20in%20macroscopic%20stage%20III%20melanoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0198-0&amp;volume=24&amp;pages=1655-1661&amp;publication_year=2018&amp;author=Blank%2CCU" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR56">Cesano, A. nCounter PanCancer immune profiling panel (NanoString Technologies, Seattle, WA). <i>J. Immunother. Cancer</i> <b>3</b>, 42 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s40425-015-0088-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s40425-015-0088-7" data-track-item_id="10.1186/s40425-015-0088-7">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26674611" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678588" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=nCounter%20PanCancer%20immune%20profiling%20panel%20%28NanoString%20Technologies%2C%20Seattle%2C%20WA%29.&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-015-0088-7&amp;volume=3&amp;publication_year=2015&amp;author=Cesano%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR57">Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. <i>Genome Biol.</i> <b>12</b>, R1 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/gb-2011-12-1-r1" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/gb-2011-12-1-r1" data-track-item_id="10.1186/gb-2011-12-1-r1">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21205303" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091298" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20scalable%2C%20fully%20automated%20process%20for%20construction%20of%20sequence-ready%20human%20exome%20targeted%20capture%20libraries&amp;journal=Genome%20Biol.&amp;doi=10.1186%2Fgb-2011-12-1-r1&amp;volume=12&amp;publication_year=2011&amp;author=Fisher%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR58">Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. <i>Nat. Biotechnol.</i> <b>27</b>, 182–189 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnbt.1523" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nbt.1523" data-track-item_id="10.1038/nbt.1523">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXht1ehs7o%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19182786" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663421" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Solution%20hybrid%20selection%20with%20ultra-long%20oligonucleotides%20for%20massively%20parallel%20targeted%20sequencing&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.1523&amp;volume=27&amp;pages=182-189&amp;publication_year=2009&amp;author=Gnirke%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR59">Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next generation sequencing data. <i>Bioinformatics</i> <b>27</b>, 2601–2602 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbioinformatics%2Fbtr446" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/bioinformatics/btr446" data-track-item_id="10.1093/bioinformatics/btr446">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFKjt7%2FL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21803805" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167057" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=ContEst%3A%20estimating%20cross-contamination%20of%20human%20samples%20in%20next%20generation%20sequencing%20data&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbtr446&amp;volume=27&amp;pages=2601-2602&amp;publication_year=2011&amp;author=Cibulskis%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR60">Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. <i>Nat. Biotechnol.</i> <b>31</b>, 213–219 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnbt.2514" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nbt.2514" data-track-item_id="10.1038/nbt.2514">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXjsFCntbc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23396013" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833702" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Sensitive%20detection%20of%20somatic%20point%20mutations%20in%20impure%20and%20heterogeneous%20cancer%20samples&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.2514&amp;volume=31&amp;pages=213-219&amp;publication_year=2013&amp;author=Cibulskis%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR61">Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. <i>Nucleic Acids Res.</i> <b>41</b>, e67 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fnar%2Fgks1443" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/nar/gks1443" data-track-item_id="10.1093/nar/gks1443">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXlsVCnu7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23303777" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616734" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Discovery%20and%20characterization%20of%20artifactual%20mutations%20in%20deep%20coverage%20targeted%20capture%20sequencing%20data%20due%20to%20oxidative%20DNA%20damage%20during%20sample%20preparation&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgks1443&amp;volume=41&amp;publication_year=2013&amp;author=Costello%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR62">Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. <i>Bioinformatics</i> <b>28</b>, 1811–1817 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbioinformatics%2Fbts271" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/bioinformatics/bts271" data-track-item_id="10.1093/bioinformatics/bts271">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVSgtr%2FM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22581179" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Strelka%3A%20accurate%20somatic%20small-variant%20calling%20from%20sequenced%20tumor-normal%20sample%20pairs&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbts271&amp;volume=28&amp;pages=1811-1817&amp;publication_year=2012&amp;author=Saunders%2CCT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR63">Ramos, A. H. et al. Oncotator: cancer variant annotation tool. <i>Hum. Mutat.</i> <b>36</b>, E2423–E2429 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fhumu.22771" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/humu.22771" data-track-item_id="10.1002/humu.22771">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25703262" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350419" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Oncotator%3A%20cancer%20variant%20annotation%20tool&amp;journal=Hum.%20Mutat.&amp;doi=10.1002%2Fhumu.22771&amp;volume=36&amp;pages=E2423-E2429&amp;publication_year=2015&amp;author=Ramos%2CAH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR64">Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. <i>Nat. Biotechnol.</i> <b>33</b>, 1152 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnbt.3344" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nbt.3344" data-track-item_id="10.1038/nbt.3344">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFWht7nO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26372948" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747795" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20analysis%20of%20cancer-associated%20somatic%20mutations%20in%20class%20I%20HLA%20genes&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.3344&amp;volume=33&amp;publication_year=2015&amp;author=Shukla%2CSA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR65">Nielsen, M. et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and HLA-B locus protein of known sequence. <i>PloS ONE</i> <b>2</b>, e796 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0000796" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0000796" data-track-item_id="10.1371/journal.pone.0000796">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17726526" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1949492" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtFGnsbjE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=NetMHCpan%2C%20a%20method%20for%20quantitative%20predictions%20of%20peptide%20binding%20to%20any%20HLA-A%20and%20HLA-B%20locus%20protein%20of%20known%20sequence&amp;journal=PloS%20ONE&amp;doi=10.1371%2Fjournal.pone.0000796&amp;volume=2&amp;publication_year=2007&amp;author=Nielsen%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR66">Olshen, A. B., Venkatraman, E. S., Lucito, R. &amp; Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. <i>Biostatistics</i> <b>5</b>, 557–572 (2004).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbiostatistics%2Fkxh008" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/biostatistics/kxh008" data-track-item_id="10.1093/biostatistics/kxh008">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15475419" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Circular%20binary%20segmentation%20for%20the%20analysis%20of%20array-based%20DNA%20copy%20number%20data&amp;journal=Biostatistics&amp;doi=10.1093%2Fbiostatistics%2Fkxh008&amp;volume=5&amp;pages=557-572&amp;publication_year=2004&amp;author=Olshen%2CAB&amp;author=Venkatraman%2CES&amp;author=Lucito%2CR&amp;author=Wigler%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR67">Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. <i>Nat. Biotechnol.</i> <b>30</b>, 413–421 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnbt.2203" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nbt.2203" data-track-item_id="10.1038/nbt.2203">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xmt1Gktb4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22544022" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383288" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Absolute%20quantification%20of%20somatic%20DNA%20alterations%20in%20human%20cancer&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.2203&amp;volume=30&amp;pages=413-421&amp;publication_year=2012&amp;author=Carter%2CSL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR68">Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. <i>Cancer Discov</i>. <b>5</b>, 1164–1177 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-15-0369" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-15-0369" data-track-item_id="10.1158/2159-8290.CD-15-0369">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvVWqsr3O" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26410082" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916970" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Genomic%20characterization%20of%20brain%20metastases%20reveals%20branched%20evolution%20and%20potential%20therapeutic%20targets&amp;journal=Cancer%20Discov&amp;doi=10.1158%2F2159-8290.CD-15-0369&amp;volume=5&amp;pages=1164-1177&amp;publication_year=2015&amp;author=Brastianos%2CPK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR69">Lee, D. D. &amp; Seung, H. S. Learning the parts of objects by non-negative matrix factorization. <i>Nature</i> <b>401</b>, 788–791 (1999).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2F44565" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/44565" data-track-item_id="10.1038/44565">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1MXntFartrg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10548103" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Learning%20the%20parts%20of%20objects%20by%20non-negative%20matrix%20factorization&amp;journal=Nature&amp;doi=10.1038%2F44565&amp;volume=401&amp;pages=788-791&amp;publication_year=1999&amp;author=Lee%2CDD&amp;author=Seung%2CHS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR70">Brunet, J. P. et al. Metagenes and molecular pattern discovery using matrix factorization. <i>Proc. Natl Acad. Sci. USA</i> <b>101</b>, 4164–4169 (2004).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.0308531101" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.0308531101" data-track-item_id="10.1073/pnas.0308531101">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2cXivFartrc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15016911" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC384712" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Metagenes%20and%20molecular%20pattern%20discovery%20using%20matrix%20factorization&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0308531101&amp;volume=101&amp;pages=4164-4169&amp;publication_year=2004&amp;author=Brunet%2CJP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR71">Gehring, J. S., Fischer, B., Lawrence, M. &amp; Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. <i>Bioinformatics</i> <b>31</b>, 3673–3675 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xht1ensr7P" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26163694" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817139" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=SomaticSignatures%3A%20inferring%20mutational%20signatures%20from%20single-nucleotide%20variants&amp;journal=Bioinformatics&amp;volume=31&amp;pages=3673-3675&amp;publication_year=2015&amp;author=Gehring%2CJS&amp;author=Fischer%2CB&amp;author=Lawrence%2CM&amp;author=Huber%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR72">Gaujoux, R. &amp; Seoighe, C. A flexible R package for nonnegative matrix factorization. <i>BMC Bioinformatics</i> <b>11</b>, 367 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/1471-2105-11-367" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/1471-2105-11-367" data-track-item_id="10.1186/1471-2105-11-367">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20598126" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912887" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXoslGiurY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20flexible%20R%20package%20for%20nonnegative%20matrix%20factorization&amp;journal=BMC%20Bioinformatics&amp;doi=10.1186%2F1471-2105-11-367&amp;volume=11&amp;publication_year=2010&amp;author=Gaujoux%2CR&amp;author=Seoighe%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR73">Forbes, S. A. et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. <i>Nucleic Acids Res.</i> <b>43</b>, D805–D811 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fnar%2Fgku1075" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/nar/gku1075" data-track-item_id="10.1093/nar/gku1075">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtV2itr3F" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25355519" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=COSMIC%3A%20exploring%20the%20world%E2%80%99s%20knowledge%20of%20somatic%20mutations%20in%20human%20cancer&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgku1075&amp;volume=43&amp;pages=D805-D811&amp;publication_year=2015&amp;author=Forbes%2CSA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR74">Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> <b>29</b>, 15–21 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbioinformatics%2Fbts635" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/bioinformatics/bts635" data-track-item_id="10.1093/bioinformatics/bts635">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhvV2gsbnF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23104886" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=STAR%3A%20ultrafast%20universal%20RNA-seq%20aligner&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbts635&amp;volume=29&amp;pages=15-21&amp;publication_year=2013&amp;author=Dobin%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR75">Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. <i>BMC Bioinformatics</i> <b>12</b>, 323 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/1471-2105-12-323" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/1471-2105-12-323" data-track-item_id="10.1186/1471-2105-12-323">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFajtLvM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21816040" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163565" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=RSEM%3A%20accurate%20transcript%20quantification%20from%20RNA-seq%20data%20with%20or%20without%20a%20reference%20genome&amp;journal=BMC%20Bioinformatics&amp;doi=10.1186%2F1471-2105-12-323&amp;volume=12&amp;publication_year=2011&amp;author=Li%2CB&amp;author=Dewey%2CCN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR76">Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. <i>Bioinformatics</i> <b>21</b>, 3439–3440 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbioinformatics%2Fbti525" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/bioinformatics/bti525" data-track-item_id="10.1093/bioinformatics/bti525">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXovVKru74%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16082012" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=BioMart%20and%20Bioconductor%3A%20a%20powerful%20link%20between%20biological%20databases%20and%20microarray%20data%20analysis&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbti525&amp;volume=21&amp;pages=3439-3440&amp;publication_year=2005&amp;author=Durinck%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR77">Thorsson, V. et al. The immune landscape of cancer. <i>Immunity</i> <b>48</b>, 812–830 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2018.03.023" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2018.03.023" data-track-item_id="10.1016/j.immuni.2018.03.023">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXntFSjt7o%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29628290" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982584" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20landscape%20of%20cancer&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.03.023&amp;volume=48&amp;pages=812-830&amp;publication_year=2018&amp;author=Thorsson%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR78">Davidson-Pilon C. et al. CamDavidsonPilon/lifelines v.0.18.5. <i>Zenodo</i> <a href="https://doi.org/10.5281/zenodo.2562267" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.5281/zenodo.2562267">https://doi.org/10.5281/zenodo.2562267</a> (2019).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR79">Waksom M. et al. mwaskom/seaborn v.0.8.1 <i>Zenodo</i> <a href="https://doi.org/10.5281/zenodo.883859" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.5281/zenodo.883859">https://doi.org/10.5281/zenodo.883859</a> (2017).</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-cancer" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Cancer">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Cancer" src="/static/images/logos/nature-briefing-logo-cancer-white-bc263e7d57.svg" width="373" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Cancer</em> newsletter — what matters in cancer research, free to your inbox weekly.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/cancer" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Cancer">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="CancerBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="CancerBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:cancer" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in cancer research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/cancer/?brieferEntryPoint=CancerBriefingBanner">Sign up for Nature Briefing: Cancer
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-019-0654-5&amp;format=js&amp;last_modified=2020-06-19" async=""></script>

<blr-tehqhmjgxvhc></blr-tehqhmjgxvhc><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>